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 Simple, effective, and minimally invasive methods for the routine screening of patients for cancer, 
the monitoring of treatment efficacy, and the early detection of relapse are needed to reduce the 
substantial burden cancer has on society. In this dissertation, we detail a microfluidic device that 
processes a patient’s peripheral blood in search for extremely rare cancer cells that are shed from the 
tumor. The technique uses cancer-specific antibodies to recognize and retain cancer cells within the 
device, which can be analyzed after purification to provide information to clinicians that can guide 
precision medicine. 
 We developed computational models that describe the binding of cancer cells to antibodies 
coated along the microfluidic surfaces, the hydrodynamic removal of the abundant normal blood 
components, and highly parallelized microfluidic networks that can reduce analysis time. All of these 
factors guided the design of a microfluidic technology that can process blood rapidly, achieve state-of-
the-art purity, and recover cancer cells efficiently. We enabled the use of mass-produced thermoplastic 
devices for the analysis by thoroughly characterizing the oxidation of polymers surface and the covalent 
attachment of antibodies. This work led to dense antibody loading and improved efficiency in cancer cell 
recovery. Further, after carefully reviewing the literature, we identified a lack of methods for the selective 
release of the purified cancer cells for off-chip analysis. Thus, we successfully developed the use of 
oligonucleotide linkers for antibody immobilization that can be enzymatically cleaved for the efficient 
release of viable cancer cells. All of these findings culminated in a pilot study where we monitored high 
  
iv 
risk patients with acute myeloid leukemia as they recovered from a stem cell transplant. Using this 
minimally invasive microfluidic assay, we frequently sampled these patients every two weeks and 
observed the progression of residual leukemia far earlier than the highly invasive and less sensitive tests 
that are currently available. Such results can pinpoint the onset of disease relapse and lead clinicians to 
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CHAPTER 1. A CRITICAL REVIEW OF TECHNOLOGIES FOR THE ISOLATION AND ANALYSIS OF 
CIRCULATING TUMOR CELLS 
1.1 Circulating Tumors Cells (CTCs) – A Biological Context 
Cancer metastasis causes ninety percent of all cancer-related deaths.1,2 Mobile cancer cells are 
released from the primary tumor and invade proximal tissue, some migrating into the lymphatic system 
or into the peripheral blood where these tumor cells circulate (circulating tumor cells – CTCs) and 
potentially colonize a distal site to form metastases.1,3,4 It has been theorized that metastasizing tumor 
cells undergo an epithelial-to-mesenchymal transition (EMT), where tumor cells lose their epithelial 
character and morph into a mesenchymal-like phenotype.5,6 The EMT posits that cells with mesenchymal 
phenotype are mobile and capable of escaping tumor tissue; remain viable during circulation by being 
resistant to anoikis, apoptosis, and necrosis; have the ability to invade distal tissues; and possess stem cell 
capability – self-renewal and tumor-initiating ability.5,7-12 The EMT process is also thought to be reversible 
so that mesenchymal CTCs can revert to an epithelial phenotype during colonization, which has been 
suggested to be critical for metastasis formation because CTCs locked into a mesenchymal state are 
apparently unable to form metastases.13-15 Thus, CTCs with an intermediate epithelial-mesenchymal 
phenotype are likely the effectors of metastasis.16,17 
Detecting metastasis within a patient is an important step in diagnosing tumor stage and 
predicting progression free and overall survival.18,19 Current imaging techniques are not capable of 
identifying early micro-metastases due to their size, which can be as small as a single tumor cell3 or, 
particularly in patients with advanced disease, small clusters of tumor cells (micro-emboli).20-22 
Alternatively, bone marrow has been used as a reservoir for detecting disseminated tumor cells, mainly 
by nucleic-acid based methods19 or immunostaining.3 Bone marrow biopsies are highly invasive and not 
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suitable for routine and frequent staging of the patient’s cancer.23 The extraction of CTCs directly from 
the blood (i.e., liquid biopsy) has received significant attention as a minimally invasive diagnostic that 
could serve as a routine screening tool for the early detection of cancer and/or provide a frequent insight 
into the effectiveness of chemotherapy treatment. This is especially beneficial for monitoring cancers that 
are anatomically inaccessible such as pancreatic ductal adenocarcinoma (PDAC). Further, molecular 
profiling of the CTCs can help identify drug resistance prior to implementation of the therapy regimen – 
e.g., therapies targeting the epidermal growth factor receptor (EGFR) are blocked by genomic mutations 
in the KRAS gene24 – and molecular or proteomic CTC analysis could potentially aid in discovering new 
therapy targets.17 
Numerous technologies have been developed over the past decade (Figure 1.1) to isolate CTCs 
directly from the blood. The primary challenge in CTC analysis has always been the low abundance of CTCs 
(1-3,000 CTCs/mL)25 against the high background of blood cells (109 total blood cells/mL; 107 white blood 
cells (WBCs)/mL).26 It is a technically complex feat to design an assay that both reliably identifies rare CTCs 
and substantially purifies the CTCs, which is necessary to eliminate the large WBC background that 
complicates CTC identification and yields abundant wild-type nucleic material that inhibits molecular 
analyses.  CTCs must then be discerned by some unique property that specifically differentiates CTCs from 
all other blood components. This can be a biological marker, such as a molecular or protein signature, or 
a physical property, such as CTC size.  




Figure 1.1 A Scopus survey of articles published from 2004 to 2014 that regard CTCs in general or 
specifically regard CellSearch or microfluidics. Scopus results were restricted to articles only and used the 
fields specified in the legend. 
 
heterogeneity in tumor biology, particularly with respect to the EMT.17 For example, CTCs were initially 
defined as negative for the WBC-specific CD45 surface protein and positive for the epithelial cell adhesion 
molecule (EpCAM) surface protein and cytokeratin (CK) cytoskeletal proteins, yet modern studies have 
identified mesenchymal CTCs that do not fit this definition due to EMT with downregulation of the  
epithelial EpCAM and CK markers.27-29 Thus, not only have technologies evolved for highly sensitive CTC 
isolation, but the community continues to explore the biological properties and clinical importance of 
CTCs. It is also interesting to note that the developed assays for CTC isolation have been adapted to other 
important clinical applications beyond surveying epithelial cancers, e.g., blood cancers such as multiple 
myeloma30 and leukemias23,31,32 and even stroke diagnostics.33 
In this review, we focus on CTC analysis from a technological perspective and attempt to untangle 
the field’s diversity, which has been rightfully noted to be somewhat unclear to the cancer research 
community.17 How have technologies evolved over the past decade? What is the state-of-the-art in 
performance, and how do we measure that? Are these academic publications translating into clinical 
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laboratories and commercial technologies? This latter point is especially important for microfluidic-based 
CTC assays that have arguably seen the most extensive development, as well as divergence in techniques.  
Microfluidics are comprised of fluidic channels or other conduits that are only <100 µm in size and 
allow the accurate manipulation of very small sample volumes. For CTC analysis, this can be used to 
carefully control the interaction of blood cells with CTC-specific antibodies (Abs) immobilized along the 
similarly sized microfluidic channels, for example. Further, by conducting the assay within a dedicated 
device, conventional laboratory procedures can be automated (i.e., lab on a chip) and packaged in a low-
cost, sample-in-answer-out format so that the technology can achieve in-clinic, point-of-care use for the 
general public or even in-laboratory, point-of-research use by cancer researchers.  
 We cannot exhaustively cover every technology in the literature due to the field’s acceleration – 
almost 350 microfluidic-based articles regarding CTCs were reported in 2014 alone (Figure 1.1) – 
therefore, we will rather focus on representative technologies with significant clinical demonstrations or 
those that illustrate fundamental principles in order to discuss nuances, technical considerations that 
affect assay performance, and steps that have been made toward commercialization. We will also 
highlight a number of analyses that can be performed using the CTCs once they are retrieved, which 
extends beyond enumeration-based prognostics and towards screening for genomic mutations, gene 
transcription profiles, protein translation, and drug susceptibility of the CTCs (Figure 1.2). 
1.2 Properties of CTCs Targeted for Isolation  
Techniques for CTC isolation have become increasingly diverse in the biological and/or physical 
properties that are exploited to discriminate CTCs from the highly abundant blood background. Biological 





Figure 1.2 Applications for CTC analyses, including enumeration,34 genomic mutation screening (FISH,30 
Sanger sequencing,35 aCGH,36 and NGS)37, RNA expression profiling (RNA-ISH,27 qRT-PCR,38 expression 
microarrays,39 and single cell RNA-seq)40, protein analysis (EPISPOT)41, and ex vivo culturing (CTC 
expansion, xenograft models, and drug susceptibility)42. FISH (fluorescence in situ hybridization); WGA 
(whole genome amplification); aCGH (array comparative genomic hybridization); NGS (next generation 
sequencing); RNA-ISH (fluorescence RNA in situ hybridization); qRT-PCR (quantitative reverse 





matrix (i.e., invasion capacity), whereas technologies employing physical properties seek to discriminate 
CTCs by size, deformability, density, and dielectric properties amongst others. Some technologies have 
emerged that combine both biological and physical properties. 
1.2.1 Biological Properties 
 The most ubiquitous biological property exploited for CTC isolation is the presence EpCAM. 
Circulating EpCAM(+) cells are generally absent in the blood of healthy donors and patients with non-
malignant diseases, and this affords technologies that use Abs or aptamers that affinity select EpCAM(+) 
CTCs with high specificity. The resultant purity of the CTC isolate depend on subtle aspects in the selection 
process that will be discussed throughout this review. EpCAM selection was first employed by the 
CellSearch™ CTC Test platform25 and later by microfluidics.44 The most recent research has documented, 
however, the presence of clinically relevant CTCs that do not express EpCAM, namely those of 
mesenchymal or stem cell nature.27,28 A number of additional markers, including N-Cadherin, O-Cadherin, 
VCAM-1, ICAM-1, CEA, MUC1, EphB4, CD44, CD133, CD146, PSMA, HER2, EGFR, TROP-2, and FAPα have 
been explored in addition to anti-EpCAM selection.27,28,35,45-48 Some of these markers lack specificity due 
to expression on normal blood cells, benign cells, and/or endothelial cells, while other markers are co-
expressed with EpCAM and thereby providing no additional benefit to the assay,48-50 or are specific for 
only a particular disease, such as the targeting of the prostate specific membrane antigen (PSMA) for 
prostate cancer.28 
In particular, Yu, et al. targeted EpCAM, EGFR, and human epidermal growth factor receptor 2 
(HER2) to simultaneously select epithelial and mesenchymal CTCs from breast cancer patients using the 
herringbone microfluidic technology (discussed below) with 41% of patients having detectable CTC 
levels.27 Witek, et al. recently demonstrated the fibroblast activation protein-α (FAPα) as a highly specific 
marker for mesenchymal CTCs (90% of CTCs did not co-express the EpCAM marker) using the sinusoidal 
microfluidic device, and by selecting both FAPα(+) and EpCAM(+) CTCs, the authors observed CTCs in 100% 
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of patients with ovarian, colorectal, prostate, and pancreatic cancers and 80% of breast cancer patients.28 
Both studies demonstrated the presence of CTCs that had weak or no expression of CK with Yu, et al. 
identifying mesenchymal CTCs by RNA in situ hybridization (RNA-ISH)27 and Witek, et al. by expression of 
the mesenchymal cytoskeletal protein vimentin (Vim).28 Further, results indicated that mesenchymal CTCs 
could be an indicator of disease progression and/or chemotherapy resistance.27,28 Such studies strongly 
suggest that the classic definition of CTCs as EpCAM(+)/CK(+)/CD45(-) is not inclusive of all CTC phenotypes 
and that assays exclusively selecting EpCAM(+) CTCs do not fully survey a patient’s disease burden. 
1.2.2 Physical Properties 
A significant amount of research has been invested in developing technologies that discern CTCs 
by physical properties, e.g., size, deformability, density, and dielectric properties. Microfabricated filter 
pores, traps, and slots; microfluidic devices that employ hydrodynamic phenomena for size-separation; 
and microfluidic devices for dielectrophoretic separation all separate CTCs by physical properties.51,52 In 
general, physical-based technologies isolate CTCs much more quickly (reduced assay time) than biological-
based enrichment technologies but at a cost of considerably lower purity (i.e., a high abundance of 
background WBCs in the isolate), which can complicate CTC identification and preclude molecular 
analyses. 
 Physical-based separations have been pursued because the exploited physical properties have 
been presumed to be independent of epithelial, mesenchymal, or stem cell phenotype, thereby offering 
superior coverage to biological methods that rely solely on the epithelial EpCAM marker. For example, 
dielectrophoretic properties, which are primarily rooted in an increased membrane surface area relative 
to blood cells, have been shown to be fairly constant over 80 cancer cell lines, including those of 
mesenchymal phenotype.53 Yet not all physical properties are consistent through EMT. Mesenchymal 
CTCs have enhanced cell deformability and flexibility due to cytoskeletal changes (e.g., CK downregulation 
and Vim upregulation) and thereby may have an increased likelihood of slipping through physical 
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entrapments or escaping fluidic trapping, thereby biasing these technologies towards epithelial CTC 
recovery.54,55 Furthermore, the consistency of CTC size (15-25 µm in diameter56) has been called into 
question with CTC clusters (micro-emboli) exceeding 25 µm57 and with evidence of “small” CTCs that are 
similar in size to the highly abundant normal blood components,26,58-63 although the clinical importance of 
these small CTCs remains to be explored. 
1.3 Figures-of-Merit for CTC Technologies 
To draw an informative comparison between CTC isolation technologies, the following important 
figures-of-merit were outlined: 
(i) Recovery – the assay’s efficiency in selecting CTCs. 
(ii) Purity – the ratio of CTCs to the total number of cells in the isolate. 
(iii) Throughput – the rate for processing samples. 
(iv) Clinical sensitivity – the assay’s ability to correctly identify patients with the disease. 
(v) Clinical specificity – the assay’s ability to correctly identify patients without the disease. 
In addition to these figures-of-merit, there are other factors that affect commercialization of the 
technology. The transition from an academic/research technology to a commercial product can be 
influenced by the cost involved in mass production of microfluidic devices and peripheral instrumentation 
and the cost and complexity of the assay, which can either promote or curb a technology’s prolificacy. 
We have compiled an extensive table comparing several technologies based on the 
aforementioned figures-of-merit (Table 1.1). It should be noted that there are discrepancies in how some 
figures-of-merit are defined. Some reports define purity as the ratio of CTCs to WBCs in the isolate, which 
would yield higher purities than if defined herein. Some reports normalize clinical CTC yields to 7.5 mL, 
others to 1 mL. The majority of recent studies report clinical yields as ranges and median CTC counts rather 
than averages and standard deviations to reflect the non-Gaussian nature of these measurements. 
Moreover, not all of these metrics were reported in text but only graphically. Thus, we have taken utmost 
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care to convert the reported figures-of-merit to the same definition and extract data from graphs via 
image processing as accurately as possible so useful comparisons can be made. 
1.3.1 How is Recovery Measured, and What Does It Mean? 
All but two sets of recoveries reported in Table 1.1 were determined by spiking cultured cancer 
cells (i.e., CTC surrogates) into buffer or blood, enumerating the recovered CTCs, and calculating recovery 
based on the estimated number of cells spiked. Compared to buffer, blood is more viscous, exhibits non-
Newtonian properties where viscosity decreases under shear, and contains a concentrated suspension of 
cells that can infer unpredictable cell-cell collisions;63 hence, spiking in physiological buffers is not 
preferred but is sometimes used to simplify cell identification. A second point to consider is that cell lines 
are relatively uniform in size, phenotype, and antigen (e.g., EpCAM) expression, although these 
parameters can vary due to culture conditions and even through passage.63,64 Cell line recoveries are then 
representative of and have been used to assess a technology’s performance in recovering a particular 
subpopulation of clinical CTCs (e.g., highly epithelial CTCs versus CTCs in EMT transition),44,47,65 which may 
or may not directly translate to yields of highly heterogeneous CTCs from clinical samples. For assays that 
rely on antigen expression, we have noted cell line antigen expression along with recoveries in Table 1.1. 
The accuracy and precision in recovering low numbers of cells (1-100 CTCs/mL) is governed by 
Poisson statistics with ~10-50% variance in the spiking process;66 our lab has concordantly observed 
calculated recoveries with standard deviations of 14-30%,30 which makes subtle shifts in assay 
performance difficult to assess. Some researchers have reduced this variability by counting spiked cells on 
the cap of a blood sample prior to mixing66 or by using a micromanipulator to physically pick individual 
cells for spiking,67 but even these methods assume that each cell is drawn from the blood tube and truly 
enters the device, which could be questionable when loading blood into a syringe, a common practice. 
Rather than relying on the spike level, two methods have been devised to enumerate lost CTCs, 
i.e., the CTCs not recovered by the assay. By one method, termed a “true mass balance”, effluent blood is 
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collected in a shallow microfluidic channel so that pre-labeled cultured cells can be identified.31,57,68 While 
the method ensures reliability of the measurement, this is a laborious process that requires one to scan 
50 cm2 (~3 microscope slides) to identify a few cells amongst 250 µL of blood57 (~3,000,000 blood cells).69 
Separately, we devised a “self-referencing” method in Chapter 4 of this dissertation, in which CTCs not 
recovered in a device are infused through an identical second device, third device, etc. The serial devices 
sequentially deplete CTCs from the sample with recoveries >70% requiring only 2 devices to sufficiently 
deplete the sample and lower recoveries requiring ≥3 devices. Average self-referencing recoveries were 
similar to spiking recoveries, but standard deviations were reduced from 35% to 6%.30 
Because the self-referencing method does not rely on pre-labeled cells, the recovery of patient-
derived CTCs in clinical samples could be determined without prior knowledge of CTC abundance. The 
authors demonstrated 79-87% recovery of M-PDAC CTCs in the sinusoidal technology and the only 
quantitative clinical CTC recoveries reported to date.28 Further, by referencing a device’s recovery to its 
own performance with the same clinical sample, the self-referencing method avoids matrix effects, which 
are fundamentally present when spiking cells into healthy blood. Cancer increases blood clotting 
(thrombosis is the second most frequent cause of death for cancer patients),70 which depletes fibrinogen, 
decreases plasma viscosity, increases sedimentation rates,71 and may have significant effects on the fluid 
dynamics occurring during CTC recovery. Chemotherapy and radiation treatment may also contribute to 
thrombosis and alter the production of blood cells altogether,71 all of which are important factors that will 
be encountered in the clinic but not represented by spiking experiments. The self-referencing method is 
easily adapted to other technologies and should enable further quantitation of clinical CTC recoveries.  
1.3.2 Purity – A Very Important but Perplexing Metric 
Purity is defined as the percent of CTCs isolated with respect to all cells (CTCs + WBCs) in the 
isolate. While the number of background WBCs should be approximately constant in a given assay 
(granted the variabilities in blood properties discussed above), CTC counts and thereby purity is heavily 
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biased by experimental design (spiking level of cells) or in clinical samples by variable disease burden. In 
other words, for the same levels of backgrounds WBCs, purity will decrease with lower levels of spiked 
cells or lower disease burden. 
These factors can lead to results that are hard to interpret, even within the CTC technological 
community. For example, the following purities have been reported: (i) 10%; (ii) 14%; (iii) 38%; (iv) 53%; 
(v) 62%; (vi) 84%; and (vii) 99%. These purities correspond to the following approximate counts of 
WBCs/mL: (i) 10;72 (ii) 5,600;68 (both iii and vii) 1,000;31 (iv) 3,500;73 (v) 10;56 and (vi) 3,500 to >24,000.74 It 
is certainly not obvious which purity corresponds to the lowest level of background WBCs, and without 
context into how each experiment was performed, it is difficult to assess an assay’s performance and 
limitations. Further, one would expect that if a particular technology’s WBC background is reproducibly 
consistent throughout clinical trials, this would be reflected by a constant purity. Our lab achieved purities 
varying from 40% to 100% for 66 clinical samples, yet this variability was due to fluctuating CTC levels and 
actually represented a consistent background of 3 ± 3 WBCs/mL.28,75,76 Therefore, throughout this review, 
we will attempt to provide background cell counts per mL blood in addition to purity values. 
1.3.3 Throughput – How Much Blood is Really Necessary? 
Throughput is of relatively straightforward importance: due to CTC rarity, milliliters of a blood 
sample must be processed within a reasonable amount of time. Based on initial studies and results, it was 
accepted that 5-10 mL is needed for CTC analysis.77 The 7.5 mL benchmark was largely driven by the first 
FDA-approved CellSearch™ CTC technology, which set CTC positivity thresholds at ≥3-5 CTCs in an entire 
7.5 mL blood draw.18,34,78 As detailed in Table 1.1 and discussed later, several technologies28,44,68,76,79-84 
developed since 2004 have observed much higher CTC levels (on the order of 10-100 CTCs in only 1 mL), 
strongly suggesting that only 1-2 mL of blood is needed for most CTC analyses, besides studies like detailed 
molecular analysis where more genetic material is preferred. 
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Some microfluidic technologies reach throughputs on the order of 1-2 mL/h without pre-
processing the blood, whereas some technologies pre-concentrate the blood, e.g., by red blood cell lysis 
or Ficoll density gradient centrifugation to obtain a buffy coat, both of which incur cell loss ranging from 
10-33%.85,86 Thus, volumetric throughput may not accurately represent an assay’s throughput for 
processing samples, and in Table 1.1, we have adjusted throughputs for dilutions and concentrations; a 
volumetric processing rate of 240 mL/h of 10X diluted is a sample throughput of 24 mL/h.63 It should be 
noted that most microfluidic devices with 1-2 mL/h sample throughput can be engineered towards 5-15 
mL/h by processing blood through multiple devices in parallel,65,87,88 and in Chapter 2 and Appendix 2.1, 
we detail methods to enable these high throughputs. However, in the short term, it is doubtful that the 
technologies with 1-2 mL/h throughput that also achieve high clinical yields will be practically hindered by 
this factor. Therefore, the 7.5 mL benchmark is not resolute and depends on assay performance. 
1.3.4 Establishing Clinical Specificity and Sensitivity 
CTC assays should first be tested against negative controls, most commonly healthy donors or 
patients with benign disease,89 in order to establish the specificity of the assay and threshold CTC levels 
above which the patient is considered to be positive. The patients that are correctly identified as CTC 






Table 1.1 Figures-of-merit for representative technologies that isolate CTCs by biological and/or physical properties, results from clinical studies, 
and demonstrations of CTC analysis beyond enumeration. 
 
† Cell line antigen expression: +1,000-15,000, ++15,000-50,000, +++50,000-150,000, ++++>150,000 
‡ Purity is defined as the ratio of CTC count to total cell count 
* Cancer type abbreviations used throughout table: AML (acute myeloid leukemia), CR (castration resistant), CS (castration sensitive), L (localized), M (metastatic), NSCLC (non-
small cell lung cancer), PDAC (pancreatic ductal adenocarcinoma) PDX (patient derived xenograft), SCCHN (squamous cell carcinoma of the head and neck) 
** CTCs were detected in 90% of clinical samples, but thresholds for positivity were not established from controls. 
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 CTC Test Profile kit  





M-Breast (N=75) 0-57 (4) 
4-2432 
(116) NR 
NSCLC (N=71) 0-53 (4) 5-1801 
(145) Others (N=90/52) 0-10 (NR)     /     0-17 
(NR) 
12% / 63% 
 Epithelial kit  
M-Breast (N=422) 0-3150 (11 mean) 26% 
M-Colorectal (N=196) 0-14 (0.1 mean) 17% 
M-Lung (N=99) 0-290 (4 mean) 14% 
M-Ovarian (N=29) 0-14 (0.8 mean) 23% 
M-Pancreatic (N=16) 0-4 (0.3 mean) 5% 
M-Prostate (N=123) 0-435 (10 mean) 41% 
Non-cancer (N=199) 0-0.4 (0 mean) - 
Healthy (N=145) 0-0.1 (0 mean)  
CTC Chip  
(Biological) 











Breast (N=10) 5-176 (78) 100% 
Clinical 
Molecular (RT-PCR, EGFR 
mutations) 
44,94 
Colon (N=10) 0-375 (57) 90% 
NSCLC (N=55) 5-1281 (73) 100% 
Pancreatic (N=15) 9-831 (120) 100% 
L-Prostate (N=7) 25-174 (103) 100% 
M-Prostate (N=19) 16-292 (50) 100% 




(Biological and  















Prostate (N=30) 0-1200 (54) NR 








NR PDAC (N=1) 102-135 (NA) - 
Ab-EpCAM ND NR 
PDAC (N=11)*** 0-59 (9) 73% 
Cystic lesion (N=21)*** 0-22 (0) (4 mean) 33% 
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 EpCAM FAPα  
Clinical 










M-Breast (N=10) 1-278 (48) 0.5-179 (24) 80% 
M-Colorectal (N=5) 7-111 (17) 10-280 (24) 100% 
M-Ovarian (N=9) 42-680 (100) 4-137 (32) 100% 
CR prostate (N=5) 2-39 (9) 13-27 (18) 100% 
M-PDAC (N=11) 4-105 (20) 6-83 (17) 100% 
Non-cancer (N=6) 0.5-4 (3) 0-4 (2) - 
Healthy (N=11) 0-1 (0) - - 
Ab-EpCAM 
Clinical Recoveries 
EpCAM: M-PDAC (N=3) 




L-PDAC (N=4) 9-19 (11) - 100% 
M-PDAC (N=4) 9-95 (51) - 100% 
Healthy (N=4) 0-2 (0) - - 
PDX-PDAC 9-29 (26) - ND 
Ab-CD33/ 
CD34/CD117 
KG-1++++ PBS 64±4% 
88-99% 
specificity 
AML (N=39) 0-2684 (90) 79% 














M-Prostate (N=15) 0.6-3168 (63) 93% 
Clinical 
CTC release (enzymatic, 
mechanical, thermal) 
Molecular (RT-PCR, 







Healthy (N=10) 0-8 (1) - 
L-Prostate (N=19) 38-222 (95), PSA+*** 56% 
M-Prostate (N=36) 14-653 (32), PSA+ 64% 
M-Prostate (N=25) 0-165 (7), PSA+/PSMA+ 72% 
NB508 Blood 35±3% 1.7±2.1% Pancreatic mouse 
model 























SK-MEL-28 Blood 90% 0-0.77% 
Melanoma (N=41)† 0-53 (3) 79% 
Healthy (N=10) 0-0.8 (0.4) - 
Si Nanopillar 
(Biological) 
Ab-EpCAM 1 mL/h 
MCF-7++++, 
PC3++, T24+ 
Blood >95% ND 
Prostate (N=26) 0-33 (1) ND* 
- 99,100 M-Prostate (N=117) 0-21 (2.4 mean) ND** 





















>90% M-Breast (N=5)‡ 0-35 (7) 75% 
PC3++ 79±7% M-Prostate (N=8)‡ 0-5 (2) 80% 
A549+ 19±7% Healthy (N=10) 0-0 (0) - 


















Breast, stage IV (N=11) 1.5-31 (8) 
Healthy (N=15) 0-1 (NR) - 
† Patients were in treatment. A median (range) CTC count/mL of pre-treatment patients (N-21) was 10 (4-53) with 100% clinical sensitivity. 
‡ Reported CTC counts were normalized to a 7.5 mL blood draw, but the volume processed for each sample was not explicitly reported by the authors. 
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(~50% efficiency selecting KG1a++++ 
cells via CD34 selection) 
50-80% 
Breast (N=3) 17-60 (60) 100% 
- 102
 
Lung (N=2) 11-31 (21) 100% 
Other cancers (N=2) 13-30 (21) 100% 
















Breast (N=26) 0.1-11 (0.7) 100% 
Clinical 
Molecular (NGS RNA-seq + 
whole exome, RT-PCR) 




Healthy (N=5) 0-0 (0) - 
L-Breast (N=20)† 0-0.6 (0.2) 70% 
M-Breast (N=30)† 0-0.6 (0.2) 70% 
Healthy/Lymphoma (N=40) 0-0 (0) - 
M-Prostate (N=12) 0.1-73 (0.8) 100% 














Breast, stage I-II  (N=32) 0-NR (13 mean) 28% 
Clinical 
Molecular (RT-PCR, copy 
number variations, 
methylation) 




Breast, stage III (N=22) 0-NR (119 mean) 86% 
M-Breast, stage IV (N=10) 18-256 (126 mean) 100% 
Ovarian, stage I/II (N=10) 0-NR (6 mean) 10% 
Ovarian, stage III/IV (N=52) 0-149 (41 mean) 75% 
CS prostate (N=13) 0-100 (48 mean) 69% 
CR prostate (N=21) 150-740 (322 mean) 100% 
M-CR prostate (N=34) 0-800 (27) 74% 
Non-cancer (N=5) 0-0 (0) 33%  






























Ab-EpCAM + size 
(posiChip) 

















M-Breast (N=12) 0-3.7 (0.4) 42% 
Clinical 
Molecular (RT-PCR, Sanger) 
20,40,42,86,
108,109 
M-Colorectal (N=2) 0.3-1.1 (0.7) 50% 
M-Lung (N=2) 0-1.2 (0.6) 50% 
M-Pancreatic (N=6) 0-1.4 (0.5) 50% 
M-Prostate (N=20) 0-611 (1.4) 75% 
CR-Prostate (N=41) 0.5-610 (3.2) 90% 
Healthy (N=13) 0-0.3 (0.2) - 
Ab-CD45/ 











<0.1% (1 log 
reduction 
from posIchip) 
Glioblastoma, progressive (N=23) 0-33 (12) 58% Molecular (RT-PCR,  
NGS RNA-seq, RNA-ISH) 
Expansion (3D culture, drug 
susceptibility, xenograft) 
Glioblastoma, stable (N=43) 0-30 (2) 29% 
Healthy (N=6) 0-6.4 (1.9) - 
Pancreatic mouse model (N=11) 0-1694 (118) NR 
†The number of CTCs that were individually aspirated with a micromanipulator for gene expression analysis were reported. We assumed every CTC was aspirated.  
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4-23 cells spiked 










M-Breast (N=167)‡ 1-2000 (29) 93% 
M-Pancreatic (N=18)± 0-9 (2)* 61% 








0.5X blood 85% ~1-10%** 























Lung (N=8) 3-42 (26) 88% 
Healthy (N=4) 2-5 (3) - 
0.2-97%  
(30±26%) 
Malignant pleural effusion (N=25) 6-4800 (25) - 




















M-Bladder (N=6) 0-6 (0) 50% 
- 117
 
M-Breast (N=11) 0.1-8 (3) 100% 
M-Colorectal (N=12) 0-3 (1) 83% 
M-Prostate (N=28) 0-24 (9) 96% 





















M-Lung (N=8) 0-3 (1) 75% 
M-Other cancers (N=6) 0-1 (0.5) 67% 


























NR (0.5 mean) 
NR (0.2 mean) 









†The authors reported a 99.33 ± 0.56% reduction in leukocyte counts and assumed 1,600,000 leukocytes per mL blood. Dividing the highest median CTC count reported by 10,720 
± 8,960 leukocytes per mL blood yielded a purity of 0.3 ± 0.3%.  
‡Reported CTC counts were normalized to a 7.5 mL blood draw, but the volume processed for each sample was not explicitly reported by the authors. 
*The authors only stained for CK and CD45, noted a large number of cells that did not stain for either marker, and suggested the presence of abundant mesenchymal CTCs. 
**The authors reported a ratio of CTCs/leukocytes of ~10% and a background of 441 ± 320 cells per mL. By dividing the highest median CTC count reported by the background 
leukocytes yielded a purity of 6.6 ± 8.8%. 
***A clearance efficiency (percentage of unclogged pores per mL blood) of 96% was reported with 104-105 pores. Thus, we assumed 800-8,000 leukocytes per mL blood and 
calculated purity based on the highest median count of CTCs acquired from clinical samples.  
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definition, but some perspective should be given regarding sample sizes. Janssen Diagnostics tested the 
FDA-approved CellSearch™ system against ~300 healthy patients and ~250 patients with benign disease 
with only 4 benign samples having ≥3 CTCs (>99% specificity). Such large cohorts are not feasible for the 
mostly academic, pilot clinical studies in Table 1.1. There will likely be at least a few false positives by 
these technologies, a limitation that must be accepted until commercial studies are fiscally feasible. 
1.4 Magnetic CTC Isolation 
1.4.1 Clinical Utility of the CellSearch™ CTC Test 
The CellSearch™ CTC Test (Figure 1.3A; Janssen Diagnostics, LLC) remains the only system cleared 
by the FDA as a diagnostic test for the enrichment and enumeration of CTCs for breast, colorectal, and 
prostate cancer patients. Blood is collected in a CellSave™ tube, which contains EDTA as an anti-coagulant 
and a proprietary stabilizer/fixative that preserves blood components for 72 h while they are shipped to 
a dedicated laboratory. A buffy coat is prepared then spiked with a ferrofluid, a suspension of magnetic 
nanoparticles functionalized with anti-EpCAM Abs. The magnetically-labeled CTCs are extracted by a 
magnetic field, immunostained against CK, CD45, and the DAPI nuclear stain, and resuspended in the 
MAGNEST® magnetic chamber, which orients CTCs for imaging by a semi-automated fluorescence 
microscopy system. Trained technicians then identify CTCs that stain CK(+)/CD45(-)/DAPI(+).25,66 
Large clinical studies have consistently shown significantly reduced progression free survival and 
overall survival for patients with metastatic breast, prostate, and colorectal cancers that have ≥5 CTCs, ≥5 
CTCs, and ≥3 CTCs per 7.5 mL blood draw, respectively.18,34,78 While for other cancers, such as ovarian119 
and pancreatic cancer,120 the CTC Test’s clinical CTC yields are lower (Table 1.1), the prognostic relevance 
of the CTC Test for the aforementioned metastatic cancers is unquestionable. 
The FDA-approved CTC Test has not been widely adopted by the clinical community; neither ASCO 




Figure 1.3 Magnetic CTC isolation technologies. (A) Workflow of the CellSearch™ CTC Test versus the 
CellSearch™ Profile Kit along with a picture of the MAGNEST® magnetic chamber used to isolate 
magnetically-labeled CTCs. (B) Workflow of sample processing using the MagSweeper technology, where 
a sheathed magnetic rod sweeps through a blood sample to isolate magnetically-labeled CTCs.103 (C) 
Workflow and diagram of the iChip, here shown in positive selection mode. The blood is debulked; the 
remaining cells are focused; and magnetically labelled cells (CTCs in positive selection mode, WBCs in 
negative selection) are preferentially force into a separate outlet.86 (D) A diagram of the Ephesia 
microfluidic technology, which aligns anti-EpCAM magnetic microbeads into solid supports for CTC 
isolation that can be released by removing the magnetic field.32,65 
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recommend routine use of this technology. It remains unclear if the CTC Test’s prognosis and patient 
stratification can be used to change clinical treatments and positively affect patient outcome.121 A recent 
phase III clinical trial by the Southwest Oncology Group (SWOG S0500 study) again confirmed the test’s 
prognostic relevance in patient stratification but found that changing therapy according to the test’s 
results did not affect a high risk patient’s overall (p=0.98) or progression free (p=0.64) survival.122 In the 
SWOG S0500 study, the test was prognostically relevant but not clinically actionable. This was likely 
because the change in therapy was left to the clinician’s discretion and not guided by the CTC test,121,122 
which highlights the importance of providing information beyond CTC enumeration. Additionally, it is 
important to note that only EpCAM(+) CTCs were interrogated in this study, and as noted earlier, these 
are not the only CTCs relevant to patient progression and therapy resistance.26,96 
The CellSearch™ CTC Test is still considered a “gold standard” by many. However, a decade has 
passed since its FDA approval, and the results secured by several different technologies28,44,68,76,79-82 and 
the CellSearch™ Profile Kit83,84 have indicated that the CTC Test’s recovery of clinical CTCs is low. This is 
reflected by test’s prognostic threshold of only 3-5 CTCs/7.5 mL blood draw30,105,106 while others have 
recovered orders of magnitude higher CTCs count from only 1-2 mL of blood (Table 1.1). Due to variability 
in small patient cohorts, it is difficult to generalize increased performance for all of the referenced 
technologies, but several studies paired their analyses with the CTC Test and confirmed increased 
performance (Figure 1.4).79,83,84 The lack of direct comparison for all technologies is understandable as 
this requires a substantial financial investment (tens of thousands of dollars).  
Due to the limited clinical recoveries, the CTC Test may incur false negative events66 and may 
preclude an accurate assessment of the degree to which a patient is responding to therapy. Further, the 




Figure 1.4 Direct comparisons to the CellSearch™ CTC Test by (A) the CellSearch™ Profile Kit,83 (B) Epic 
CTC,60 (C) the posiChip,86 (D) the GEDI micropillar device,79 and (E) the Ephesia technology.65 Note that the 
GEDI device selected PSMA(+) CTCs, whereas the CTC Test targeted EpCAM(+) CTCs. Kirby, et al. noted 
that 60% (median) of CTCs were PSMA(+)/EpCAM(+), indicating the GEDI yields were roughly 10-fold 
greater than by the CellSearch™ CTC Test.79 
 
The CTC Test has been demonstrated to have very poor (2%) recovery for mesenchymal breast cancer cell 
lines,90 which has been subsequently discoursed.123-126 Mesenchymal EpCAM(-) subtypes have been 
identified in breast cancers127-129 as well as for PDAC,130 for which the CTC Test had only 19% clinical 
sensitivity.25 Finally, the CTC Test enriches fixed CTCs with a high background of contaminating WBCs 
(0.01-0.1% purity; thousands to tens of thousands of WBCs/mL),131 the origins of which will be discussed 
in subsequent sections. Both fixation and high WBC counts preclude molecular analysis of the CTCs that 
could guide therapy.122 Based on all of these factors, the CTC Test should rather be regarded as the only 
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common benchmark for which the diverse range of CTC technologies can be compared; albeit from a cost-
reward basis, the benchmark may not be financially warranted for all academic groups. 
1.4.2 Improved Performance by the CellSearch™ Profile Kit 
Janssen Diagnostics has also developed the CellSearch™ Profile Kit, which is designed to extract 
genetic material from CTCs for molecular testing rather than enumerate the CTCs. The workflow for the 
two tests are very similar (Figure 1.3A), differing only in that the Profile Kit collects the blood sample in 
an EDTA tube, presumably because the proprietary fixative/stabilizer in the CellSave™ tube compromises 
genetic material, and CTCs are lysed rather than immunostained. Flores, et al. modified this protocol by 
immunostaining the CTCs that were recovered by the Profile Kit83 and showed, along with others,84 that 
the Profile Kit recovered 30-100 times more CTCs than the CTC Test with the additional benefit of lower 
background cell counts (~200-1,000 background cells per test).83 Given the two differences in protocol, 
these results may be attributed to the use of an EDTA tube and/or the different immunostaining 
procedures (cytospin centrifugation for the Profile Kit, and semi-automated analysis with the CellSearch™ 
instrumentation for the CTC Test). 
Flores, et al. compared the performance of an EDTA tube versus the CellSave™ fixative and saw 
no difference in performance for the Profile Kit, even up to 72 h after the blood draw.83 Others have 
observed similar performance using EDTA tubes but only if maintained at 4°C;132 whereas others report 
that assay performance decreased within hours using an EDTA tube at room temperature, which was the 
reason for the CellSave™ tube’s use for stabilizing blood during shipping.132-134 Reduction in performance 
is presumed to occur if the CTC’s protein antigens are not stabilized ex vivo and lose their defined 
structures. This would reduce the number of bound anti-EpCAM nanoparticles (𝑁𝐹) and the magnetic 
susceptibility of the CTC (∆𝜒𝐶𝑇𝐶) that are utilized to magnetically pull CTCs out of solution: 
∆𝜒𝐶𝑇𝐶 = 𝑁𝐹∆𝜒𝐹𝑅𝐹/𝑅𝐶𝑇𝐶
3  (1.1) 
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where ∆𝜒𝐹  is the magnetic susceptibility of the ferrofluid; 𝑅𝐹  is the ferrofluid nanoparticle’s radius; and 
𝑅𝐶  is the CTC’s radius.
135  
If we accept the results of Flores, et al.83 and assume 𝑁𝐹  is the same between an EDTA tube and 
CellSave™ tube, another factor could be at play: the CellSave™ tube is known to increase viscosity by 18% 
during the magnetic separation procedure.135 This increased viscosity imparts a higher fluidic drag, making 
it more difficult to separate CTCs with low EpCAM expression (low 𝑁𝐹  and ∆𝜒𝐶𝑇𝐶). By switching to an EDTA 
tube, the Profile Kit may be recovering these CTCs. However, we would also expect weak magnetic 
susceptibility of WBCs, which can be caused by nonspecific nanoparticle binding and/or cellular uptake by 
viable WBCs,136-138 to increase WBC counts; the opposite trend was observed using the Profile Kit.83,84  
It was also suggested that “fragile” CTCs, which are undergoing apoptosis and have compromised 
membranes, can break apart during extensive handling and were lost during the CellSearch™ semi-
automated immunostaining but were retained by the cytospin protocol used for the Profile Kit.83 For 
example, the majority (86%) of CTCs detected by the CTC Test are apoptotic and not counted by 
CellSearch™ if not intact,139 which is somewhat surprising given that a large number (2-480 per sample) 
of viable and proliferative CTCs were isolated by the Profile Kit compared to only 1-6 per sample by the 
CTC Test.83 Further, in microfluidic technologies, CTCs are retained on a solid surface while fluid is pumped 
through the microfluidic channels; this generates a fluidic shear force that is more likely to break apart 
fragile CTCs compared to the diffusion-based magnetic separation by CellSearch™. Many of these 
technologies, like the Profile Kit, recover orders of magnitude higher CTC counts that also high 
viability.28,44,68,76,79-82 Given these results, the supposition that the CTC Test’s poor clinical recoveries are 
due to the loss of fragile, non-viable CTCs is unlikely. 
There is not enough information in the literature to conclusively pinpoint the source of the 
increased CTC yields and reduced WBC counts by the Profile Kit in comparison to the CTC Test, and we 
refrain from speculating further. Yet these results are very promising for the molecular analysis of CTCs 
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using the CellSearch™ platform.83,84,91,92 A potential problem may be the CellSearch™ infrastructure itself, 
which relies on the CellSave™ tube to stabilize samples during transit to dedicated laboratories that are 
equipped with the instrumentation and technical staff capable of performing the analysis.133 The use of a 
standard EDTA tube typically offers ~6 hours of optimal stability, although the available literature conflicts 
in this regard as well.83,132-134 Merging the Profile Kit into the CellSearch™ infrastructure will require 
rigorous testing of EDTA-based performance, the development of more advanced blood stabilizers, 
and/or less expensive, automated point-of-care instrumentation to be broadly applicable to the public, 
i.e., the driving force behind lab-on-a-chip systems. 
1.4.3 MagSweeper – Improving Purity for Magnetic Isolation by Shear Forces 
The MagSweeper technology (Figure 1.3B; licensed to Illumina, Inc.) labels CTCs with magnetic 
microbeads coated with anti-EpCAM Abs37,72,103,104 and then recovers the CTCs using a magnetic stirring 
rod, which is coated with a non-adherent plastic sheath and is swept or stirred through either a lysed37,72 
or diluted blood sample.103-105 After several rounds of washing, CTCs can then be released into a purified 
solution by removing the magnetic force. Critical to the MagSweeper’s performance, the rod’s sweeping 
motion generates shear forces (with an undisclosed magnitude) along the rod’s surface that disrupt 
nonspecifically and weakly adhering cells,103 thereby achieving very high purities (10 ± 6%, ~10 WBCs/mL) 
that are orders of magnitude higher than the CellSearch™ CTC Test.72 Clinical CTC yields from the 
MagSweeper platform have been concordant with the CellSearch™ CTC Test,72 hence with low median 
cell counts <1 CTC/mL for several types of cancer (Table 1.1).72,103,104  
Beyond enumeration, CTCs have been individually aspirated for further analysis using a 
micromanipulator. While the use of this expensive instrumentation has arguably led the technology away 
from point-of-care applications, the MagSweeper has generated significant findings in tumor biology by 
single-cell expression profiling72,104 and whole exome sequencing,37 which is a natural trajectory 
considering Illumina’s sequencing expertise.  
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Lohr and coworkers utilized the MagSweeper technology to isolate CTCs from patients with 
advanced prostate cancer, and the CTCs were sequenced to identify somatic single nucleotide variants 
(SSNVs; i.e., point mutations) in the tumor cell’s protein-coding exome. As NGS required 100 ng of DNA, 
each CTC’s genetic material (~6 pg) was amplified by whole genome amplification (WGA). WGA introduced 
amplification errors when bases were incorrectly inserted during DNA replication, which could not be 
differentiated from SSNVs using the material from only one CTC. For “single cell” analysis, it was necessary 
to combine high quality NGS sequences from ≥5 single CTCs to eliminate random amplification errors and 
accurately identify SSNVs common to these CTCs.37 Due to variable success of 11-100% for WGA of CTCs 
from five patients, it was estimated that >10 CTCs would need to be pooled prior to WGA to reduce false 
positives for SSNVs.  
Consequently, the MagSweeper platform’s low CTC yields restricted whole exome sequencing to 
patients with metastatic prostate cancer (i.e., patients with high CTC burden). In contrast, other 
technologies may have provide sufficient CTCs to sequence many types of localized and metastatic cancers 
by this method.37 These results highlight the relationship between clinical yields and purity with 
downstream SSNV mutation profiling. Pooling CTCs for NGS is highly advantageous to reduce the financial 
cost of the assay but requires high clinical yields, and if the use of a micromanipulator is avoided and the 
purified CTC isolate is directly analyzed or banked in a biorepository, the number of background WBCs 
(i.e., wild type genomes) will directly affect the ability to identify high frequency mutations that can be 
confidently called SSNVs. 
1.4.4 CTC-iChip – Microfluidic Magnetic Separation 
The iChip86,140 (Figure 1.3C) is a microfluidic technology that is dedicated to magnetic-based CTC 
isolation and has been partially sponsored by Janssen Diagnostics, LLC.82,155 Blood is first incubated in a 
static, diffusion-limited environment with magnetic microbeads, and the iChip integrates several 
microfluidic technologies to isolate the CTCs86 by: (i) the blood is “debulked” by deterministic lateral 
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displacement,141 a hydrodynamic technique that depletes cells smaller than 8 µm (monocytes, 
lymphocytes, red blood cells, and platelets) and cells larger than 30 µm86 (potentially large CTC clusters);57 
(ii) the remaining cells are aligned into a uniform trajectory by inertial focusing;86,142 and (iii) a magnetic 
field is applied to displace labeled cells into a separate outlet than non-labeled cells.86 Blood debulking 
essentially integrates a conventional laboratory procedure (red blood cell lysis or buffy coat preparation) 
in a microfluidic format, thereby minimizing CTC loss,85,86 while inertial focusing mates the blood debulking 
preparatory step with the primary mechanism of magnetic CTC separation. 
 The iChip can be operated in positive-selection mode (posiChip), where anti-EpCAM magnetic 
microbeads target epithelial CTCs, or negative-selection mode (negiChip), where the WBCs are labeled and 
depleted from the CTC isolate using microbeads conjugated to anti-CD45, anti-CD15,86 and anti-
CD66b.40,140 The posiChip yielded high cell line recovery (78-99% depending on EpCAM expression, Table 
1.1) and slightly better results than the CellSearch™ CTC Test (Figure 1.4) but still modest clinical yields 
(median CTC counts range from 0.4-3.2 CTCs/mL for breast, colorectal, lung, pancreatic, and prostate 
cancers; Table 1.1). The posiChip achieved an order of magnitude improvement in average purity over 
negiChip selection (1,500 WBCs/mL versus an extremely high background of 32,000 WBCs/mL, 
respectively),86 yet the negiChip has been used for subsequent clinical applications because the negative 
selection mode isolates both epithelial and mesenchymal CTCs,20,40,42,108,109 including exclusively 
mesenchymal brain tumor CTCs.108 Similar to the MagSweeper technology, a micromanipulator has been 
used to aspirate individual CTCs for further analysis, which mitigates the negiChip’s low purity. Thus, the 
iChip, particularly when operated in negative selection mode, has served as an effective front-end 
purification tool for substantial research endeavors, but the modest clinical yields and poor purity of the 
CTC isolate, which is only mitigated with costly instrumentation, may hamper its point-of-care clinical use. 
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1.4.5 Ephesia – Magnetic Microbeads as a Microfluidic Solid Support  
The Ephesia microchip (Figure 1.3D) also uses anti-EpCAM magnetic microbeads but operates in 
a unique format – magnetic fields are concentrated by contact-printed, magnetic ink microdots in order 
to magnetically align the microbeads as a self-assembling architecture within a larger microfluidic channel. 
This self-assembly process greatly simplifies device fabrication and antibody immobilization processes. As 
the assembly process is reversible, CTCs bound to the microbeads can be released and eluted off-chip by 
simply removing the external magnet.32,65,143 The main dilemma facing the Ephesia technology has always 
been the strength of the microbead assembly versus fluidic force65 and has created three issues: (i) limited 
throughput, (ii) incompatibility with whole blood that requires sample pre-processing, and (iii) limited 
fluidic forces, which will be discussed in more detail subsequently, available to disrupt nonspecific WBC 
attachment. 
Throughput was rectified from the first generation design (~10 µL/h, 1 mm/s)32 by enlarging the 
device substantially with the sample processed in parallel by four large bead-filled chambers connected 
by a custom bifurcation network (3 mL/h, 1 mm/s).144 Secondly, blood was either prepared by Ficoll 
density gradient centrifugation32,65 or RosetteSep™ preparation,65 the latter of which uses cross-linked 




Figure 1.5 (A) CTCs labeled with magnetic nanoparticles pass over a µHall sensor and induce a voltage 
linearly proportional to number of MNPs. (B) Sample stream (pink) focused over 8 staggered µHall sensors 
that compensate for variable CTC positions. (C) Assembled µHall device.101 
 
be selectively removed by centrifugation.32 Likely due to limited fluidic shear forces, WBC impurities were 
abundant when the blood was prepared by Ficoll; where although >98% of a WBC cell line was cleared 
from the device,32 this still translates to impurities on the order of 100,000 WBCs/mL. In contrast, the 
RosetteSep™ front-end WBC removal increased purity substantially with <100 WBCs retained per sample, 
although the sample volume was not reported. CTC yields, however, were low (Table 1.1), being 
concordant with the CellSearch™ CTC Test (Figure 1.4)65 and similar to both the MagSweeper and iChip 
technologies. CTC loss may have occurred during WBC cross-linking and centrifugation. In spite of that, 
due to the arguably unparalleled simplicity in device fabrication and release of the CTC isolate, the Ephesia 
technology has been well poised for rapid commercialization and point-of-care application, the only 
exception being that manual blood pre-processing is necessary.  
1.4.6 Magnetically Labeled CTCs – Sensing Rather than Separating 
The µHall sensor is designed to detect rather than separate magnetically-labeled CTCs. When a 
labeled CTC flows past a µHall sensor (Figure 1.5A), super-paramagnetic anti-EpCAM nanoparticles 
generate a local magnetic field that causes the current flowing between two contact pads to shift closer 
towards one of two transverse contact pads. This generates a voltage signal that is proportional to the 
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strength of the CTC’s magnetic field and the distance between the detector and the magnetic CTC. The 
effect of CTC position on voltage signal was mitigated by three factors (Figure 1.5B): (i) sheathing flow 
channels compressed CTC position into the middle of a microchannel; (ii) chevron grooves created a 
convective flow pattern (similar in mechanism to the herringbone grooves discussed below) that moved 
CTCs close to the micropatterned detectors; and (iii) a set of eight µHall detectors staggered along the 
microchannel that were used to mathematically correct for slight variations in CTC position. Thereby, the 
voltage signal was linearly proportional to the number of magnetic nanoparticles and antigen 
expression.101 
Using the µHall sensor, Issadore, et al. demonstrated 91% clinical sensitivity in detecting CTCs 
from advanced ovarian cancer (Table 1.1), a substantial increase compared to the CellSearch™ CTC Test 
(25% sensitivity). However, this direct comparison was biased as the µHall assay added several Abs, 
including EGFR and HER2, in addition to anti-EpCAM for magnetic-labeling (Table 1.1). A significant benefit 
of this method, especially compared to fluorescence-based flow cytometry, is the low magnetic 
background as red blood cells are lysed before the assay is performed. This allowed a concentrated 
suspension of cells to be processed rapidly (~105 cells/s; 3.25 mL/h),101 but this may have complicated 
sorting the identified CTCs into a purified fraction without also obtaining a large number of contaminating 
WBCs. As CTC sorting was not demonstrated, the µHall sensor is limited to enumeration only. 
1.5 Microfluidic Technologies for Positive-Affinity CTC Selection 
1.5.1 Colliding CTCs with Ab-Coated Microposts 
The CTC Chip (Figure 1.6A) was the first microfluidic device for positive-affinity CTC selection and 




Figure 1.6 Microfluidic technologies for the affinity selection of CTCs. (A) Assembly of the silicon CTC chip, 
SEM of a pseudo-colored cancer cell isolated on the Ab-coated micropillars, and simulation of fluid velocity 
field through micropillars.44 (B) A schematic of the GEDI device that hydrodynamically induces a strong 
bias towards recovering cells >18 µm (blue dot) and minimizing WBC (yellow dot) interaction.56  (C) Picture 
a PDMS herringbone chip, which uses convective mixing to encourage CTCs to interact with Ab-coated 
surfaces.68 (D) A schematic of the silicon nanopillar chip, where a convective mixing chamber is attached 
to a silicon substrate that is etched to produce nanotexturing prior to Ab-functionalization.100 (E) Another 
nano-textured device, where standard polyurethane tubing is coated with naturally occurring halloysite 
nanotubes and adsorbed Abs and selectins.145 (F) The thermoplastic-based sinusoidal chip uses narrow, 
Ab-coated microchannels to isolate CTCs. CTC release enables off-chip enumeration and viability testing 
by impedance sensing and phenotyping in a microfluidic imaging module, which are combined in an 
integrated microfluidic system.146 
  
30 
enclosed with a PDMS substrate. Every third row of microposts was staggered to form a triangular array 
that encouraged the collision of CTCs with anti-EpCAM polyclonal Abs immobilized on the micropost 
surfaces. The device was tested against several cell lines and showed consistently high recovery (74-80%) 
regardless of the cell’s EpCAM expression (Table 1.1).44 In contrast, others have found that cell line 
recovery decreased along with decreasing antigen expression,65 which has been theoretically predicted 
by the Chang-Hammer model. This model describes a cell rolling along an Ab-coated surface and details 
that the probability of Ab-CTC binding and CTC recovery (𝑃𝑅) scales as:
147 
𝑃𝑅 = 1 − 1/𝑒
𝐶∞ 𝐿 𝑘𝑓
𝑉  (1.2) 
 Thus, recovery should decrease with the cell’s velocity (𝑉) and increase with the density of 
antigens on a cell’s surface (𝐶∞), the length of the rolling interaction (𝐿), and the forward binding constant 
(𝑘𝑓), which is a complex function of how often the Ab-antigen interactions occur and how probable a given 
binding event is considering the balance of binding kinetics with interaction time.147 As the CTC Chip’s 
recovery was independent of antigen expression, either rolling distances would need to be very long, 
which is unlikely as the micropillar design limits CTC-Ab interactions to ~75 µm per collision (one quarter 
of a pillar),28,87 or a reduced velocity would be needed to lengthen the CTC-Ab interactions. The latter 
explanation is more likely as the CTC Chip’s flow rate was limited to 1-2 mL/h (0.5-0.9 mm/s velocity), 
above which recovery dropped precipitously.44 
Clinical samples were tested for several cancers (Table 1.1) with median CTC yields that were 
much higher than those reported for the CellSearch™ CTC Test, which was a very promising result for 
microfluidic-based CTC analysis. Of note, patients with localized prostate cancer had higher CTC counts 
than for metastatic prostate cancer,44 indicating that the screening for early cancer detection may be 
feasible.17 Relative to other micropillar technologies,47,56 the CTC Chip had a relatively low purity of only 
34 ± 8% (~233 WBCs/mL).44 In microfluidics, two primary factors can cause such nonspecific WBC 
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retention. The low fluid shear stress during blood infusion (maximally 0.4-0.8 dynes/cm2), which was 
limited by recovery,44 may have been too weak to disrupt nonspecific interactions; or more likely, low 
shear regions behind the micropillars (Figure 1.6A), which had flow velocities of <0.05 mm/s due to the 
equilateral arrangement,44 could have acted as stagnate zones and reservoirs for the WBCs.28,87 
A second micropillar device, termed the geometrically enhanced differential immunocapture 
(GEDI) device56 (Figure 1.6B), used 5,000 silicon micropillars of similar dimensions to the CTC Chip (80 µm 
diameter, 100 µm spacing). While the device was operated at lower shear stress (~0.1 dynes/cm2)79 than 
the CTC chip, the GEDI device achieved very high purities (62 ± 2%, ~10 leukocytes/mL) by staggering each 
row of microposts in a manner that developed hydrodynamic lift forces, which strongly encouraged pillar 
collisions for cells >15-18 µm and discouraged interactions with cells <15-18 µm.47,56 The size threshold 
for the GEDI technology is arguable large and a drawback for the GEDI technology, because CTC below 
this targeted size range, which have been noted in prostate cancer,99 were recovered with very low 
efficiency (~30% recovery for 13 ± 3 µm BxPC-3 cells; ~60-70% for cells >15 µm ).47  
Early clinical research with the GEDI device used the highly specific J591 mAb to target PSMA(+) 
CTCs for prostate cancer,56,79 and the authors demonstrated a 2-400 fold increase in CTC recoveries 
relative to the CellSearch™ CTC Test79 but with an undisclosed clinical sensitivity.56,79 It should be noted 
that PSMA(+) CTCs had variable EpCAM expression with only ~60% of CTCs being PSMA(+)/EpCAM(+);79 
after our adjustment to exclude PSMA(+)/EpCAM(-) CTCs based on these results, the GEDI device’s yields 
would still be approximately 10-fold greater than the CellSearch™ CTC Test. More recently, EpCAM(+) 
CTCs have been isolated from 33% of patients with pre-cancerous pancreatic lesions, which could be used 
to identify patients at risk for the development of PDAC.95 Also, Abs targeting both EpCAM and 
hypoglycosylated mucin 1 (hMUC1),47 also an epithelial CTC marker,148 were immobilized within the GEDI 
device, but expression of the markers was correlative in pancreatic cancer cell lines; there was no 
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improvement in cell line recovery;47 and there was too limited a clinical data set to draw substantial 
conclusions regarding differences in CTC phenotype by including the hMUC1 target. 
1.5.2 Chaotic Mixing to Propel CTCs towards Surfaces, and Nano-Texturing of Ab-Coated Surfaces 
In 2002, Stroock, et al. reported a microfluidic design with staggered herringbone grooves 
entrenched into a larger microchannel. These grooves created low resistance fluidic conduits along the 
microchannel’s axial direction,149 creating lateral movement of the fluid that generated microvortices and 
convective, chaotic mixing. A version of this geometry, the herringbone CTC Chip (Figure 1.6C), was 
utilized by Stott, et al. to disrupt CTC trajectories and enhance the encounter rate of CTCs with the Ab-
coated surfaces.68 Unlike the group’s previous CTC Chip, which were etched directly into silicon, these 
herringbone devices were repeatedly replicated from a silicon template into poly(dimethylsiloxane) 
(PDMS), a silicon-based polymer. The herringbone device exhibited >90% recovery of PC3 cells (moderate 
EpCAM expression), which was a ~26% improvement from the CTC Chip at approximately the same 
throughput. It is somewhat unclear why later reports indicated low (~3%) recovery of MDA-MB-231 cells 
(very low expression)35 that was not observed for the CTC Chip44 or for the iChip.86 The herringbone device 
improved purity to 14% (~5,600 WBCs/mL) from 9% (~9,000 WBCs/mL) for the CTC Chip,68 although the 
latter background is almost 40-fold greater than previously reports.44 This high level of background cells 
has been largely conserved throughout the herringbone device’s use96,97 and could potentially be due to 
low velocity and low shear stagnate regions within the crevices of the herringbone grooves.74 The 
herringbone chip has been used in many clinical demonstrations (Table 1.1) with high median CTC counts, 
especially for prostate cancer, and clinical sensitivities ranging between 56% and 93%.27,35,68,80,96,97,109 
In another demonstration, Wang, et al.100 attached a similar PDMS chaotic mixer to a nano-
textured silicon surface rather than a glass surface (Figure 1.6D). The nano-texturing process used 
chemically wet etching (ionic Ag HF solution)150 to produce 12-15 µm long silicon nanowires. The entire 
device, both the PDMS chaotic mixer and nano-textured silicon surface, was then functionalized with anti-
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EpCAM Abs. Nanotexturing has been used to improve the adhesion of microvilli and invadopodia of CTCs 
to surfaces,151,152 which was been shown to steadily increase over 45 min in a static chamber.153 Relative 
to a flat surface, such as those used in the herringbone device, the nano-textured surfaces produced a 
~70% increase in cell line recovery and >95% absolute recovery, even for cell lines with very low EpCAM 
expression.100,154 However, when testing patients with prostate cancer, clinical CTC yields were low for 
this technology with a median of 1 CTC/mL and similar performance to the CellSearch™ CTC Test was 
observed.100 Unfortunately, thresholds for positivity were not established, so clinical sensitivities could 
not be reported. Purity was not assessed for the silicon nanowire device,155 but a similar study, which used 
anti-CD146 Abs and electrospun nanofibers, showed high nonspecific effects when conducting controls 
(~15% recovery of cell lines when no Ab was immobilized; ~8% recovery of a WBC cell line),154 suggesting 
that the nano-textured chaotic mixer’s WBC background is high. 
Hughes, et al.102,156 also employed nanotexturing for CTC isolation but used halloysite nanotubes 
(Figure 1.6E), an inexpensive aluminosilicate mineral that naturally forms hollow tubular structures (40-
200 nm in diameter, ~1 µm length). The use of a naturally occurring material is appealing for simplified, 
cost-effective fabrication compared to silicon chemical etching. Poly(urethane) microtubes (300 µm ID, 
50 cm length) were dynamically coated with poly(L-lysine), generating a positively-charged surface that 
could electrostatically bind the negatively-charged halloysite nanotubes. This coating resulted in a 
heterogeneous and incomplete nano-texturing (~50% of the microtube surface). Protein G, which binds 
the Fc region of Abs and is negatively-charged at physiological pH, was then incubated,102,156 
electrostatically binding to poly(L-lysine) and/or adsorbing to the nanotubes in spite of electrostatic 
repulsion. Anti-EpCAM (or anti-PSMA) Abs, along with ~10% E-selectin-IgG chimera, were then bound to 
the surface by protein G.  
Selectins are naturally expressed on inflamed endothelium, and it is believed to cause CTCs, and 
WBCs to a lesser degree, to transiently adhere during rolling. Cell interactions with selectins effectively 
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reduces cell velocity and lengthens cell-Ab interactions to improve recovery (see Eq. (1.1)), which permits 
higher throughput (4.8 mL/h) compared to Abs alone.102,156 For example, the incorporation of selectins 
improved the recovery (to 50%) for a leukemia cell line. However, selectins are highly dependent on the 
presence of Ca2+ ions, which would be chelated by the use of EDTA or citrate anti-coagulants. This method 
then requires the use of heparin blood collection tubes or, as the authors demonstrated, Ficoll preparation 
and resuspension in Ca2+ supplemented PBS,156 which is a process that requires user intervention and is 
known to incur cell loss.85,86 Further, additional salts can have a significant effect on Ab-antigen binding 
affinity,157 which could create an interesting interplay where selectins are activated by Ca2+ to elongate a 
CTC’s interaction with Abs that have reduced affinity. 
By infusing samples at 4.8 mL/h (4.5 dynes/cm2) through nano-textured and Ab-functionalized 
microtubes, a high CTC purity (50-80%; ~20 WBCs/mL) was achieved. While nano-texturing was noted to 
improve purity, the coating did not significantly improve CTC recoveries from a small patient cohort, 
although all CTC yields were generally higher than the CellSearch™ CTC Test.102 It should be noted that 
CTC identification differed from other reports; CTCs were not immediately immunophenotyped with the 
traditional CK/CD45/DAPI cocktail, presumably as imaging the 50 cm long microtube was difficult. Rather, 
CTCs were released into a culture dish using proteolytic enzymes, which digested the Ab-coated surface), 
and identified by EpCAM (or PSMA) staining 5 days later,102,156 although CK expression should also be 
confirmed. Such proteolytic release methods158 preclude immunostaining/fixing of the CTCs prior to 
release30 (discussed below) and then require manual handling in most cases. In summary, the halloysite 
nanotube technology is simple to fabricate, cost-effective, and yields high purity, but extensive sample 
handling and unclear long-term stability/activity of the Ab coating, which is based on electrostatic 
interactions, may hamper commercial scaling of the technology. 
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1.5.3 Rolling CTCs along Sinusoidal Microchannels at High Shear 
The sinusoidal technology (Figure 1.6F; Biofluidica, Inc.) uses Ab-coated microchannels with a 
narrow width (25 µm) that traverse in a sinusoidal pattern.3,38,49,50,66,67,144-147 As detailed in Chapter 2, the 
channel width is only slightly (~5-10 µm) larger than CTCs to encourage CTC-Ab interactions but is large 
enough to clear WBCs, and the sinusoidal pattern has been estimated to provide small centrifugal forces 
to push CTCs towards the Ab-coated surfaces.87 In comparison to collisions with discrete micropillars, 
where low velocities and low shear stress are necessary to prolong an otherwise limited CTC-Ab 
interaction,44 the continuous design of the sinusoidal microchannels affords uninterrupted CTC 
rolling.28,87,147 This enables the sinusoidal technology to operate at high (14 dynes/cm2) shear stress,75 
which is orders of magnitude higher than in other devices,44 and has generated the highest purities 
reported to date (~90%, ~3 ± 3 WBCs/mL).28,75,76 In other devices, high purity has also been generated at 
high shear stress (~30 WBCs/mL at 1.25 dynes/cm2 in a simple microfluidic chamber) but typically at the 
cost of reduced recovery (14%).31 Likely due to CTCs’ long rolling distances in the sinusoidal device,28,87 
high (>80%) recovery of CTC cell lines with moderate antigen expression was preserved.3,38,50,66,147 High 
recovery has also been demonstrated for clinical CTCs in patient samples (79-87% recovery) using the self-
referencing method.28  
The sinusoidal technology has been used in several clinical studies,23,28,30,75,76 and in Chapter 5, we 
present the first microfluidic-based clinical study to detect minimal residual disease (MRD) in patients 
with acute myeloid leukemia (AML).23 Witek, et al. recently selected CTCs by targeting both EpCAM and 
FAPα,28 a mesenchymal surface protein28,29,159,160 that showed high specificity and orthogonality to the 
EpCAM marker (90% of FAPα CTCs did not express EpCAM). By targeting both markers, the technology 
achieved excellent clinical sensitivity (100% for all tested cancers except for breast cancer, 80%; Table 
1.1). These results are very promising for both the technology and the FAPα mesenchymal marker; but 
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the cohort size was relatively small,28 and the clinical relevance of FAPα(+) CTCs has yet to be conclusively 
demonstrated. 
Recovery in the sinusoidal device is dependent on cell size due to several factors (Chapter 2) that 
reduce CTC-Ab interactions for small cells;87 the AML KG-1 cell line (12-15 µm, very high antigen 
expression) was selected with 65% recovery,30 and T cell recoveries (7-8 µm, medium expression) were 
only 10%.33 While this was not prohibitive for monitoring MRD in AML patients23 or for stroke diagnostics 
due to higher cell abundance,33 the technology is likely be biased with higher recoveries for large CTCs,58-
61 a limitation that is likely to be shared by many positive-affinity microfluidic devices. Also, it has been 
proposed that lower shear stress is a gentler recovery process necessary to maintain CTC viability.44 While 
the sinusoidal technology’s applied shear stress is within the range of physiological shear stress in 
arteries,161 >85% CTC viability has been demonstrated,30 and median CTC counts are also high (Table 1.1), 
it is possible that CTCs that are undergoing necrosis or apoptosis may succumb to shear stress and are 
broken apart, thereby being not detected. While this is somewhat of a limitation, the end goal of CTC 
analysis is to detect the key effectors of metastasis, which are not likely to be necrotic or apoptotic. 
Several reports have suggested the ability to scale up throughput by inserting more sinusoidal 
channels in parallel. Whereas the Ephesia technology used a compact bifurcation network to parallelize 
blood delivery, the sinusoidal technology uses a Z-configuration network, where blood is addressed using 
a straight inlet and outlet channels poised perpendicular to 50 sinusoidal channels, in a very compact size. 
To place 10 times more channels in parallel (15 mL/h throughput), the inlet/outlet channels are simply 








Table 1.2 The properties of materials that are generally used to manufacture CTC selection devices, 





Silicon PDMS COC PMMA PC 
Manufacturing 
Fabrication method for 
master mold 
- Lithography Micromilling or LiGA 
162,163 Material for master - 
Silicon or 
photoresist 
Brass or nickel 
Time for device 
replication 
Hours Minutes 
Minutes (hot embossing) to 
seconds (injection molding) 
Ab attachment 
Method for chemical 
modification 
Alkoxysilane UV/ozone or O2 plasma 27,28 






Very low Low Low Very high 34,35 
Biocompatibility 
Cytotoxicity 














- 20% 0% 20% 0% 
CO2 permeability* - 3489 1.77 2.33 22.23 
165-170
 
O2 permeability* - 695 0.765 0.0653 2.96 
† PDMS [poly(dimethylsiloxane)]; COC [cyclic olefin copolymer]; PMMA [poly(methyl methacrylate)]; PC [poly(carbonate)]. 
‡ Results were for 7-ethoxycoumarin, and similar results were found for testosterone. 
* Permeability units are (𝑐𝑚3 ∙ 𝑐𝑚)/(𝑐𝑚2 ∙ 𝑠 ∙ 𝑃𝑎), and values are scaled down by 1013. 
 
impart variable CTC recovery and purity in a single device.76 A method has been proposed in Chapter 2 
to correct this non-uniformity88 but has only been described numerically and has yet to be empirically 
validated. 
1.5.4 Mass Production of Affinity-Based Microfluidic Devices – Thermoplastics for CTC Analysis 
The sinusoidal device is unique in that it is fabricated in thermoplastic materials so as to enable 
mass production methods such as injection molding,146 which is far superior to lithography-based 
fabrication in silicon as well as casting PDMS devices for its high production rate and low cost per 







Table 1.2, which shows that thermoplastic materials, particularly cyclic olefin copolymer (COC), 
are well suited for Ab attachment and fluorescence imaging.75 While thermoplastics aid in the 
commercialization of microfluidic technologies,32,146 factors such as microstructure design constraints163 
and Ab immobilization methods75 differ from other lithography-based materials, which would require the 
reproduction of previous results if transitioning from a silicon or PDMS substrate to thermoplastics to take 
advantage of their mass production capabilities.  
For example, the majority of reports using silicon or PDMS devices use a multi-step Ab 
immobilization process, where an O2 plasma-modified surface (silanol groups) are reacted with a series of 
tri-alkoxysilane-to-sulfhydryl and maleimide-to-succinimide ester linkers that can be then reacted with a 
myriad of primary amine-containing moieties (including Abs and DNA linkers).44,56,68,100 In comparison, 
Soper, et al. developed methods for Ab immobilization in thermoplastic-based microfluidics that maximize 
Ab loading for efficient CTC recovery and that are commercially scalable are generally simpler.171 This 
process involves UV/ozone irradiation to oxidize thermoplastic surfaces, forming carboxylic acid groups 
that activated to form the succinimide ester using standard EDC/NHS coupling reactions and then reacting 
the surface with primary amine-containing Abs28,75,158,172 and DNA linkers.30,171 However, the efficiency of 
activating high aspect ratio microchannels by UV/ozone irradiation and immobilizing mAbs was not well 
characterized, especially with respect to the choice of polymer substrate, the microchannel dimensions, 
and the thermal fusion bonding process that is used to assemble and seal devices. Thus, we conducted a 
thorough study to this end in Chapter 3, where optimization of these processes led to improved CTC 
recovery. 
1.5.5 In Vivo, Affinity-Based CTC Collection 
The in vitro measurements discussed throughout this review contrast substantially with the in 
vivo CTC isolation strategy by the CellCollector® (Figure 1.7, Gilupi GmbH), a medical guidewire that is 
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coated with a 2 µm layer of gold and a poly(carboxylate) hydrogel, which is then covalently reacted with 
 
 
Figure 1.7 (A) The CellCollector® guidewire is inserted into a patient’s cubital vein for in vivo CTC recovery. 
(B) Functionalization of the gold-coated guidewire with a hydrogel and anti-EpCAM Abs.173 
 
anti-EpCAM Abs via EDC/NHS coupling. The guidewire is inserted into the cubital vein of a patient with 
similar discomfort to a blood draw and no medical complications reported thus far; 1,000 to 1,500 mL of 
blood passes over the wire for 30 min; the wire is then removed and washed by incubating in buffer; and 
CTCs bound to the wire are immunostained and imaged.173 
It is difficult to assess the analytical figures-of-merit for this technology because cell line recovery 
and purity have not been reported and the exact volume of blood passing over the wire is not metered 
(CTC counts are not normalized); only the CTC counts in clinical samples have been reported.173 Gilupi 
GmbH has conducted direct comparisons with the CellSearch™ CTC Test for patients with localized and 
metastatic prostate cancer and demonstrated increased clinical sensitivity for the CellCollector® (53% and 
78%, respectively) versus the CellSearch™ CTC Test (12%, 61%) as well as a prognostic threshold at 5 CTCs 
for a study of prostate cancer patients.174 However, a median recovery of only 3 CTCs175 per 1,000-1,500 
mL indicates that the intravenous recovery process is extremely inefficient using the guidewire and attests 
to the accuracy with which microfluidics can reliably manipulate hemodynamics for efficient CTC recovery. 
Thus, the current CellCollector® technology is similar to the CellSearch™ system’s prognostic strategy with 
both benefits and pitfalls in mind, which have been discussed above. 
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1.6 Microfluidic Catch and Release  
Assays that use magnetic beads as the solid support for the affinity selection Abs have the 
advantage that the recovered CTCs can be released into a purified solution by simply removing the 
magnetic field.25,32,103 In contrast, positive-affinity microfluidic devices typically attach Abs directly to the 
microfluidic surfaces, and the CTC-Ab-surface complex must be selectively broken in order to release the 
purified CTCs off-chip. This “catch and release” strategy has not been a trivial feat in bioassay design and 
has been pursued to enable several off-chip analyses, such as CTC enumeration and viability testing by 
label-less impedance detection146 or flow cytometry,30 CTC culturing,30,35,42,102,176 xenograft 
transplantation,42 FISH cytogenetic analysis,30,68 single cell molecular profiling,35,37 and automated 
microscopy that reduces the time and effort required for phenotyping23 (~6-8 h of microscopy time has 
been reported for on-chip analysis).23,68 
Almost all literature regarding microfluidic-based CTC recovery and release has emerged since 
2011. Only a few of the detailed assays fulfill all of the ideal requirements: (i) achieves or maintains high 
specificity and recovery of CTCs; (ii) high release efficiency; (iii) high viability (i.e., minimally invasive to 
the isolated CTCs); (iv) is compatible with a broad range of off-chip analyses; and (v) is compatible with 
standard clinical practices such as the use of all blood anti-coagulants. An additional metric is that the 
assay should involve simple workflow and instrumental requirements. For example, laser microdissection 
systems have been used to release CTCs by cutting out a section of a disassembled device,154,177,178 but the 
technique is laborious, expensive, and results in nonviable CTCs.154,176 
In general, three avenues have been pursed to selectively release CTCs: enzymatic digestion of 
the affinity agent; linkers between the affinity agent and microfluidic surface that can be specifically 
cleaved; and polymeric coatings that can be degraded or externally manipulated.  
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1.6.1 Digest the Affinity Agent 
Adams, et al. proteolytically digested the entire Ab-antigen complex by trypsinization (Figure 
1.8A), which is a similar method to standard tissue culture practices. The authors were able to release 
~95% of cells with no evidence of cell damage.158 Sheng, et al. using the herringbone CTC chip and Hughes, 
et al. using the halloysite nanotube technology employed similar strategies and achieved high viability of 
the released CTCs74 and cultured viable patient-derived CTCs for 5 days,102 respectively. However, CTC 
release via trypsinization has not translated well to the silicon nanowire technology with poor release 
efficiency ranging from 10%176 to 60% with <10% viability.179 It is difficult to pinpoint the origin of these 
conflicting results without experimental details,176,179 but we speculate that stronger adherence of CTCs 
to the nano-textured substrate153 may require unusually long or harsh trypsinization conditions. It is 
important to note that trypsinization has limitations. Proteolytic digestion can damage fluorescent Abs, 
which precludes on-chip immunostaining that mitigates CTC loss in off-chip processing steps (e.g., 
centrifugation), and the method is not compatible with formaldehyde fixation, which is commonly used 
for DAPI staining and/or to stabilize CTCs for off-chip imaging, because trypsin cannot digest cross-linked 
proteins.30,76 
Alternatively, when DNA aptamers have been used in place of Abs for affinity selection, 
exonucleases can be used to digest the aptamer and release CTCs (Figure 1.8B). Shen, et al. functionalized 
a streptavidin-coated, silicon nanowire device with biotinylated aptamers that were generated by 
systematic evolution of ligands by exponential enrichment (SELEX) against the A549 non-small cell lung 
cancer (NSCLC) cell line. These cells were isolated from blood with 70-80% recovery then released by 
exonuclease digestion with ~85% efficiency and ~80% viability. The release process also reduced WBC 




Figure 1.8 Strategies to release CTCs after microfluidic affinity selection. (A) Proteolytic digestion of Ab-
antigen complex.158 (B) Exonuclease digestion of DNA aptamers.176 (C) Uracil-specific enzymatic digestion 
of oligonucleotide linkers that anchor Abs to surface, which is presented in Chapter 4.30 (D) Thermally 
responsive polymer that internalizes the attached Abs when cooled.179 (E) Electrostatic assembly of nano-
films containing biotinylated-alginate that can be enzymatically digested.73 (F) Gelatin nano-films 
assembled by avidin cross-linking that can be thermally melted or locally dissociated by mechanically 




background (300-1,500 WBCs/mL) by a second round of selection and release,176 a strategy proposed by 
others as well.69 However, multiplicative inefficiencies in recovery and release are inevitable and reduce 
CTC recovery.176  
In a separate aptamer demonstration, Zhao, et al.31 used the herringbone technology and a 
process called rolling circle amplification, where a polymerase continuously replicates a single-stranded 
circular DNA template. This process generated a multivalent aptamer coating on the herringbone surface 
that was comprised of long (10-100 µm) DNA molecules with repeating aptamer units targeting protein 
tyrosine kinase 7 (PKT7), a useful antigen for monitoring ~30% of AML patients. The multivalent surface 
isolated a leukemic cell line from blood with improved purity (38%, ~1000 WBCs/mL) and recovery (~60%) 
relative to an Ab-modified herringbone device (8% purity, ~2300 WBCs/mL; ~20% recovery). However, a 
10 min infusion of concentrated exonuclease released only 68% of cells and with reduced (66%) viability,31 
potentially a byproduct of the aptamer’s extensive valency and/or short exonuclease incubation. 
1.6.2 Polymer Coatings for Severing the Entire Binding Complex from the Modified Microfluidic Surface 
Hou, et al. grafted silicon nanowire substrates with thermally-responsive poly(N-
isopropylacrylamide) (PNIPAm) polymer brushes (Figure 1.8D).179 This hydrogel has seen extensive use in 
the Cell Sheet culturing technology, where the polymer remains hydrophobic for cell attachment at 37°C 
but rearranges and becomes hydrophilic when cooled to 4°C, thereby releasing a sheet of cultured cells.180 
The authors biotinylated the polymer and then functionalized the hydrophobic hydrogel179 with 
biotinylated anti-EpCAM Abs via an avidin bridge. The recovery of MCF-7 cells was assessed in a static 
chamber incubated at 37 °C.179 Both recovery and specificity were similar to previous reports using a 
silicon nanowire substrate151 with the additional benefit that ~95% of 90% viable cells could be released 
by cooling the substrate to 4°C, inducing the polymer’s hydrophilic switch and internalizing the anti-
EpCAM Abs. However, the authors did note a ~20-25% decrease in recovery when MCF-7 cells were spiked 
  
44 
in blood serum rather than buffer,179 which may suggest an underlying non-specific interaction between 
serum proteins with the PNIPAm polymer that interfere with cell-Ab binding. 
In a micropillar device, Hatch, et al. constructed an alginate hydrogel by cross-linking (via EDC/NHS 
coupling) carboxylic acid-containing alginate polymer with four-armed, amine-terminated PEG cross-
linking molecules and anti-CD34 Abs, which targeted endothelial progenitor cells that are useful for tissue 
engineering. As the entire hydrogel was negatively-charged, divalent cations were critical to 
electrostatically stabilize the surface during cell recovery; EDTA-chelation was then used to destabilize the 
coating and release the isolated cells. While release efficiency was not assessed, recovery and viability 
were ~33% and 90%, respectively. Nonspecific cell adhesion to the alginate hydrogel (74% purity, ~8,000-
9,000 WBCs/mL) was a significant limitation of the method,181 which was observed previously for another 
alginate hydrogel.182 Further, the chelation release mechanism precludes the use of common EDTA and 
citrate anti-coagulants for blood draws, requiring heparin blood collection tubes only. A different 
biotinylated alginate hydrogel by Shah, et al. avoided this latter constraint by photo-cross-linking the 
polymer. CTCs were isolated by anti-EpCAM selection with similar recovery as standard Ab-immobilization 
methods, but nonspecific cell adhesion led to a purity of 10%183 that was similar to results of Hatch, et 
al.181 Enzymatic digestion of the hydrogel with alginate lyase released cells with 99% efficiency. However, 
the photo-polymerization process was only conducted on a flat surface,183 likely because it would be 
difficult to conduct in-chip photo-polymerization without clogging the device with polymer.  
A method that avoids channel clogging was developed by the Stott group in two reports using the 
herringbone technology35,73 that deposited polymer coatings in a layer-by-layer approach. A bulk polymer 
solution was infused into the herringbone microfluidic device, and a nano-layer film of polymer was 
stabilized on the surface while the bulk polymer solution was washed away without the risk of clogging. 
Li and coworkers used this technique to coat ten alternating layers of negatively charged biotinylated 
alginate and cationic, amine-containing polymers (Figure 1.8E) on top of an O2 plasma-modified, silanol 
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surface.73 With a final functionalization of streptavidin and biotinylated anti-EpCAM Abs, PC3 prostate 
cancer cells were isolated with 79% recovery and 53% purity (~3,500 WBCs/mL,73 on the order of previous 
reports),68 and CTCs were recovered from lung cancer patients at 3-5 CTCs/mL.73 But unlike the DNA linker 
assay, which showed efficient release incubating a small amount of enzyme,30 the authors found that a 
persistent infusion of alginate lyase (30 min at 2.5 mL/h) was necessary to efficiently (95%) release CTCs. 
Thus, the recovered CTCs were diluted in 1.25 mL solution,73 which would likely require additional manual 
handling (e.g., centrifugation) for many downstream applications. 
In a second layer-by-layer demonstration by Reátegui, et al., four layers of biotinylated gelatin 
proteins were stabilized by alternating layers of streptavidin (Figure 1.8F) and were capped with 
biotinylated anti-EpCAM Abs. Unlike the previous layer-by-layer method, PC3 recovery was only 20% with 
the coating alone, and a final layer of streptavidin-coated, polystyrene nanoparticles was necessary to 
achieve >90% recovery. Clinical recoveries were also demonstrated using a mixture of EpCAM, EGFR, and 
HER2 Abs (Table 1.1). Notably, the nano-coating reduced non-specific cell adhesion from ~3,500 WBCs/mL 
to ~1,300 WBCs/mL,35 although this background remains high compared to other microfluidic 
technologies.18,28,47,56,75,76 Release was enabled by two methods. The gelatin coating was melted at 37°C 
for 10 min to release all cells (88% viability, 93% efficiency)35 within an unspecified elution volume. A 
second release technique used an 80 µm, vibrating microtip to depress on the PDMS substrate, which 
produced an inertial force throughout the microfluidic channel but only within 145-215 µm of the 
microtip. This technique was utilized to locally dissociated cells from the substrate and was useful to 
exclude the majority of contaminant WBCs from further analysis, such as Sanger sequencing of individual 
CTCs after PCR-amplification;35 the potential pitfalls regarding amplification errors at the single cell level 
have been noted elsewhere.37 As the selective release method required a modified fluorescence 




Each assay for releasing CTCs in affinity-based microfluidic devices has some shortcoming, ranging 
from complex instrumentation to substantial additions in assay workflow. Given this literature survey, 
there was a need to develop an alternative strategy that is effective, simple, and offers flexibility in 
downstream application. Thus, in Chapter 4, we develop the use of oligonucleotide linkers for Ab 
immobilization that can be enzymatically cleaved for the controlled release of viable CTCs. 
1.7 Discriminating CTCs by Physical Properties 
1.7.1 CTC Filtration – Size and Deformability 
The physical separation of CTCs by size discrimination (Figure 1.9A) is a technique that dates back 
to the 1960s.184,185 Early methods termed isolation by size of tumor cells (ISET; Rarecells, Inc.45,177,178,186-193 
as well as ScreenCell)194 filtered blood that was subjected to red blood cell lysis and fixation (to eliminate 
CTC deformability and improve recovery)177 through poly(carbonate) (PC) membranes, which were track-
etched (i.e., irradiated with charged particles) to produce 8 µm pores.189,190 Because the track etching 
process is random, porosity of the PC membranes is kept low (<2%)195 to avoid cell loss through fused 
pores; unfortunately, pore fusion occurs even at low porosity. The common problem associated with 
filtration are low CTC recoveries (~50%) and clogging of the filters as the pores become occupied by the 
highly abundant WBCs.191,196 To mitigate the issue of filter clogging, the ISET technology uses 10 filters to 
process 10 mL of lysed blood (diluted 10 fold), each processing only 1 mL of sample.186,192,193 In several 
side-by-side comparisons with the CellSearch™ CTC Test, the ISET technology recovered similar CTC levels 





Figure 1.9 (A) Cell abundance versus cell diameter of blood cells26 and CTCs,83 and common size ranges 
for CTC discrimination.115,195 WBC sizes can be smaller in free solution than when plated for 
microscopy.62,63 (B) (i) A CK(+)/DAPI(+) CTC amongst CD45(+)/DAPI(+) WBCs on a silicon filter 
membrane.197 (ii) SEM of a fixed CTC on a parylene C membrane.198 (iii) Picture of a clogged filter after 
processing 7.5 mL of blood.199 (iv) Schematic of a 3D parylene C membrane.195 (v,vi) Images of CTCs 
trapped in a microfluidic filtration device.200 (C) The Cluster-Chip, a microfluidic chip for filtering CTC 
micro-emboli.57 (D) The Vortex Technology hydrodynamically traps large CTCs in side channels at high flow 
rates.63 (E) Dean Flow Fractionation, a hydrodynamic centrifugation method for size-dependent 
separation of CTCs.115 (F) Dielectrophoretic crossover frequencies for cancer cell lines, leukemia cell lines, 
and WBCs.201 (inset) Working principle of DEP, showing field lines for positive and negative DEP 
experienced by CTCs and WBCs at 65 kHz, respectively.202 (G) Schematic of the ApoStream™ technology 
for DEP-flow field fractionation of CTCs.69 
  
48 
Modern filter membranes or microfluidic architectures that are similar to pores have utilized 
lithographic methods to precisely pattern pores into silicon197,203 and polymers such as parylene-
C,117,195,198 poly(ethylene glycol diacrylate) (PEGDA),118 and PDMS.200 As long as pores can be reliably 
fabricated and the membrane is mechanically stable and biocompatible, the membrane’s material is of 
little consequence for CTC filtration. However, the workflow and cost for filter fabrication directly 





Table 1.2) and has ranged from extremely expensive palladium microfilters204 to multi-stage deep 
reactive ion etching for each set of silicon or parylene-C microfilters195,197 and replication of a 
lithographically-patterned master by PEGDA photo-polymerization118 or PDMS casting,200 the latter 
methods being more amenable to mass production. 
    Filtration methods achieve much higher throughput than positive affinity methods (Table 1.1), 
being limited only by the fluidic force that can be imposed on a trapped CTC without the CTC deforming 
and passing through the pore118 or the CTC breaking apart entirely.195 For example, Lin and coworkers 
used a parylene-C microfilter117 (16,000 pores, 8 µm diameter; Figure 1.9B(ii))198 to process 7.5 mL of 
formalin-fixed blood in only 2 min (see Table 1.1 for clinical results, which showed a 45% increase in 
clinical sensitivity compared to paired CellSearch™ CTC Tests).117 Fixation was critical because under these 
fluidic pressures, live CTC cell lines were shredded and lost entirely.195 
To reduce the tension and stress on the trapped CTCs that leads to cell lysis, a 3D parylene-C 
microfilter was designed (Figure 1.9B(iv)). The 3D filter was fabricated by multiple deep reactive ion 
etching (DRIE) processes and was composed of two surfaces patterned with 7,000 pores (8-9 µm 
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diameter) that were offset, creating a fluidic conduit through the 6.5 µm spacing between the layers. A 
CTC that passed through the top pore then rested on the bottom surface, which physically supported the 
cell and reduced mechanical tension. Smaller and/or more deformable cells squeezed through the 6.5 µm 
gap between the layers to escape the filter. Unfixed MCF-7 cells could be recovered (~86%) from 1 mL 
blood (diluted 10 fold) in 3-5 min, but a substantial number of leukocytes (~4,500-11,000/mL) were also 
retained, causing the filter to clog if more than 1 mL blood was processed195 (an example of which is shown 
in Figure 1.9B(iii)).199 While filtration can process samples rapidly, the maximum blood volume that can 
be processed is limited by contaminating WBCs plugging the available pores. 
In contrast, a silicon-based membrane (Figure 1.9B(i)) with 100,000 pores (10 µm diameter) per 
device recovered ~80% of live MCF-7 cells from 1 mL blood (diluted 2 fold) but without any 3D pore 
structuring.197 The technology’s ability to isolate unfixed cells may be attributed to the high number of 
pores, a large proportion of which likely remain open as a significantly lower number of WBCs (~200-
6,000/mL) were retained.197 The open fluidic paths likely reduced fluidic pressure on trapped cells and 
prevented cell lysis. However, more deformable cell lines should be tested with these relatively large 10 
µm pores to ensure these results are reproducible across CTC types.  
Kim, et al. fabricated a system of micropillars that were “hollowed” with an internal, large open 
chamber that was connected on either side with two sequential 8 µm channel gaps, i.e., 8 µm “pores”. 
CTCs passed through the first pore and became trapped in the chamber, where fluidic stress was reduced 
by 23% at the second gap and reduced the probability that CTCs escape. The authors found that ~85% of 
un-fixed MCF-7 cells (17 µm diameter) easily squeezed through both 8 µm pore structures,203 which is 
surprising given retention of live MCF-7 cells using 10 µm pores.197 In order to retain these cells in the 
micropillar system, Kim, et al. labeled the MCF-7 cells with 3 µm anti-EpCAM beads to increase their 
diameter to 23 µm, which provided 92% recovery. This method was designed to improve recovery and 
purity by selectively amplifying the size of CTCs, but leukocytes still remained (~350/mL) outside the 
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micropillars203 where shear stress was likely too weak to disrupt nonspecific interactions. Further, the 
method appears to require very high EpCAM expression to reliably amplify CTC size. 
Common to the above filtration technologies, low purity of the CTC isolate has been the most 
persistent obstacle. Yet one filtration method detailed in 2009205 and 2010200 by Tan, et al. achieved 
purities that rival the MagSweeper,72 GEDI,47,56 and sinusoidal28,75,76 positive-affinity technologies. By 
PDMS casting, the authors fabricated a 20 µm deep microfluidic channel filled with cell traps: sets of three 
3-4 µm posts spaced by 5 µm in an arc shape (Figure 1.9B(v,vi)). Blood samples (diluted 3 fold) from five 
cancer patients were processed, and the larger CTCs were trapped (10-42 CTCs/mL; median 18). WBCs 
were effectively cleared through the traps, and extremely high purities were achieved (89%, 2-6 
leukocytes/mL). Unfortunately, further reports to expand on this small cohort have not been published. 
For example, it would be advantageous to release clinical CTCs for subsequent molecular analysis by 
reversing the flow direction, as the authors have demonstrated for cell lines.205 Also, some technical 
aspects remain to be resolved. (i) Due to the microchannel’s small dimensions, the technology has low 
sample throughput (0.23 mL/h)205 that required >8 h to process each diluted 2 mL blood sample, although 
this could be resolved in a similar manner as developed by the Ephesia technology.65 (ii) The recovery of 
cell lines spiked into blood or clinical CTCs should be determined as well to add to the recoveries from 
phosphate buffer (~80% recovery).200,205 
Lastly, a filtration-based method for specifically isolating micro-emboli or clusters of CTCs (defined 
as ≥2 joined CTCs) was developed by Sarioglu and coworkers (Cluster-Chip; Figure 1.9C). CTC clusters have 
been associated with increased metastatic potential and poor patient prognosis but are even rarer than 
single CTCs (~0.1-0.5/mL blood).57 CTC clusters have been identified by membrane filtration technologies 
as well.177,197 The Cluster-Chip created a 12 µm gap between the bases of two triangular micropillars, 
where the passing fluid then split around the top of another triangular micropillar. A cluster of CTCs 
attempting to split around the micropillar would be retained by cell-cell junctions; the efficiency of this 
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mechanism increased with as the number of CTCs in a cluster increased (Table 1.1). The authors 
demonstrated improved recovery of CTC clusters compared to 5 µm PC membranes,57 but it was likely 
that clusters were not lost but broken apart by fluidic pressures on the membrane so they could not be 
differentiated from single CTCs. The rarity of CTC clusters was evident as the Cluster-Chip detected them 
in only 30-41% of 58 cancer patients (4 mL blood), which showed no correlation to the number of 
individual CTCs in the samples. Further, CTC clusters could be released by reversing the flow direction and 
increasing flow rate by 10-fold to 250 mL/h. The authors noted that release efficiency was temperature 
dependent and best at 4°C, which supposedly reduced nonspecific cell adhesion.57 However, absolute 
purity of the cluster isolate was not discussed, and it is not clear to what degree the stagnant flow regions 
behind the triangular pillars retained contaminating WBCs. As in other reports,86 the group used 
micromanipulator peripheral instrumentation to physically select CTC clusters for further molecular 
transcriptional analysis.57  
1.7.2 Hydrodynamic Size Separation 
Recently, technologies have emerged that use hydrodynamic forces to select CTCs based on size 
and deformability without the use of physical structures. This strategy reduces the risk of device clogging 
and potentially improves purity. Here, we discuss two examples of such hydrodynamic size selection. 
The Vortex technology (Figure 1.9D; Vortex Biosciences, Inc.) is comprised of eight long and 
narrow microfluidic channels with occasional short segments of side channels that abruptly enlarge the 
channel width by a factor of ~25. When the sample is infused into the central channel, high volumetric 
flow rates (~30 mL/h per channel) align cells at an equilibrium position closer to the wall.63  This is well-
known as the Segré-Silderberg effect and is in part due to a shear-gradient force (𝐹𝑠) that propels cells 
away from the channel’s midline, which scales as 
𝐹𝑆 = 𝑓𝐿𝜌𝑉𝑚𝑎𝑥
2 𝑎3/𝑊 (1.3) 
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where 𝑓𝐿 is a dimensionless lift coefficient; 𝜌 is the fluid’s density; 𝑉𝑚𝑎𝑥 is the fluid’s maximum velocity; 
𝑊is the channel’s smallest axial dimension; and 𝑎 is the cell’s diameter. As the cell approaches the wall, 
a lift force 𝐹𝑊 is generated that pushes the cell back towards the midline and counters 𝐹𝑆: 
𝐹𝑊 = 𝑓𝐿𝜌𝑉𝑚𝑎𝑥
2 𝑎6/𝑊4 (1.4) 
 After establishing an equilibrium position based on the balance of Eqs. (1.3) and (1.4), the cells 
reach a side channel where the channel abruptly widens (i.e., channel height is now the smallest 
dimension). 𝐹𝑠 alone now propels the cell into the trap with a velocity that scales by 𝑎
2 after taking into 
account Stokes fluidic drag force. Hence, larger cells (CTCs) move laterally faster, and since the side 
channel is relatively short, smaller cells including WBCs are less likely to enter the side channel. Uniquely, 
at these very high volumetric flow rates, circulating vortices form in the side channels that can effectively 
trap CTCs if they enter the side channel by 𝐹𝑆,
63,206 unless too many CTCs enter and push one another out 
of the vortex (limit of 500 CTCs per device).63 To release the trapped cells, the flow rate can be reduced 
significantly (0.75 mL/h per channel), at which point the vortices discontinue and the cells elute off-chip.206 
 The Vortex technology has improved significantly since its inception. The first report 
demonstrated a recovery of ~23% of MCF-7 cells spiked into WBCs that were pre-purified by red blood 
cell lysis. The spike ratio was 1:100 CTC:WBC (1:107 is expected in clinical samples), yet even with a ~50-
fold dilution in WBC concentration prior to entering the device, purity was limited to 6.6% (~6,500 
leukocytes/mL).206 In a more recent study, the central channel’s dimensions were fine-tuned for initial cell 
focusing and the side-channels were lengthened for an undisclosed effect. The recovery of MCF-7 cells 
spiked into 10X diluted whole blood remained low at 8-26% with similar results from lysed blood; 
variability in the recovery between experiments was reported to be due to culture conditions. Clinical 
sensitivities of 50% and 88% were achieved for small cohorts of breast and lung cancer patients, 
respectively (Table 1.1).  However, purity rose to a very high 57-95% (0.5-12.7 WBCs/mL). A comparison 
to Hur, et al.’s results (~6,500 leukocytes/mL)206 was unfortunately not drawn in the latest report;63 it 
  
53 
would be especially interesting to delve into the fluid dynamics that reduced the WBC background. 
Notably, the side channels were lengthened by ~50%,63 and we would assume that the WBCs (with smaller 
𝐹𝑠 forces) would have more time to migrate laterally and potentially interact with the vortices (reducing 
purity), which was not observed. We suspect that either the fine tuning of cell alignment or subtle 
dynamics within the vortices themselves may have improved purity. 
 Another hydrodynamic size separation technology utilizes Dean Flow Fractionation (Figure 1.9E; 
Clearbridge BioMedics Pte Ltd.). When fluid is infused around a curved channel at high flow rates (6 mL/h), 
centrifugal forces push fluid in the center of the channel outward, causing two recirculation profiles to 
form in the top and bottom of the channel (Dean vortices). To utilize these Dean vortices for size 
separation, a blood sample (diluted 2-fold) is infused into the device, and blood components are pushed 
to the outer wall of the spiral channel by a sheathing flow of PBS. The channel then spirals for ~10 cm, 
which is enough time for the blood cells to make one full recirculation and return to the outer edge of the 
channel. However, larger cells (CTCs) experience a wall-induced lift force (𝐹𝑊) as they approach the 
channel’s inner edge, thereby slowing their rotation and causing them to achieved one half of a full 
recirculation. Thus, at the outlet, CTCs reside on the inner side of the channel, where they are skimmed 
to a separate outlet than the blood components.  
Because random cell-cell interactions likely resulted in the ~1% retention of WBCs, the CTC 
effluent was fed into a second rendition of the device to achieve ~85% cell line recoveries, 100% sensitivity 
for 20 lung cancer patients (Table 1.1), and a purity of ~1-10% (~440 ± 320 WBCs/mL). Interestingly, a 
wide size range of CTCs was isolated, including 10 µm CTCs that hypothetically should not have been 
recovered by Dean Flow Fractionation, suggesting that either cell deformability115 or cell-cell interactions 
should be included in the underlying theory. The commercialized technology utilizes red blood cell lysis 
rather than dilution115 and has been designed to be a preparatory tool that simply elutes purified CTCs in 
a tube within an hour to be processed by the user’s discretion, a very fast route to commercialization as 
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Clearbridge Biomedics Pte Ltd. has already launched its first CTC processing hub (contracted research 
organization) in China. 
1.7.3 Dielectrophoretic (DEP) Separations 
When an AC voltage is imposed across two electrodes of different sizes, asymmetric field lines are 
generated that are more concentrated (higher field strength) closer to the smaller electrode. Depending 
on the AC frequency, a cell will shift position in this response to this field, either with or against the 
gradient depending on the cell’s physical properties (Figure 1.9F, inset). At low AC frequencies, buffer ions 
accumulate on the cell membrane’s surface and form a capacitive layer, excluding field lines from the cell 
and repelling the cell away from high field regions (negative DEP). At higher AC frequencies, the field shifts 
too frequently for the capacitive layer to build up, and the electric field passes through the cell and is 
concentrated by cytosolic ions, shifting the cell towards the higher field (positive DEP). Positive or negative 
DEP only occurs if the cell’s membrane is intact and the cytosolic conductivity, ~1,400 mS/m, is greater 
than the buffer conductivity; thus, buffer conductivities are kept low, ~30 mS/m, but physiologically 
isotonic using non-conductive osmolytes such as sucrose.202  
DEP is only useful for cell separation if two distinct cell types respond differently in the electric 
field. This separation is performed by adjusting the AC field frequency, because each cell has a 
characteristic DEP crossover frequency that marks the transition from negative to positive DEP as the AC 
frequency is increased. Physically, these differences relate to the cell membrane’s surface area, with larger 
surface areas requiring more ions and then lower field frequencies to form capacitance. Not only are CTCs 
larger, but a CTC’s membrane is intricately folded, an artifact of transitioning from an epithelial matrix 
with many cell-cell junctions to a liquid blood matrix, with a surface area ~60% greater than a WBC of the 
same size. This endows CTCs with a DEP crossover frequency of 20-75 kHz (compiled from over 80 tumor 
cell lines, Figure 1.9F), whereas 15 types of WBCs were found to crossover at >85 kHz.202 At 45-65 kHz, 
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CTCs either attract towards or only slightly repel from the smaller electrode, whereas WBS are strongly 
repelled.69,202 
Many forms of DEP separations have been performed, such as DEP trapping by the DEPArray™ 
technology (well-reviewed by Gascoyne and Shim),202 but here we focus on DEP-flow field fractionation, 
which has been commercialized as the ApoStream™ technology (Figure 1.9G; ApoCell, Inc.). A dilute buffy 
coat is infused into and focused to the bottom of a flow chamber using the sucrose DEP solution as a 
sheathing buffer. Cells then pass over the DEP electrode, and by a function of DEP force, sedimentation, 
and wall lift forces, CTCs are siphoned into the bottom outlet while WBCs levitate and pass into a waste 
reservoir. Using DEP-flow field fractionation, both epithelial and mesenchymal CTC cell lines have been 
recovered with ~70% efficiency,69 and clinical results have been promising (Table 1.1).114-118 However, the 
method has limitations as well. Besides the pre-processing requirement for red blood cell removal, poor 
purity (<1%) is the method’s biggest drawback with ~2,500-10,000 WBCs/mL.69 While all viable WBCs 
should experience negative DEP at 45-65 kHz and levitate, approximately 0.1% of WBCs in a blood draw 
are nearing the end of their lifespan and have compromised membranes that will not form a capacitive 
layer; these dying or dead WBCs will sediment into the CTC fraction.202 While Gupta, et al. did improve 
purity to ~10% (approximately a few hundred WBCs/mL) by a second round of DEP, recoveries dropped 
to ~50% due to CTC loss.69 
1.8 Those That Don’t Fit the Biological/Physical Mold 
1.8.1 Only the Invasive CTCs 
The Vita-Assay™ (Vitatex, Inc.) was designed to recover only those CTCs that exhibit one of the 
key criterion for metastasis, the proclivity to invade the collagenous matrix of a distal site. While this is a 
biological action, the Vita-Assay™ targets no specific CTC marker; WBCs and CTCs, fractionated from whole 
blood by Ficoll centrifugation, are seeded into a culture dish coated with collagen adhesion matrix (CAM). 
Cells that do not bind to the CAM after a few hours are washed away,36 and within 1 day of culturing,29 
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cells that degrade and uptake CAM can be released for subsequent analysis, such as immunostaining and 
molecular analysis, by enzymatically degrading the collagen matrix.36 Several variations of the assay are 
available from Vitatex, Inc., including CAM-coated blood collection tubes (Vita-Cap™) that do not require 
Ficoll centrifugation at the cost of reduced CTC recovery (47% for Vita-Cap™ versus 77% for Vita-Assay™). 
Fluorescently-labeled CAM, which causes cells that degrade the matrix to become fluorescent,29 is useful  
Figure 1.10 CTCs isolated by the Vita-Assay™. (A) A CTC (white arrow) and CTC cluster (yellow arrow) that 
stained positive for CAM uptake, the nuclear stain Hoechst, and PSMA and/or EpCAM while negative for 
hematopoietic lineage (HL) markers such as CD45. (B) Two CTCs positive for DAPI and Vim but negative 
for CD45. (C) Two CTCs positive for CAM, Hoechst, and CD44 and/or Seprase and negative for HL markers. 
The staining patterns were indicative of (A) epithelial, (B) mesenchymal, and (C) tumor progenitor CTC 
phenotypes.107  
 
to discriminate CAM(+) CTCs from the ~2,000 nonspecifically bound WBCs that will be CAM(-).36 
Alternatively, CAM(+) CTCs could be cultured over a longer time span, forming colonies within 10 days 
that transitioned to epithelial morphology after 20 days, while WBCs senesced, reducing in number.29 
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The Vita-Assay™ has been used to monitor patients with several cancers and have demonstrated 
relatively high clinical sensitivities depending on the stage of the cancer (Table 1.1).29,36,82,106,107 CTCs that 
have been identified to invade the CAM matrix varied with phenotype (Figure 1.10), ranging across the 
EMT continuum from epithelial to mesenchymal and tumor progenitor (cancer stem cell) markers.107 
Several downstream analyses have been explored as well, including cell sorting by flow cytometry and 
 
Figure 1.11 (A) Workflow for Epic CTC analysis. (B) Images of CTC types (traditional CTCs and CTC clusters) 
as well as small CTCs similar in size to WBCs, CK(-) CTCs that are possibly mesenchymal CTCs, and apoptotic 
CTCs characterized by nuclear abnormalities such as fragmentation. DAPI, CK, and CD45 are false colored 
blue, red, and green, respectively.58  Inlaid into each image are the frequencies of each CTC type in 47 
NSCLC samples,61 with each set of data scaled to the distribution of traditional CTCs and CTC clusters in 
the central image and a red line marking the break in scale. 
 
molecular analyses to determine gene expression,29 copy number variations,36 and the frequency of DNA 
methylation.107 Given the standard tissue culture and molecular biology techniques used, the Vita-Assay™ 
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is well suited to enter laboratory settings, but given the exclusively manual handling of the assay, the 
technology is unlikely to be used for high throughput or in-clinic cancer diagnostics.  
1.8.2 Just Scan Everything – An Epic Task 
Along with competing technologies (CytoTrack™ fast scanning technology207 and MainTrac™ semi-
automated microscopy),208 the Epic CTC platform (Figure 1.11; Epic Sciences, Inc.) identifies CTCs by 
immunophenotyping all nucleated cells in a blood sample: red blood cell lysis is performed on a 10 mL 
blood sample; nucleated cells are deposited on 12 glass slides per sample; and some slides are 
immunostained against CK, CD45, and DAPI, whereas the remaining slides are frozen. The 3,000,000 
immunostained cells per slide are scanned by fiber-optic array scanning (FAST) technology, which can 
rapidly (within a few minutes) scan the slide209 to identify potential CTC events that are then imaged in 
detail with a high magnification microscope objective.60 A proprietary image analysis algorithm then 
identifies CTCs for a trained technician to confirm the CTC’s immunophenotype.58,60  
As there is no purification, CTC identification is not biased by size or phenotype. This has allowed 
Epic CTC to classify three CTC types that do not fit the traditional CK(+)/CD45(-)/DAPI(+) definition of CTCs 
or CTC clusters (Figure 1.11B): (i) CTCs that fit the traditional immunophenotype but are similar in size to 
WBCs (~8 µm),58 which have been observed by others;18 (ii) CTCs undergoing apoptosis and nuclear 
fragmentation; and (iii) cells that stain CK(-)/CD45(-)/DAPI(+). With regards to the latter cell type, these 
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CK(-) cells have been referred to as CTCs,58 but a more stringent definition to confidently classify CK(-) 
mesenchymal CTCs would require the inclusion of a confirmatory stain, e.g., Vim.27-29 Such analysis is 
possible using the Epic platform’s un-used fourth fluorescence channel58 but to our knowledge has not 
been demonstrated 
In comparison to the CellSearch™ CTC Test, the Epic CTC platform recovered orders of magnitude 
more CTCs from metastatic breast cancer patients (Figure 1.4).60 This comparison was drawn only from 
traditional CTC types (including CTC clusters), because the biological relevance of the non-traditional types 
of CTCs remains under investigation.58 For example, the distributions of the non-traditional CTC types 
shown in Figure 1.11B were acquired from a study of NSCLC patients that found no correlation between 
non-traditional CTCs and traditional CTC counts,61 while a different study of metastatic castration 
resistant-prostate cancer patients found far fewer non-traditional CTCs (1-4/mL) than the NSCLC study, 
although the inclusion of these CTC types increased clinical sensitivity from 89% to 100%,58 which is similar 
to observations made by Witek, et al.28  
Downstream analysis of the CTCs identified by Epic has been demonstrated as a proof-of-concept 
by performing FISH analysis and NGS copy variation number analysis for prostate cancer cell lines spiked 
into healthy blood.58 The practical methodology for physically isolating CTCs from the microscope slides 
was not disclosed, but this type of subsequent analysis for CTCs identified by immunofluorescence is 
certainly of interest. A competing fast-scanning technology has added a CytoPicker™ technology to its 
scanner207 (CytoTrack, ApS), which physically picks individual CTC off a glass disc for subsequent analysis, 
although these details remain proprietary as well. Lastly, it is interesting to note that the Epic CTC platform 
can also be used as a biorepository of patient slides,58 which is a significant endeavor because if an Epic 
CTC lab were to process only 10 samples (12 slides per sample) per work day (250 days per year), 30,000 
slides would accumulate in cold storage in just one year. In comparison, technologies such as Clearbridge 
BioMedics’ (Dean Flow Fractionation) laboratories and other microfluidics could also serve this role by 
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dispensing the CTCs in a concentrated and pure sample without fixatives, i.e., with minimal alteration to 
the CTC’s genetic material. 
1.9 Beyond Enumeration 
CTC enumeration will likely become an invaluable tool in preventative screening of individuals, 
prognosing cancer patient outcome, and monitoring patients in remission for minimal residual disease, 
i.e., cancer relapse.43 But CTC enumeration alone does not provide the information needed to guide 
changes in clinical/therapeutic actions that can positively affect patient outcome, other than to say that 
current clinical actions are not optimal if CTC counts continue to progress in spite of treatment.43,122 
Towards addressing this limitation, several downstream analyses have been explored (Figure 1.2 and 
Table 1.1). 
CTCs can be screened for genetic mutations in known oncogenes, such as mutations in the KRAS, 
EGFR, HER2, and estrogen receptor (ER) genes in different cancers that are clinically actionable.17 Several 
genomic analyses have been conducted (Figure 1.2), including: fluorescence in situ hybridization (FISH) 
imaging of cytogenetic abnormalities,30,58,68,83,84,93,113 array comparative genomic hybridization (aCGH) to 
assess copy number variations;36,210,211 Sanger sequencing to identify SSNVs, insertions, and deletions in a 
limited number of oncogenes;28,35,84 ligase detection reaction (LDR) for detecting SSNVs with improved 
sensitivity relative to Sanger sequencing;28 and NGS studies, which can range in coverage from 
simultaneously targeting tens to hundreds of oncogene exons,28,210 for which commercial kits are 
available, to sequencing the whole exome.37,212  
A number of studies have compared CTCs with the primary tumor as well as metastatic sites with 
biological implications that have been thoroughly reviewed by Pantel and Speicher.43 In brief, the 
emerging view is that the mutation patterns differ between CTCs and the dominant clones in the primary 
tumor, thereby demonstrating enhanced metastatic capability of some CTCs.43 The importance of securing 
genetic/genomic information from CTC is obvious, however, not easy to achieved. A number of technical 
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difficulties need to be considered for single-cell genomic analysis. For a single cell, whole genome 
amplification by isothermal multiple-displacement amplification is commonly performed. One has to 
realize that although the polymerases employed are characterized by high fidelity, errors such as allelic 
dropout, random and potentially recurrent base-copying errors, and distortion of copy number variations 
can nevertheless occur, all of which has been expertly reviewed elsewhere.213,214 As discussed above, 
single-cell genomic sequencing is not truly possible with current sequencing methods, requiring multiple 
single-cell reads to confidently identify mutations,37 which ties a CTC isolation technology’s clinical CTC 
yields and purities to the applicability of downstream genomic sequencing. 
Compared to mass limitations in DNA sequencing, mRNA analysis offers the advantage that each 
CTC harbors multiple transcripts of a single gene.43 These mRNA transcripts can be reverse transcribed 
into cDNA and amplified by PCR (RT-PCR),215 giving rise to an abundance of material. Transcripts expressed 
at >10 copies per CTC214 can be reliably sequenced above technical noise, which is caused by amplification 
biases/losses and biological variability caused by factors such as the phase of a CTC’s life cycle.215 
Techniques for transcription analysis of CTCs have included: fluorescence-based RNA-ISH;27 quantitative 
RT-PCR (qRT-PCR);38,80,86,91,93,216-218 RT-PCR44 followed by Sanger sequencing;47,68,86 multiplexed microarray 
analysis;29,39,104 and NGS-based RNA sequencing (RNA-seq).40,57,72,96 Amongst several important 
observations,43 RNA sequencing has identified mesenchymal features in CTCs27,39 and unique transcription 
profiles associated with metastatic potential and therapy resistance.39,96,104,217  
CTC-specific protein profiles are commonly analyzed, being fundamental to all 
immunophenotyping analyses. A technique, the epithelial immunospot (EPISPOT) assay, detects proteins 
such as CKs or PSA that are secreted from viable and RosetteSep™-enriched CTCs via a sandwich 
immunoassay strategy,219 which has been applied to patients with breast, prostate,220 and colorectal 
cancers221 as well as patients with benign colon diseases.89 Lastly, ex vivo expansion of patient-derived 
CTCs has been extensively explored and has led from 2D culturing of CTCs that morph into an epithelial 
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morphology on CAM substrata,29 3D culturing of tumor cell spheres42 and organoids,222 and implantation 
of CTCs in immunocompromised mice for xenograft studies41,42,223,224 to the recent establishment of the 
first immortalized cell line (CTC-MCC-41) from patient-derived colon cancer CTCs.41 Landmark studies223,224 
have formally demonstrated the capability of some CTCs to form metastases;43 therefore, the 
establishment of CTC-derived cell lines would potentially enable the ex vivo testing of therapeutics.42,43 
1.10 Conclusions and Future Outlook 
In this review, we have discussed a decade’s worth of technological developments that have been 
dedicated to the goal of isolating and analyzing CTCs from patients with epithelial cancers. Not only have 
we outlined a comprehensive review of representative technologies using standardized figures-of-merit, 
we have critically analyzed each technology, sourcing their unique advantages and limitations to 
fundamental principles, e.g., assay design, fluid dynamics, and CTC biology. Lastly, we briefly outlined the 
numerous paths by which CTCs can be further interrogated, highlighting the importance of the outlined 
figures-of-merit in affording a wide breadth of downstream analyses and enabling technologies to evolve 
beyond enumeration in tandem with fundamental discoveries in tumor biology. 
As we have examined this very dynamic field, we have placed a significant focus on 
commercialization, providing perspective on the transition from academic/research technologies to 
commercial products that can be used by the general public to afford “precision medicine” for cancer 
patients. Several technologies for CTC isolation are undergoing commercialization, and it appears that 
several of these commercial entities (Clearbridge BioMedics, Epic Sciences, CytoTrack, and Biofluidica) are 
following a trajectory (Chapter 6) towards immediate implementation as platforms for CTC purification, 
user-defined analyses, and biorepository services. In retrospect, this trajectory is shared by the majority 




Far less research has been dedicated towards the integration of the CTC isolation technologies 
within self-contained systems that fully automate the sample-to-answer workflow for CTC isolation, 
enumeration, and downstream analysis. As such developments will likely play a substantial role in 
enabling point-of-care clinical diagnostics, especially for low resource settings, some technologies attempt 
to transition substantial efforts towards such integrated microfluidic systems (Figure 1.6F, Biofluidica, 
Inc.).146 Thus, in Chapter 6, we detail the technological developments being made towards this objective. 
Furthermore, new technologies continue to emerge that analyze the genomic material of a single 
cell without amplification,225-228 thereby eliminating errors associated with it, and it is likely that these 
technologies will find niche application in CTC molecular analysis (i.e., DNA/RNA sequencing, copy number 
variations, etc.). Lastly, additional markers, such as cell-free tumor DNA229-231 and exosomes,231-233 that 
also circulate in the blood are likely to be explored as complementary to CTCs for the monitoring and 
management of cancer patients.43,230 
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CHAPTER 2. THERMOPLASTIC REPLICATION, AND FLUID DYNAMICS OF CELL ISOLATION IN THE 
SINUSOIDAL MICROFLUIDIC DEVICE 
2.1 Introduction 
The sinusoid technology isolates cells directly from unprocessed and unfractionated blood using 
microfluidic devices that are comprised of parallel arrays of microchannels. In each high aspect ratio, 
sinusoidal microchannel (Figure 2.1G), cells are selected by antibodies (Abs), for example CTC selection 
via anti-EpCAM Abs, or aptamers coated on the microchannel surfaces. Critical to selection, cell-Ab 
interactions are promoted by several aspects of the channel design:  
(i) The channel width (~25 µm) approaches the cell diameter (12-25 µm) and can increase 
the probability of cell-wall interactions but reduces normal leukocyte (7-15 µm) 
interactions that can aid in achieving high purity of the selected cells; 
(ii) The 150 µm channel depth increases throughput while reducing pressure drop, especially 
when an isolated cell could potentially “clog” the channel; 
(iii) Channels generate an order of magnitude larger fluidic shear stress than in pillar-based 
devices (Figure 2.1J) that can interrupt non-specific interactions; 
(iv) The sinusoid’s tight radius of curvature (125 µm) induces centrifugal forces that propel 
cells out of laminar streamlines and towards channel walls improving recovery; and  
(v) The channel’s continuous design (as opposed to discrete microposts) enables 




Figure 2.1 (Left) Schematics of the first generation, high-throughput CTC selection device showing: (A) A 
scaled AutoCAD diagram of the sinusoid capture channels with brightfield optical micrographs; (B) the 
integrated conductivity sensor consisting of cylindrical Pt electrodes that were 75 μm in diameter with a 
50 μm gap; (C) single port exit where the device tapers from 100 μm wide to 50 μm while the depth tapers 
from 150 μm to 80 μm over a 2.5 mm region that ends 2.5 mm from the Pt electrodes; (D) micrograph 
taken at 5X magnification showing the sinusoidal cell capture channels; and (E) 3D projection of the 
topology of the device obtained at 2.5 μm resolution using noncontact optical profilometry (arrows 
indicate the Pt electrode conduits). (Right) Second generation sinusoidal device: (F) Schematic operation 
of the CTC selection module with 50 parallel, sinusoidal microchannels and inlet/outlet channels arranged 
in the Z-configuration. The large arrow indicates sample flow direction through the selection channels. (G) 
SEM of the selection bed showing high-aspect ratio (~25 μm × 150 µm, w × d) sinusoidal microchannels 
and the output channel. (H) Composite fluorescence images of a CTC stained with DAPI, CK8/19, and CD45. 
(I) Three WBCs staining positively for DAPI and CD45 and negatively for CD8/19. (J) Fluid dynamics 
simulation results showing the distribution of flow velocities and shear stress in microfluidic selection 
channels. 
 
All of these factors contribute to efficient cell recovery (>80%) with high purity 
(>90%).28,75,76,158,172,234 Furthermore, while the volumetric throughput of each cell isolation channel is small 
(~30 µL/h), arraying channels in parallel (Figure 2.1F) increases throughput and enables tuning devices for 
processing a range of sample volumes (from 1 mL to 7.5 mL) in a practical amount of time (<30 min).76,88 
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2.2 Production of in vitro Diagnostic Devices in Thermoplastics 
Clinical testing requires that devices be manufactured as disposable units in order to avoid sample 
carry-over and/or cross-contamination artifacts during analysis. Thus, microfluidic devices must be 
produced in high volumes and at low unit cost to be successfully implemented for in vitro diagnostics.235 
For this purpose, thermoplastics, such as poly(methyl methacrylate) (PMMA), cyclic olefin copolymer 
(COC), and poly(carbonate) (PC), are ideal because they are inexpensive and a variety of low-cost 
fabrication techniques are available for both rapid prototyping and mass production of finished devices, 
even those with high aspect ratios.236-238  
Significant cost advantages as compared to other polymer microfabrication techniques can be 
realized when using replication techniques such as hot embossing or injection molding.238 Among the 
replication techniques for mass production, injection molding is considered to be the least expensive and 
fastest (<10 s per device), but it also carries the highest initial capital costs, machine set-up, and molding 
condition optimization.162,236 For the purpose of laboratory research, hot embossing can be employed for 
fabricating cell selection devices.  Each embossing cycle takes 10-15 min and can produce several devices 
in a single cycle.  However, it is important to realize that microfluidic devices can easily be transitioned 
into high scale production via injection molding with relative ease as the same thermoplastic polymers 
are used and similar design rules are followed during device development. This approach avoids or at least 
minimizes well recognized problems associated with transferring academic ideas into manufacturable 
products due to incompatibility of the materials and microfabrication methods between early 
development and high-volume production.235 
The first step in fabricating microfluidic devices by hot embossing or injection molding is the 




Figure 2.2 (A) High precision micromilling of a brass substrate using solid carbide bits on the order of 500 
to 50 µm or smaller in diameter. (B) A completed brass master mold that can be used for (C) repeated 
micro-replication by hot embossing the mold master into a thermoplastic substrate.  
 
precision micromilling (HPMM) of a brass substrate via a commercial milling machine and micrometer-
sized solid carbide tools.239 HPMM offers significant advantages over other mold master fabrication 
methods such as X-ray-LiGA (Lithographie, Galvanoformung, and Abformung in German for Lithography, 
Electroplating, and Molding) or UV-LiGA as it allows for shorter turnaround times, low cost, and single 
step fabrication of multi-level structures.237-239 Although HPMM is not capable of achieving the fine 
resolution or minimum feature size of lithography-based techniques (i.e., sub-µm for X-ray LiGA) due to 
milling bit size limitations, it is well suited for many microfluidic devices such as those shown in Figure 2.1, 
which usually employ structures in the range of 10 – 500 µm with aspect ratios <20 and inter-structure 
spacing >30 µm that are easily obtainable using micromilling.234,239  
Hot embossing involves compressing a thermoplastic that is heated to near its glass transition 
temperature, Tg (or softening temperature), into the mold master with precise control over both 
temperature and force (Figure 2.2C).162 When the polymer is cooled and released, the inverted 
microstructures are imprinted into the thermoplastic with high replication fidelity (Figure 2.3A); 




Figure 2.3 SEMs of a CTC selection device in Figure 2.1F hot embossed into a COC thermoplastic. (A) Low 
resolution SEM showing a series of sinusoidal, high aspect ratio channels. (B) High resolution SEM of one 
channel with the inset showing surface roughness due to milling. For reference, the marks left by the 
milling bit have an average roughness of 115 nm and mean peak height of 290 nm when measured 
vertically along the channel wall and 55 and 200 nm when measured horizontally, respectively, while the 
typical average roughness of the polymer used for embossing is <20 nm.25,60,61,99,115,239 (C) SEM of the 
channel prior to thermal fusion bonding of the cover plate. (D) SEM of a channel following thermal fusion 
bonding of the cover plate. The cover plate is also made from COC. 
 
thermoplastic (Figure 2.3B inset). Note that the replicated channels (Figure 2.3C,D) have a trapezoidal 
cross section with slightly tapered walls with an average draft angle of 1.4°, which is not intentionally 
imposed by the mold fabrication but rather the result of selected milling conditions and flexing of the 
straight (not tapered) micromilling tools during brass removal. Draft angles of this magnitude are 
advantageous for the replication process as they reduce friction between the molded part and mold 
master during de-molding, reducing replication errors due to polymer pull-out and prolonging the molding 
master usable lifetime.234  
One can perform >1,000 replications using a single brass mold master without noticeable 
reduction in the quality of the embossed structures or deterioration of the mold master. For the device 
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shown in Figure 2.1G, the average microchannel dimensions measured after the first 30 embossing cycles 
were 20.0 ± 1.0 µm x 27.4 ± 0.8 µm x 152 ± 1 µm (bottom width x top width x depth) and after 300 
embossing cycles, these dimensions were 19.7 ± 0.5 µm x 27.8 ± 1.0 µm x 152 ± 1 µm, well within 
measurement error and indicating high dimensional stability of the mold master and long term 
reproducibility of the hot embossing process.234 
Following hot embossing, each microstructured sheet is diced into individual devices, and the 
devices are sealed using a cover plate made from the same material as the substrate. Typically, thermal 
fusion bonding is employed in which the cover plate and substrate are brought into conformal contact 
under a fixed pressure (~1 N/cm2) and slowly heated to a temperature slightly below the Tg of the 
thermoplastic so that the microstructured substrate and cover plate thermally fuse. Bonding conditions 
must be carefully selected to preserve structural integrity of the high aspect ratio microchannels as much 
as possible while still yielding high bond strengths that easily withstand the fluidic pressure of pumping 
whole blood through the device.75,234 It should be noted that most thermoplastics are inert with respect 
to chemical reactions that associated with immobilizing biomacromolecules to their surfaces. Thus, 
devices must be activated by UV/O3, O2 plasma, or chemical exposure prior to the immobilization 
reaction.75 
2.3 Cell Selection in Sinusoidal Microchannels from a Fluid Dynamics Perspective 
Positive selection microfluidic devices use various microchannel geometries to improve cell 
recovery by increasing the probability and duration of cell-Ab interactions. Because cells do not typically 
cross flow streamlines, geometries are designed to induce some cross-stream forces on cells such as 
centrifugal forces, or cause laminar flow streamlines to interact with surfaces, such as arrayed micropillars 




Figure 2.4 Recovery of 24 µm MCF-7 cells via anti-EpCAM monoclonal Abs in 35 µm and 50 µm wide 
channels that are either straight or sinusoid. In all configurations, optimal recovery occurs at 2 mm/s linear 
velocity. Recovery increased by ~30% due to decreasing channel width and increased by ~20% due to 
channel curvature. This figure was reproduced with permission from Adams, et al.158 
 
that fluid shear stress must be generated on all surfaces to disrupt non-specific interactions throughout 
the entire device,75 meaning that wide channels, where substantial shear forces are not generated, and 
low velocity regions or “dead zones” should be avoided.  
 We will subsequently provide a framework of the physical dynamics of cell selection in sinusoidal 
channels. We will detail how cells are delivered to Ab-coated channel walls and discuss the dynamics of 
Ab-cell binding as the cell rolls along the channel wall. The proposed dynamics are supported by the 
following experimental observations (Figure 2.4): 
(i) Relative to straight channels, curved channels increased recovery by ~20%.158 
(ii) Narrowing the channel width from 50 µm to 35 µm improved recovery by ~30%.158 In our 
most recent devices (Figure 2.1F-J), channel width has been reduced to ~25 µm, which 
approaches the cell diameter (12-25 µm) while remaining larger than leukocytes (7-15 
µm).75,76  
(iii) Cell recovery was optimal at an average linear velocity of 2 mm/s.158,172 
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Figure 2.5 Three-dimensional computational fluid dynamics simulations conducted on blood flow through 
the sinusoidal cell isolation channel utilizing the Carreau model240,241 for blood’s non-Newtonian viscosity. 
Shown are: (A) Longitudinal velocity profile of blood flow; (B) cross sectional velocity streamlines of weak 
Dean flow on the order of 0.1 µm/s; (C) cross sectional centrifugal forces acting on a 16 µm CTC due to 
the channel’s radius of curvature, where positive forces act from left to right as shown by the force vector; 
(D) cross section of non-Newtonian viscosity profile generating fluidic drag that opposes the centrifugal 
forces; and (E) cross sectional centrifugal velocities obtained by balancing centrifugal and drag forces, 
where positive velocity is a left-to-right motion as shown by the velocity vector. Note that negative 
centrifugal velocities in (E) are due to the velocity streamlines in (B). 
 
2.3.1 Centrifugal Forces in Sinusoidal Microchannels 
The delivery of cells to Ab-coated surfaces is critical to any microfluidic device employing positive- 
selection. In sinusoidal-based devices, as cells traverse about the channel’s curvature, they experience a 
centrifugal force that propels them out of streamlines and towards the Ab-coated channel walls. It is 
important to note that channel width is critical to the centrifugal force’s effectiveness. For example, in 
narrow channels (25 µm wide), only a 4.5 µm shift in position is needed for a 16 µm cell to interact with 
the Ab-coated wall. Because a cell traveling through a single channel experiences 102 alternating 
curvatures (Figure 2.5A), even small centrifugal forces can accumulate into a significant shift in cell 
position. Computational fluid dynamics (CFD) simulations were used to assess the magnitude of the 
centrifugal forces likely experienced by cells traveling in the curved microchannels and how these forces 
translate to shifts in the cell’s axial positions. 
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Centrifugal forces are experienced by both cells and other blood components. It is well known 
that incompressible fluids such as blood recirculate in response to centrifugal forces to conserve mass and 
energy. The magnitude of the secondary, recirculating flow profiles in the channel’s cross section (known 
as Dean flow) are gauged by the Dean number; 
𝐷𝑒 = 𝑅𝑒√𝐷ℎ/2𝑟𝑐  (2.1) 
where 𝑟𝑐  is the radius of the channel’s curvature, 𝐷ℎ  is the channel’s hydraulic diameter and in rectangular 




, where 𝜌, 𝜇, and 𝑉 are the fluid’s density, viscosity, and average velocity, respectively. 
When 𝐷𝑒 exceeds 35.92, flow instability occurs,242 but below this, stable Dean flow has been utilized in 
inertial microfluidics to separate particles or cells based on size.142,243 However, in the sinusoidal channels 
of the devices shown in Figure 2.1 and Figure 2.3, 𝑅𝑒 and 𝐷𝑒 are 0.02 and 0.01, respectively, due to the 
relatively slow linear velocity (2 mm/s) and the small channel dimensions. Thus, the secondary rotational 
flows in the sinusoidal channel’s cross section (Figure 2.5B) are very slow with velocities of ~0.1 µm/s. 
 As blood components travel through the sinusoidal channel’s curvature, cells experience a 





2/𝑟𝑐  (2.2) 
where 𝑉 is the cell’s forward velocity, 𝑟𝑐 = 125 µ𝑚 is the channel’s radius of curvature, and the term in 
parentheses rephrases the cell’s mass in terms of the cell’s radius (𝑎 = 8 µ𝑚) and density (𝜌𝐶𝑇𝐶 =
1,056 𝑘𝑔/𝑚3).244 In Figure 2.5C, we plot 𝐹𝑐  over the sinusoidal channel’s cross section. A cell experiences 
the highest centrifugal forces (up to 0.7 pN) in the center of the curving channel; elsewhere, the channel 





Figure 2.6 The maximum centrifugal velocity (Eq. 2.4) experienced by a CTC traversing through sinusoidal 
microfluidic channels. 𝑉𝑐  is critical to force CTCs out of laminar streamlines and towards microchannel 
surfaces and scales with the CTC’s size and the fluid’s forward linear velocity squared. 
 
arbitrary because the number does not convey how fast the cell moves in response to this force. The cell’s 
axial velocity due to 𝐹𝑐  (𝑉𝑐, which is positive towards the outer channel wall) is given by balancing 𝐹𝑐  with 
blood’s reciprocal drag force (𝐹𝑑); 
𝐹𝑑 = 6𝜋𝜇𝑎(𝑉𝑐 − 𝑉𝑓) (2.3) 
𝐹𝑑 increases with the blood’s viscosity (𝜇), the cell’s radius 𝑎, and as the cell moves faster relative 
to the Dean flow’s axial velocity (𝑉𝑓). Because 𝐹𝑑 must equal and oppose 𝐹𝑐, the cell’s 𝑉𝑐  can be determined 




𝑎2𝑉2 + 𝑉𝑓  (2.4) 
For an average 16 µm cell traveling at 2 mm/s (Figure 2.5E), the magnitude of 𝑉𝑐  ranges from 1.1 
µm/s towards the outer wall to -0.2 µm/s (negative where 𝐹𝑐  is too small to counter the Dean flow), which 
is significant considering the average 15 s required for a cell to traverse the 30 mm long channel at 2 mm/s 
and the 4.5 µm shift needed to deliver the cell to the microchannel wall. Note that in Eq. 2.4, 𝑉𝑐  scales 
with the square of the cell diameter and forward linear velocity (Figure 2.6). Thus, centrifugal forces 
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operating on smaller cells, such as 8 µm leukocytes, propel the cells with a velocity four times slower than 
cells with a 16 µm diameter. In general, centrifugal forces are sensitive to the linear velocity, becoming 
negligible at lower flow rates. This latter point likely causes reduced recovery at lower linear velocities 
(Figure 2.4), whereas at higher velocities, recovery drops due to the Chang-Hammer model that is 
discussed below. 
The influence of the fluid’s viscosity, 𝜇, in Figure 2.5E is especially interesting. Blood is a non-
Newtonian fluid; in response to shearing, blood viscosity decreases.245 In narrow channels as used for the 
device shown in Figure 2.1 and Figure 2.3, drag along the walls rapidly slows fluid flow and induces a large 
shear effect. The same shear that produces large fluidic shear stresses for disrupting non-specific 
interactions in turn roughly halves blood viscosity near the channel walls (Figure 2.5D). Effectively, if a cell 
is at a central position (midway between the walls) and is “pushed” towards the wall, the cell experiences 
less drag as it approaches the wall. However, at the next alternating curvature, where centrifugal forces 
act in the opposite direction, a cell encounters an increase in fluidic drag as it is “pushed” back towards 
the channel’s midline, likely resulting in a net centrifugal velocity towards the channel walls. 
Note that a major limitation for this model’s viscosity (Figure 2.5E) is that the non-Newtonian 
nature of blood arises from red blood cells. The cell membranes of red blood cells rotate around the 
cytoplasm under shear, spinning the cytosolic fluid with the surrounding plasma and transitioning the cell 
from a particle-like object to a less viscous flowing liquid. Red blood cells are biconcave discs that are 8 
µm in diameter and 2 µm thick;246,247 assuming a red blood cell cross section of 16 µm2, the channel cross 
section of 3750 µm2, and 40% hematocrit, on the order of 100 red blood cells are likely to occupy a given 
cross section of the sinusoidal microchannel. Especially when a WBC or CTC simultaneously occupies the 




Figure 2.7 Schematic of the Chang-Hammer model describing (A) a cell rolling along a surface coated with 
recognition elements such as Abs. (B) The probability of cell adherence is governed by the relative motion 
of the cell’s antigens with the surface elements. 
 
dynamics in the actual device are likely to be dominated by cell-cell interactions. However, conceptually 
speaking, the layer of high viscosity blood, which was hypothesized to bias CTC position away from the 
channel midline, could be envisioned to be red blood cells that occupy the remaining fluid space and resist 
axial movement of the cell. This argument is surely only applicable to conceptualization, and truly accurate 
fluid dynamics simulations would require extensive modeling using deformable particles. Rather, particle 
imaging velocimetry would be a more viable strategy for capturing enough single-cell dynamics to 
statistically assembled CTC trajectories.. 
Lastly, we note that particle lift forces were disregarded in the above analysis. Briefly, two primary 
lift forces are imposed on cells flowing in a channel: (i) Cells lag behind the fluid’s velocity and are forced 
towards lower velocity regions near the channel wall; and (ii) fluid flows faster over the cell’s surface that 
faces the channel midline, producing a lift towards the channel midline (as well as the Magnus effect due 
to the cell’s shear-induced rotation).142,243,249 These two opposing forces result in an equilibrium position 
nearer the wall (not the channel’s midline), which was first empirically observed by Segre and 
Silberberg.250 The lift forces acting on a cell in a single shear profile are complex.142,243,249  
Lastly, lift forces were not incorporated in this analysis because traditional models are not 
applicable. Existing physics assumes that a cell experiences one shear profile,249 but in narrow channels 
where 𝑎 > 𝑊/2, a cell experiences shear profiles along both walls. Thus, cell rotation and the forces 
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causing cells to lift off the channel walls are likely to be dampened but to an unknown extent. 
Nevertheless, the centrifugal effects described above are independent and additive to these lift forces.  
2.3.2 Transient Dynamics of Cell-Ab Binding 
With increasing linear velocity, centrifugal forces increase the delivery of cells to the selection 
surfaces, but clearly in Figure 2.4, there was an optimal linear velocity of 2 mm/s for cell recovery.158,172 
Above this linear velocity, slow binding kinetics of the cell-Ab reaction supersede centrifugal delivery of 
cells to the surface. The Chang-Hammer model147 thoroughly describes the cell-Ab binding process taking 
into account Ab-antigen binding kinetics, the transient motion of the antigen and its associated residence 
time in proximity to the surface-confined Ab, and the distance over which the cell rolls along the surface 
(Figure 2.7).  
In the high Peclet number regime, where convective mass transport of the antigen to the Ab 
dominates over diffusion, which is clearly applicable as the cell rolls over the Ab-coated surface, the 
Chang-Hammer model147 can be simplified to a few key equations (see Appendix 2.1 for full expressions). 
Firstly, as the cell rolls, the forward rate constant 𝑘𝑜  for the encounter of antigens with a surface-confined 
Ab is given as; 
𝑘𝑜 = 2𝑎𝑖𝑉𝑒𝑓𝑓 (2.5) 
In Eq. 2.5, 𝑎𝑖 is the Ab-antigen interaction radius (2 nm), and 𝑉𝑒𝑓𝑓 is the velocity of the antigen 
relative to the surface, which is approximately half (0.47 times) the rolling cell’s velocity due to the 
opposing rotational motion. Furthermore, as the antigen encounters the Ab, the probability that they 








As the cell’s linear velocity increases, 𝜏 decreases, meaning that less time is available for the Ab 
and antigen to form a complex, and 𝑃 decreases as well. Both the encounter rate, 𝑘𝑜 , and the binding 
probability, 𝑃, are weighted against one another to yield an effective forward rate constant, 𝑘𝑓; 
𝑘𝑓 = 𝑘𝑜𝑃 (2.7) 
Lastly, the overall rate of cell adhesion 𝑘𝑎𝑑 combines 𝑘𝑓  with the cell’s antigen surface density 
𝐶∞; 
𝑘𝑎𝑑 = 𝑘𝑓𝐶∞  (2.8) 
To review, 𝑘𝑎𝑑 takes into account the cell’s antigen expression and the velocity of the cell’s 
antigens, both in terms of how often the antigens encounter Abs and how probable a given binding event 
is by the balance of the antigen-Ab interaction time and the Ab’s binding kinetics. To relate 𝑘𝑎𝑑 to 
experimental systems, consider a cell rolling along an Ab-coated surface at a linear velocity (𝑉) for only a 
limited distance (𝐿). The percent of cells that will adhere is; 
%𝑏𝑜𝑢𝑛𝑑 = 1 − 1/𝑒
𝑘𝑎𝑑𝐿
𝑉   (2.9) 
Two aspects of Eq. 2.9 that improve cell recovery are immediately apparent: (i) Decrease linear velocity; 
and (ii) maximize the interaction length between the cell and the surface. Note that improving recovery 
by decreasing linear velocity is limited by throughput and purity because high shear forces are required 
to break non-specific interactions. For example, due to the narrow width of the sinusoidal channels (Figure 
2.8), the average fluid shear stress observed in the sinusoidal channels in the device shown in Figure 2.1F 
is 3.4 dynes/cm2 for buffer flow and 13.3 dynes/cm2 for blood flow, which is approximately an order of 





Figure 2.8 (A) Schematic of flow fields generated in a micropillar device (0.65 mm/s) and a close-up of a 
pillar with a maximal roll distance of 75 µm. (B) An SEM of the high-aspect ratio sinusoid channel (2 mm/s)  
with a period of 750 µm, 125 µm radius of curvature, and an effective roll distance of >300 µm. (C) The 
recovery of CTCs (EpCAM expression = 49,700 molecules/cell) for different roll lengths and translational 
velocities according to the Chang-Hammer kinetic model. 
 
Figure 2.8 provides an example of cells rolling along different surfaces. In one case, cells are 
isolated by 100 µm diameter micropillars used in many microfluidic devices (at a linear velocity of ~0.65 
mm/s56,251), and in the other case, cells are isolated in sinusoidal channels (at ~2 mm/s158,172). Despite the  
lower linear velocity used in the micropillar designs, which enhances cell binding, the limited rolling 
distance (approximately 75 µm) yields a similar probability of cell recovery (~65%) than in the sinusoidal 
channels (~71% for a 250 µm rolling distance; 92% for a 500 µm roll), but the sinusoidal device operates 
at nearly triple the linear velocity and thereby offers increased processing throughput and increased shear 
stress for disrupting non-specific interactions. For a brief comparison, the CellSearch™ technology offers 




Figure 2.9 Recovery of the MCF-7 CTC surrogates (cell line), which expresses high levels of EpCAM and is 
commonly used to assess recovery, versus clinical CTCs that vary significantly in EpCAM expression. Cell 
recoveries were determined by the Chang-Hammer model assuming a cell size of 16 µm, a 100 µm rolling 
distance, and various translational velocities. 
 
the anti-EpCAM magnetic nanoparticles. In this case, encounter rates can be increased by increasing 
nanoparticle concentrations, but the probability of non-specific interactions increases as well. Without 
any fluidic shear stress to break these non-specific interactions, poor purity results in the CellSearch™ 
system.25 
A less immediate observation of Eq. 2.9 is that cell recovery depends on 𝐶∞, the density of 
antigens on the cell’s surface. In Figure 2.8, EpCAM expression was fixed to 49,700 EpCAM molecules  
(mean) distributed over the surface area of a 16 µm cell, but EpCAM expression levels are known to be 
clinically heterogenous and have been reported to range from 9,900 to 246,000 EpCAM molecules/cell. 
As a reference, MCF-7 cells over-express EpCAM relative to clinical samples (400,000 EpCAM 
molecules/cell252). Figure 2.9 shows that as EpCAM expression decreases, the probability of cell recovery 
drops significantly (over a 100 µm rolling distance), and long rolling distances become even more critical 
to clinical cell recovery.  
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Figure 2.10 Time to process 7.5 mL of blood as a function of microchannel depth and channel number for 
a channel width of 25 µm and a linear flow velocity of 2 mm/s. AR = aspect ratio.  
 
2.3.3 Parallel Channel Arrays for High Throughput Sample Processing 
Considering the rarity of some target cells (1-3,000 CTCs/mL blood), relatively large blood volumes 
(ideally an entire 7.5 mL blood draw) should be processed through the microfluidic cell selection device. 
Due to the Chang-Hammer kinetics discussed above, throughput is limited by linear velocity; thus, 
balancing recovery and analysis time is a common issue for positive cell selection devices.234 For example, 
the device in Figure 2.1F has an internal volume of only ~10 µL.75 Processing 7.5 mL of blood using this 
device would require 5 h. 
A relatively straightforward method to increase throughput without affecting the fluid dynamics 
of cell recovery (namely optimal channel width and linear velocity) is to either deepen the channels and/or 
increase the number of parallel channels (Figure 2.10). By increasing channel depth to 250 µm (a practical 
fabrication limit) and increasing the number of channels, 7.5 mL of blood can be processed in less than 30 
min with 300 channels or less than 17 min using 500 channels.234 However, there is a practical question 
to consider; namely, can more than 300 channels be addressed while ensuring that flow through the entire 




Figure 2.11 Comparison of different inlet/outlet geometries for a CTC selection device. (A) Results of 
computer simulations for the distribution of flow velocities within the CTC isolation bed with 50 
microchannels arranged in the Z-configuration or 51 microchannels with triangular inlets and outlets. 
Pictures of devices filled with blood for (B) the triangular configuration and (C) the Z-configuration. 
 
The first generation sinusoidal devices (Figure 2.1A) utilized large triangular inlet/outlet regions 
to address a cell isolation bed comprised of 51 parallel channels (Figure 2.11B).158,172,253 CFD simulations 
confirmed uniform flow between the parallel channels in this triangular configuration with the exception 
that flow was slightly reduced in the outer channels due to viscous drag along the inlet/outlet walls by the 
no-slip condition (Figure 2.11A). However, slow linear velocities in the large, triangular regions (~0.2 
mm/s) did not generate high enough fluidic shear stress to remove all blood cells non-specifically adhering 
in the triangular regions, resulting in lowered purity. Also, pressure differences in the triangular regions 
were not large enough to reliably displace air bubbles inadvertently introduced into the system during 
operation (Figure 2.11B). Disruption of the flow dynamics by compressible air bubbles is well-known in 




Figure 2.12 (A) Schematic diagram and (B) electrical representation of a Z-configuration network with 
three parallel channels. (C) Color-coded illustration of mass and pressure balance equations in the fluid 
network. In (A), grey regions represent fluidic channels, and black arrows represent the direction of flow 
 
cells and contaminating blood cells can be trapped about the air-liquid interface at the bubble surface, 
which are extremely difficult to control during washing and staining procedures. Washing at higher flow 
rates caused the loss of cells (reducing recovery).234 
 To alleviate issues associated with triangular inlets and outlets, a different fluidic architecture 
was designed (Figure 2.1F) that offered improved scalability and consisted of the so called Z-configuration 
(Figure 2.11C) that is well-known in the field of fuel cells.254 Fluid enters the device through a single inlet 
channel that is poised perpendicular to the parallel channels and exits through a single outlet channel that 
is also perpendicular to the sinusoidal microchannels. The Z-configuration offers: (i) Pressure drops 
throughout the inlet and outlet channels that are sufficient to efficiently remove air bubbles; (ii) easily 
scaled to any number of parallel channels by simply lengthening the inlet and outlet channels; and (iii) the 
smallest possible footprint relative to other designs.234 For example, a bifurcation network was used to 
address parallel channels in a recently proposed device for neutrophil isolation.255 The device’s footprint 
nearly doubled compared to a similar number of parallel channels arranged in the Z-configuration. 
 The Z-configuration is a highly parallelized fluid network and uniform flow distribution is uniquely 
sensitive to the number of parallel channels and their length, or more accurately, the fluidic resistance of 
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the parallel channels. To conceptualize this, the network is analogous to parallel, electrical resistors. It is 
well known that if one connects a set of resistors in parallel using wires with negligible resistance, the 
current (or flow rate) will be identical if all the resistors have the same resistance (and all cell isolation 
channels have the same fluidic resistance). What happens if the wire connecting the parallel resistors has 
non-negligible resistance? If the parallel resistors are not very resistive (for example, short parallel 
channels for cell isolation) or if the inlet and outlet channels have significant resistance (narrow channels), 
then the current or flow distribution is no longer uniform. For this exact reason, numerically tractable CFD 
simulations with short, narrow parallel channels cannot be used to assess flow uniformity in Z-
configuration networks, and an alternative numerical model must be used. The most tractable model 
treats the entire network as a set of fluidic resistors to construct a so called network analysis model (a 
small model with only 3 parallel channels is shown in Figure 2.12 for visualization).88 This model is briefly 
described here because it is useful when CFD simulations are numerically intractable. 
Every fluidic channel or segment of the inlet and outlet channel in a Z-configuration network can 
be modeled as a simple fluidic resistor with a resistance (R) to fluid flow predicted by its geometry and 






  (2.10) 
In Eq. 2.10, the channel’s geometry is defined by its cross sectional area (𝐴), perimeter (𝑃), length (𝐿), 
width (𝑊), height (𝐻), and hydraulic diameter (𝐷ℎ). The product of the Reynolds number and friction 
factor (𝑅𝑒 𝑓) is approximated by Kays and Crawford256 as 13.84 + 10.38 ∙ exp (−3.4/𝛼), where 𝛼 is the 
channel’s aspect ratio (≥ 1).88 
The velocity field throughout the 3-channel Z-configuration network in Figure 2.12 is comprised 
of 7 unknown velocities, the velocities through the 3 parallel channels and the 4 velocities in the inlet and 
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outlet channel segments. Thus, we need a system of 7 equations to solve for the velocity field. Pressure 
balance equations provide 2 of these equations (each term in these equations is a pressure drop):  
𝑣1𝑟1 + 𝑉1
′𝑅1
′ = 𝑉1𝑅1 + 𝑣2𝑟2 (2.11a) 
𝑣2𝑟2 + 𝑉2
′𝑅2
′ = 𝑉2𝑅2 + 𝑣3𝑟3  (2.11b) 
The remaining 5 equations are mass balance equations (each term is a volumetric flow rate): 
𝑉𝑖𝑛𝐴𝑖𝑛 = 𝑉1𝐴1 + 𝑣1𝑎1  (2.11c) 
𝑉1𝐴1 = 𝑉2𝐴2 + 𝑣2𝑎2  (2.11d) 
𝑉2𝐴2 = 𝑣3𝑎3 (2.11e) 
𝑉𝑖𝑛𝐴𝑖𝑛 = 𝑉1𝐴1 + 𝑉1
′𝐴1
′  (2.11f) 
𝑉𝑖𝑛𝐴𝑖𝑛 = 𝑉2𝐴2 + 𝑉2
′𝐴2
′  (2.11g) 
In the above equations, 𝑣𝑖, 𝑟𝑖, and 𝑎𝑖 are the average linear velocity, resistance, and cross sectional area 
of the parallel channels. Similarly, 𝑉𝑖, 𝑅𝑖, and 𝐴𝑖  describe the inlet channel segments, and 𝑉𝑖′, 𝑅𝑖′, and 𝐴𝑖′ 
correspond to the outlet channel segments.88 These definitions are illustrated in Figure 2.12B as well. 
After minor rearrangements to Eqs. 2.11a-g, we rewrite the system of equations in matrix form 
that is easily expanded to any number of parallel channels. 
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Figure 2.13. (A) Various stages of filling of a 320-channel Z-configuration device (20 mm long parallel 
channels) with a dye solution. (B) Numerical simulation results showing the distribution of flow velocities 
for different configurations of the CTC selection beds arranged in a Z-configuration. (C) Average linear 
velocities of fluid in 16 groups of 20 adjacent sinusoidal, high aspect ratio microchannels based on the 
results in Figure 2.13A (filled bars) and theoretical values obtained via the network analysis model (empty 
bars). (D) Distribution of cells selected in 20 mm long microchannels. 
 
the velocities through the parallel channels (Eq. (2.12d)). Using a custom-built program written in the 
FORTRAN coding language, the flow distribution in a Z-configuration cell selection device with 500 
channels can be solved in a matter of seconds, whereas with modern computing, an accurate CFD 
simulation of the 50 channel device in Figure 2.11C is difficult.234 Moreover, the network analysis model 
agrees extremely well with CFD simulations88 as well as experimental results (Figure 2.13A,C).33,76 
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Numerical analysis of high throughput cell isolation devices similar to those in Figure 2.11C shows 
that a parabolic flow distribution can be generated in certain Z-configuration networks, where fluid 
velocities increase in the outer channels while fluid in the central channels slows (Figure 2.13B,C). This is 
reflected in the profiles observed when filling the device in Figure 2.13A. Qualitatively, if each channel of 
the array was filling under a constant linear velocity, the filling profile of the array should approximately 
show a linear gradient.76 
Uniformity of the fluid flow in Z-configuration networks is highly dependent on the ratio of fluidic 
resistance of the inlet/outlet channels to the fluidic resistance of the parallel channels. In general, wider 
(lower fluidic resistance) inlet channels and longer and/or narrower (higher fluidic resistance) parallel 
channels show higher flow uniformity throughout the array. Inhomogeneity of the flow rate is 
exacerbated by the number of parallel channels in the array (Figure 2.13B).76,88 As can be seen from this 
data, the 320 channel device with 8.4 mm selection channel lengths generates maximum and minimum 
linear velocities that range from roughly 1 mm/s to 4 mm/s, which have been shown to provide above 
80% recovery of MCF-7 cells that is only moderately efficient compared to the maximal 97% recovery 
observed at 2 mm/s.158 Lengthening the 320 parallel channels to 20 mm or 30 mm (Figure 2.13B) adds 
resistance to the parallel channels and improves flow uniformity, but clearly the flow distributions in these 
devices still vary about the optimal 2 mm/s linear velocity.76  
To enable Z-configuration devices with very high throughputs that also retain flow uniformity, the 
inlet and outlet channels can be tapered (Figure 2.14) to systematically correct the parabolic profiles. If 
all parallel channel velocity terms in Eq. 2.11a-g are replaced with a constant linear velocity (uniform flow 
distribution), the equations can be reduced into a single equation that describes the geometry of Z-












Figure 2.14 (Left) AutoCAD renderings of Z-configuration cell isolation units with 250 parallel channels 
that utilize straight and tapered inlet and outlet channels. The Z-configuration with tapered inlets and 
outlets offers (top right) constant linear velocity throughout the parallel array and (bottom right) 
controlled shear stress throughout the tapered inlet and outlet channels to ensure mechanical stability of 
the CTCs.  
 
Eq. 2.13 provides a method of designing the inlet and outlet channel geometries. For the 250 
channel Z-configuration shown in Figure 2.14, the geometry of the segment of the inlet channel joining 
the 1st and 2nd parallel channels (𝑖 = 1) is related to the geometry of the segment joining the 249th and 
250th parallel channels (𝑖 = 249) by Eq. 2.13, which requires that the first segment is widened. Continuing 
this trend, tapered inlet and outlet channels are generated like those shown in Figure 2.14 and provide 
uniform flow distributions, with very good agreement to CFD simulations as demonstrated in the field of 
fuel cells (see 0).88 These optimized designs offer the ability to scale up Z-configuration systems well 
beyond 320 channels, enabling extremely high throughput microfluidic devices while retaining optimal 
linear velocity throughout all parallel channels. 
2.4 Conclusions 
While there are a number of attractive and innovative technologies for cell selection using either 
biological or physical properties, the implementation of any of these technologies into clinical research 
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and eventually clinical practice requires a number of important operational characteristics such as high 
recovery, high throughput, favorable purity levels, and good clinical sensitivity and specificity. Many of 
the microfluidic technologies demonstrate most of these operational characteristics, but very few 
demonstrate favorable operational characteristics on all fronts, with many showing less than favorable 
purity that can make molecular profiling problematic due to the high infiltration rate of contaminating 
leukocytes. The ability to produce cell selection technologies that generate high clinical yields while at the 
same time producing high purity of the selected fraction will be necessary as molecular profiling becomes 
more important in the clinical implementation of cells and CTCs for guiding therapy through patient 
stratification based on genetic profiles. 
The sinusoidal microfluidic technology can provide some important operational characteristics 
that will make it an attractive platform for clinical implementation, including high recovery (>80%), high 
throughput (15 mL/h), high clinical sensitivity (~100% for metastatic disease) and more importantly, high 
purity (>90%). We have extensively detailed the sinusoidal technology, using fluid dynamics to elucidate 
the fundamental phenomena that lead to high recovery and high purity and also developing novel 
numerical tools that enable the design of devices with extremely high throughput. Finally, we have also 
detailed the methods used to fabricate the sinusoidal microfluidic device in thermoplastic substrates, 
which make it appropriate for manufacturing via hot embossing or injection molding. These methods 
enable the production of microfluidic devices in a high production mode and at low cost, yet also with 
tight compliance for high assay reproducibility.
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CHAPTER 3. UV ACTIVATION OF POLYMERIC HIGH ASPECT RATIO MICROSTRUCTURES: 
RAMIFICIATIONS IN ANTIBODY SURFACE LOADING FOR CIRCULATING TUMOR CELL SELECTION 
3.1 Introduction 
Many chip-based systems are built using glass or silicon substrates because their well-defined 
fabrication modalities and established chemistries allow the facile attachment of biologics to their 
surfaces.238,257 However, as the development of suitable polymer manufacturing techniques, such as hot 
embossing and injection molding, can generate high quantities of microfluidic chips at low cost, 
thermoplastics have been explored as alternatives to glass or silicon. Therefore, devices made from 
thermoplastics can be particularly attractive for in vitro diagnostics due to the ability to accommodate the 
need for one-time-use operation.238,258-274 This is particularly true for circulating tumor cell (CTC) analyses, 
where whole blood clinical samples serve as the input and rare cells are selected and enumerated directly 
within the device. The rarity of CTCs makes potential sample carryover issues problematic; CTC analysis 
demands one-time use devices that can be produced in large quantities and with high fidelity. 
For most microfluidic systems designed for in vitro diagnostics, surface functionalization and 
immobilization of biologics must be undertaken. For many non-functional surfaces, passive adsorption of 
the biologic to the surface is used, which can result in high loss of activity of the adsorbate.275,276 
Alternatively, activity may be retained using covalent coupling chemistry, which requires surface 
functional groups on the substrate. For example, a substrate containing surface-confined carboxylic acids 
can be reacted with EDC/NHS reagents to form an ester intermediate that subsequently reacts with 
primary amine bearing biologics.158,172,276  
Many thermoplastics do not contain surface functional groups, necessitating activation protocols 
to create the appropriate surface scaffolds. For example, devices using positive selection of CTCs require 
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the attachment of monoclonal antibody to appropriately prepared surfaces. A typical thermoplastic chip 
production and assembly pipeline using thermoplastics involves: (i) Forming the fluidic network on the 
appropriate substrate by molding; (ii) UV irradiation of exposed surfaces (cover plate and substrate) to 
generate functional scaffolds via photo-oxidation reactions; (iii) thermal fusion bonding the irradiated 
cover plate to the substrate to enclose microfluidic channels; and (iv) covalent coupling of biologics to the 
surfaces of the enclosed channels.277,278   
The UV activation process is more accurately described as UV/ozone (UV/O3) treatment using a 
quartz Hg lamp, which continually generates and destroys O3 yielding a steady-state concentration of 
strongly oxidizing atomic O. At sufficiently high energy, both UV exposure and oxidative stress can 
generate radicals within the polymer, which may break or scission polymer chains into smaller fragments, 
crosslink polymer chains, cause intramolecular rearrangements, and/or react with water or oxidative 
species to form carboxyls or other O-containing species.279-291 Thus, polymer surfaces are exposed to both 
intense UV light and highly reactive oxidizing species; we will refer to this UV/O3 process as UV activation 
in this chapter.277,292 
Even though there has been extensive work characterizing UV-induced functionalization of 
thermoplastics, most of these studies assessed the activation performance using planar substrates or thin 
films as models.279-289 For microfluidics, microchannels of various aspect ratios require surface 
functionalization, and it is not clear if the observations made for planar surfaces are applicable to 
microchannel surfaces.290,291,293 Several variables are implicitly different between planar surfaces and 
microstructured surfaces: (i) The bulk polymer’s optical transmissivity may affect the flux of radiation 
reaching the interior of microchannel surfaces; and (ii) the channel’s geometry may determine the 




UV irradiation of polymer surfaces may result in the formation of photo-fragments due to 
scissioning of the polymer backbone and these photo-fragments can be more thermally mobile compared 
to the pristine polymer due to their lower molecular mass. Thus, thermal fusion bonding, which is 
accomplished near the glass transition temperature (Tg) of the polymer, may bury generated surface 
functional groups.294 Such effects have been indirectly observed for the long-term aging of appropriately 
modified thermoplastics.290 Therefore, the surface accessibility of functional groups could differ 
dramatically before and after thermal processing depending on the polymer substrate’s tendency to 
fragment upon irradiation. 
In this chapter, we determined the extent and uniformity of the UV-induced generation of 
surface-confined carboxyl groups within thermally fusion bonded microchannels of different aspect ratios 
using UV-Vis spectroscopy, a uniquely adapted colorimetric assay, and imaging fluorescent dye-labeled 
oligonucleotides covalently immobilized to surface-generated functional groups. We also employed an 
array of surface characterization tools, including water contact angle measurements, atomic force 
microscopy (AFM), attenuated total reflectance Fourier-Transform Infrared (ATR-FTIR), Raman, and X-ray 
photoelectron spectroscopy (XPS) to assess thermal processing effects of UV-modified plastics. 
Poly(methyl methacrylate), PMMA, cyclic olefin copolymer, COC, and polycarbonate, PC, were evaluated. 
PCs poor optical properties did not permit CTC evaluation via fluorescence imaging.295 Therefore, the CTC 
assay was abandoned using this polymer; however, surface characterizations of functionalized PC are 
presented in Appendix 3.8.  
The importance of high surface loading of a biologic to the appropriate high aspect ratio micro-
structured thermoplastic device was demonstrated using the covalent attachment of monoclonal 
antibodies (mAbs) directed against the epithelial cell adhesion molecule (EpCAM) to UV activated, high 
aspect ratio thermoplastic microchannels. EpCAM has been used extensively for the positive selection of 
CTCs from whole blood using microfluidics.32,44,68,80,94,100,153,158,172,296-298  Performance metrics such as the 
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recovery and purity of isolated CTCs were evaluated, both of which depend intimately on the proper 
surface activation protocol of microchannel walls. Comparison of PMMA and COC for the isolation of CTCs 
was evaluated using clinical samples to select the appropriate thermoplastic substrate for maximizing the 
CTC clinical yield and purity.  
3.2 Experimental Methods  
3.2.1 Materials 
PMMA and 6013S-04 COC were purchased from Plaskolite and TOPAS Advanced Polymers, 
respectively. Frame-sealed incubation chambers were purchased from Bio-Rad. Chemicals and reagents 
used in these studies included: Micro-90, sodium dodecyl sulfate (SDS), sodium hydroxide, sodium 
carbonate and bicarbonate (Fisher Scientific); reagent-grade isopropyl alcohol (IPA), 2-(4-morpholino)-
ethane sulfonic acid (MES), bovine serum albumin (BSA), Triton X-100, and paraformaldehyde solution 
(FA) (Sigma-Aldrich); toluidine blue O (TBO) (Carolina Biological Supply); phosphate-buffered saline (PBS, 
pH = 7.4) (Life Technologies); 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) and N-
hydroxysuccinimide (NHS) (Pierce); Cy3-labeled oligonucleotides (5’NH2-C6-TTT-TTT-TTT-TTC-CGA-CAC-
TTA-CGT-TTT-TTT-T-Cy3-3’; Integrated DNA Technologies); NorthernLights 493-streptavidin (NL493-
streptavidin), monoclonal anti-EpCAM Abs, and Fc blocker IgG (R&D Systems); and 4’,6-diamidino-2-
phenylindole (DAPI), and CD45-FITC and cytokeratin 8 and 19 (CK8/19-PK) Abs (eBioscience). Nuclease-
free water and microtubes (Ambion) were used for preparation and storage of all samples and reagents. 
3.2.2 Fabrication and Assembly of Microfluidic Chips 
Polymer microfluidic chips were hot embossed from a metal mold master. Fabrication of the CTC 
chip followed steps previously reported.158 Unless noted otherwise, microfluidic chips and planar 
substrates were sonicated in 10% Micro-90 for 10 min, rinsed with IPA and DI water, dried at 70oC, and 
UV-modified for 15 min (22 mW cm-2) in a home-built UV activation chamber equipped with a quartz, low-
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pressure Hg lamp. Chips were thermally fusion bonded for 20 min at temperatures between 98oC-102°C 
for PMMA and 132-134°C for COC. 
3.2.3 Water Contact Angle Measurements 
Sessile water contact angle results were obtained using a VCA Optima instrument (AST Products). 
The measurements entailed depositing 2.0 µL of DI water onto the appropriate substrate followed by 
collecting the image and measuring the contact angle using the manufacturer’s software.  
3.2.4 Quantification of Carboxylic Acid Surface Densities 
An in-situ incubation chamber (BioRad) was attached to the substrate’s surface and filled with 
0.1% (w/v) TBO in carbonate buffer (50 mM, pH = 10.5). After 15 min, the substrate was submersed in the 
same buffer for 15 min and air dried. TBO was desorbed using 40% acetic acid (d = 1.0196 g mL-1), collected 
in a pre-weighed microfuge tube, and analyzed with an Ultrospec 4000 UV/Vis spectrophotometer 
(Pharmacia Biotech) against a 40% acetic acid blank. All TBO-determined carboxy surface densities were 
corrected for surface roughness as determined by AFM imaging. 
The 40% acetic acid solution was chosen to avoid dissolution of the PMMA surface, which 
occurred at >50% acetic acid concentrations. The 40% acetic acid solution could, however, potentially 
remove any photo-fragments generated by scissioning of the polymer backbone during UV irradiation and 
thus produce low-molecular weight polymer chains (i.e., photo-fragments).289,299 We observed that 50% 
acetic acid solutions did produce noticeable dissolution of UV-activated PMMA surfaces. We concluded 
that the modified PMMA surface must differ in terms of its intermolecular forces compared to the 
unmodified material. This coincides with spectroscopic and water contact angle measurements suggesting 
the formation of oxidized species on the polymer’s surface after UV exposure. 
3.2.5 Spectroscopic Analyses 
AFM images were acquired with an MFP3D AFM instrument (Asylum Research) in repulsive 
tapping mode at a rate of 0.40 Hz over a 100.0 µm2 area with 65,536 points per image. The Tap300A1-G 
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cantilever tips (Ted Pella) had a frequency of 300 kHz and force constant of 40 N/m. The manufacturer’s 
software was used for image analysis. For XPS measurements, C 1s and O 1s photoelectron signals were 
acquired using an Axis Ultra DLD X-ray photoelectron spectrometer (Kratos Analytical) under ultra-high 
vacuum conditions (10-8 to 10-10 Torr) with a monochromatic Al Kα X-ray source, 20 eV pass energy, 370 s 
acquisition time, 1,600 ms dwell time, and 20° electron take-off angle. Given an inelastic mean free path 
of 3-4 nm, ~95% of the resultant signal originated 9-12 nm from the surface.300-302 ATR-FTIR spectra were 
scanned from 375-4000 cm-1 using an ALPHA FTIR spectrometer and a Platinum ATR module (Bruker 
Optics). Raman spectra were recorded using an inVia Raman Confocal microscope (Renishaw) excited 
using the 457.9 nm output of a Stabilite 2017 Ar ion laser (Spectra-Physics). A neutral density filter was 
used to produce 10 mW of laser power at the sample. Spectra were scanned from 610-2300 cm-1 with 10 
s exposure averaged over 3 scans. For SEM, substrates coated with a 3-4 nm layer of Au/Pd were imaged 
under high vacuum with an FEI Quanta 200 field emission gun at a 10 kV accelerating voltage and an 
Everhart-Thornley detector. 
3.2.6 Conjugation Reactions and Fluorescence Imaging 
Cy3-labeled oligonucleotides (40 µM) suspended in PBS buffer (100 mM, pH = 7.4) containing EDC 
(10 mg mL-1) were either spotted (0.25 µL) on planar substrates or filled into assembled microfluidic 
devices. NL493-streptavidin was conjugated by functionalizing an activated surface with EDC (20 mg mL-
1) and NHS (2 mg mL-1) in MES buffer (pH = 4.8) for 15 min, air drying, spotting (0.25 µL) with NL493-
streptavidin (1 mg mL-1) in 150 mM PBS (pH = 7.4). These conjugation reactions proceeded overnight at 
4˚C in the dark in a humidified incubation chamber. Planar substrates were incubated in 0.1% SDS 
overnight in the same manner. Microchannels were rinsed with >2 mL of 150 mM PBS (pH = 7.4) and >2 
mL of 0.1% SDS in DI water. Microchannels were cut using a saw and were sonicated in DI water for 15 
min prior to imaging. All images were 16-bit resolution without binning and were acquired for 230 ms 
using a 200M inverted microscope (Zeiss) that contained an XBO 75 Xe arc lamp, a single band filter set 
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(Omega Optical), and a Cascade 1K CCD camera (Photometrics) with Micro-Manager software. Final 
images were analyzed using the Image-J software. 
3.2.7 Microfluidic Chips for CTC Selection 
CTC microfluidic chips were fabricated in PMMA or COC substrates. The chip design,76 which 
consisted of a z-configuration and was a second generation chip compared to our reported design,158,172 
consisted of a 26.3 x 20.5 mm footprint with inlet and outlet leading channels (20.5 mm long, 400 µm 
wide, and 150 µm deep) connecting a series of 50-curvilinear channels that in concert formed the cell 
selection bed. Figure 3.6 shows the CTC selection chip design and an SEM image of a section of the mold 
master with microchannels. Each curvilinear selection channel was 30.6 mm long, 150 µm deep, and 30 
µm wide. The surface area of the CTC selection bed was 596 mm2 (11 mm2/channel) with 45.1 mm2 of 
that surface area in the lead channels. The chip’s total volume was 9.4 µL (138 nL/channel) with 2.5 µL 
volume for the lead channels.  
Antibody immobilization was carried out in a two-step process. A UV-activated thermally 
assembled device was loaded with a solution containing 20 mg mL-1 EDC and 2 mg mL-1 NHS in 100 mM 
MES (pH = 4.8) for 15 min at room temperature to obtain a succinimidyl ester intermediate. After this 
incubation, the EDC/NHS solution was removed by aspirating through the microchip with a vacuum pump 
followed by immediately flooding the chip with an aliquot of a solution containing 0.5 mg mL-1 of the 
monoclonal anti-EpCAM antibody in 150 mM PBS (pH = 7.4). The reaction was allowed to proceed at 4oC 
overnight. The device was then rinsed (4 mm/s) with 2 mL of PBS/0.5% BSA (pH = 7.4) to remove any non-
specifically bound anti-EpCAM antibody. 
3.2.8 Patient Derived Xenografts (PDX) Models for Pancreatic Ductal Adenocarcinoma (PDAC) and Clinical 
Sample Processing 
Patient derived xenograft (PDX) models were generated from PDAC patient tumors and were 
grafted into the subcutaneous tissue of NSG/NOD or Nude mice under approval by the University of North 
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Carolina’s IRB following protocols set by the University of North Carolina School of Medicine Institutional 
Animal Care and Use Committee. 
Nude mice (6-8 weeks of age) were purchased from Harlan Sprague Dawley. The mice were 
anesthetized with 100 mg kg-1 ketamine and 1 mg kg-1 domitor. When the proper plane of anesthesia was 
reached, a sterile ophthalmic gel was placed in each eye. The injection area was sterilized with ethanol 
and betadaine. A flank xenograft procedure was as follows: (i) a 3 mm incision was made on each flank by 
lifting the skin with forceps and cutting with microdissecting scissors; (ii) hemostat forceps were used to 
loosen the skin inside the incision for subsequent tumor implantation, which was obtained from a patient 
biopsy sample possessing a tissue biopsy sample from a metastatic pancreatic ductal adenocarcinoma 
patient; (iii) a maximum of three 1 mm matrigel-coated pancreatic tissue cubes were then transferred 
into the subcutaneous space of each incision; (iv) the incision was closed with a Nexaband liquid and 
simple interrupted sutures using monofilament 3-0 nylon (Maxon) or surgical clips; and (v) 500 µL of 0.9% 
sterile saline was injected IP. The mouse was transferred to a recovery area and was warmed with a 
heating blanket. Lidocaine was used pre-operatively as an analgesic. After the procedure, the anesthesia 
was reversed with an injection of anti-sedan. Tumors were grown to a size ~2 cm3 for a period of 1 to 6 
months, after which whole blood was collected from the IVC into sodium citrate tubes (final 
concentration, 0.38%). Cardiac puncture was determined as the optimal route for collection of blood to 
minimize contamination by epithelial cells.303 A total of 9 PDX models were used for this study. 
Two patients with advanced melanoma and two with colorectal cancer were recruited according 
to a protocol approved by the University of North Carolina’s IRB. All blood specimens were collected into 
BD Vacutainer® (Becton-Dickinson) tubes containing the anticoagulant EDTA and were processed within 
3 h of the blood draw.  
 For CTC analysis from patient derived xenografts, a 0.5 mL volume of whole blood was infused, 
and for clinical samples, 2 mL of blood was infused directly into the CTC chip at 1.6 mL/h, or a linear 
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velocity of ~2.5 mm/s.158 Following infusion of the blood sample, a post-selection rinse was performed 
with 1 mL of 150 mM PBS/0.5% BSA (pH = 7.4) at 3.2 mL/h (~5.0 mm/s). Selected cells were analyzed and 
identified via immunostaining by: (i) treating with Fc blocker (IgG); (ii) incubation with anti-mouse or anti-
human CD45-FITC Abs for 30 min; (iii) cell fixation with 2% FA; (iv) poration with 0.1% Triton-X100; and (v) 
incubation with CK8/19-PK Abs and the nuclear dye, DAPI. Images of stained cells were obtained using an 
Olympus IX71-DSU Spinning Disk Confocal inverted microscope controlled via MetaMorph software and 
furnished with 10x, 20x, and 40x dry objectives, a mercury arc lamp illumination source, two cameras 
(high sensitivity Hamamatsu EMCCD and high resolution Hamamatsu ORCA-03G CCD), and DAPI, FITC, 
TRITC, and Cy5 filter sets. CTCs from clinical samples were also enumerated with an impedance sensor. As 
the CTCs traversed through the impedance sensor, an electrical signal was recorded for single cells using 
electronics designed and built in-house as described previously.158 The raw output data was subjected to 
a 1,000 point adjacent averaging algorithm to establish the baseline for the measurement without 
generating signal bias. Baseline was then subtracted from the data in order to correct for signal drift. 
Impedance responses were counted as CTCs when the signal-to-noise threshold exceeded 3:1.   
Figure 3.1 Meshed geometry for CFD simulation of curvilinear channels with trapezoidal cross sections 
after hot-embossing and stringent annealing. Each mesh contains >1,600,000 elements (shown on the 




3.2.9 Computational Fluid Dynamics Simulations 
To investigate the dynamics of fluid flow through the curvilinear microchannels, we conducted 
CFD simulations using COMSOL Multiphysics® 4.3a. The hot-embossed curvilinear channel architectures 
was constructed in three dimensions using AutoCAD and SolidWorks and imported into COMSOL, where 
a mapped mesh was applied to the cross section and swept across the curvilinear channel to generate a 
final mesh with >1,600,000 elements (shown with dimensions in Figure 3.1). Laminar flow was applied 
throughout the geometry with inlets and outlets for the fluid governed by the experimental linear velocity 
for optimal CTC capture (see main text) and solved using the PARDISO algorithm, pseudo-time stepping, 
and a minimum convergence tolerance of at least 10-4. In the case of describing blood’s non-Newtonian 
behavior, the Carreau model was applied, where the effective viscosity (𝜇𝑒𝑓𝑓) was given by: 
𝜇𝑒𝑓𝑓 = 𝜇∞ + (𝜇0 − 𝜇∞)[1 + (𝜆 · ?̇?)
2]
𝑛−1
2  (3.1) 
where 𝜇∞ = 0.0345 𝑔/(𝑐𝑚 · 𝑠) and 𝜇0 = 0.56 𝑔/(𝑐𝑚 · 𝑠) and are blood’s viscosity at infinite and zero 
shear rate (?̇?), respectively, 𝜆 = 3.313 𝑠 is the relaxation time, and 𝑛 = 0.3568 is the power index. 
Additionally, the blood’s density (𝜌) was set to 1.06 𝑔/𝑐𝑚3.240,241 
3.3 Results and Discussion 
Herein, we investigated issues associated with UV activation of microstructured polymers to form 
surface-confined functional groups for biologic attachment. Specifically, we seek to address the following 
questions: What is the surface coverage uniformity of functionalities (i.e., carboxyl groups) in high-aspect 
ratio microchannel surfaces following UV-activation? Does the surface coverage depend on the channel’s 
geometry and the polymer’s optical properties? Does the thermal fusion bonding process affect surface 
functional group densities generated by UV irradiation? We will finally demonstrate how these issues 
impact the performance of a microfluidic device for CTC analysis. 
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It has been documented that the surface density of mAbs on selection channel walls determines 








where 𝐴𝑐  is the cell contact area with the surface, kB is Boltzmann’s constant, θ represents the absolute 
temperature, NR is the receptor density (antigen expression level of the CTC), lb is the extent of stretch 
to reach the critical force before breaking the antigen/Ab association, NL is the surface density of active 
mAbs, KD is the antigen/mAb dissociation constant, and η is an adjustable fitting parameter.158 Because a 
CTC can be lifted from the surface when the hydrodynamic shear force (Fs) exceeds FA, selected CTCs can 
be more easily removed when Nr or NL is small (i.e., when the selection Ab load is low or when CTCs 
have low target antigen expression levels). One could operate at extremely low shear to improve CTC 
yield in these cases44 but at the expense of both throughput and purity.296 Therefore, to improve CTC 
clinical yield, it is imperative to maximize NL by generating uniformly and highly activated microchannel 
surfaces on which selection mAbs can be covalently tethered. We hypothesized that the substrate 
material (i.e., transmissivity to the activating radiation), channel geometry and thermal processing post-
activation would affect the surface functional group density and thus, NL. 
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Figure 3.2 Carboxy surface densities determined by collecting TBO solution from UV-modified and thermal 
fusion bonded PMMA and COC microchannels with several different aspect ratios. Zero aspect ratio 
indicated UV/thermal, planar substrates. 
 
3.3.1 Assessing UV Activation Efficiency and Uniformity within Microfluidic Channels 
The polymer’s optical properties and the channel’s dimensions are two primary factors that may 
affect the efficiency of UV activation within microfluidic channels. If the polymer substrate’s optical 
transmissivity is poor, the flux of modifying radiation reaching microchannel surfaces could be reduced, 
and this would be especially true for high aspect ratio microchannels, which enable high throughput 
processing of clinical specimens without sacrificing yield.296  
We first evaluated the transmissivity of 250 µm thick polymer films before and after UV activation 
(Appendix 3.8). Pristine PMMA’s 1.5% transmissivity at 254 nm was reduced to 0.5% after UV activation. 
Pristine COC showed a transmissivity of 53.8% that changed to 36.8% after 15 min UV irradiation. Due to 
the low transmissivity of PMMA, the flux of the UV radiation reaching surfaces of high aspect ratio 
structures will be damped, whereas this is less likely for COC microstructures. 
We determined the carboxyl group surface densities for various aspect ratio microchannels using 
a colorimetric assay with the cationic TBO dye that binds electrostatically (1:1 ratio) to deprotonated 
carboxylic acid functionalities.304,305 Thermally fusion bonded microchannels were incubated with a TBO 
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solution, then washed, and the remaining TBO molecules were released using acetic acid and the effluent 
evaluated spectrophotometrically. As a note, the TBO assay employed not only probed surface functional 
groups, but also could probe molecules in underlying layers due to photo-fragmentation of surfaces. 
Photo-fragmented surfaces were essentially porous to the small TBO molecules. Consequently, absolute 
carboxyl surface densities were biased by the extent of surface photo-fragmentation.  
As the microchannel’s aspect ratio increased, the carboxyl surface densities in both PMMA and 
COC microchannels decreased (Figure 3.2). Even with an aspect ratio of 0.5, the carboxyl surface densities 
for PMMA decreased from 12.4 ± 1.8 nmol/cm2 to 3.5 ± 0.1 nmol/cm2 relative to UV-activated and 
thermally treated, planar substrates. Similarly, the respective values were 9.5 ± 2.3 nmol/cm2 to 2.6 ± 0.3 
nmol/cm2 for COC microchannels. Further decreases in these signals due to increasing aspect ratio were 
likely caused by optical filtering of UV light, even in the more transparent COC substrate; however, it is 
unknown whether decreased UV flux would lead to less surface carboxyl formation or enhanced efficiency 
of photo-fragmentation processes. 
To specifically assess the surface densities of carboxyl groups that are accessible to biologic 
macromolecules on the microstructures, we coupled fluorescently-labeled (3’ end) oligonucleotides 
containing a pendant amino group on their 5’ end to accessible carboxyl groups in microchannels. Results 




Figure 3.3 (A) Curvilinear channels (30 x 80 µm, w x d) were cut along their length to expose Cy3-labeled 
oligonucleotides immobilized along sidewalls. 5X fluorescence images of controls and Cy3-labeled 
oligonucleotides are shown for (B,C) PMMA and (D,E) COC, respectively. 20X fluorescence images for (F) 
PMMA and (G) COC are presented along with (H) line plots as indicated by the thick, dotted lines. Controls 
were Cy3-labeled oligonucleotides immobilized without the EDC coupling agent and measure non-specific 
adsorption and autofluorescence. Only control images are scaled to the same intensity as their 
counterparts. All other fluorescence images are not normalized. 
 
± 72 cps vs. 2357 ± 218 cps, respectively (Figure 3.5G-H). These observations match spectroscopic 
evidence (see below) that show more efficient carboxyl formation on COC surfaces, likely due to highly 
competitive scissioning pathways leading to more photo-fragmentation for PMMA. 
In microchannels cut along their lengths to expose oligonucleotides immobilized onto the sidewalls, we 
observed non-uniform coverage of Cy3-labeled oligonucleotides on the PMMA channel wall (Figure 3.3), 
where the top third of the microchannel showed significantly higher levels of fluorescence (384 ± 81 cps)  
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Pristine 76.4±1.4 1.4 0.2±0.1 0.32 0.0 21.4 3.1 
UV 36.7±0.9 8.6 14.7±2.6 0.38 1.9 25.2 13.9 
UV + 102˚C 63.9±1.2 9.0 12.4±1.8 0.32 1.0 24.8 8.5 
COC 
Pristine 95.5±1.8 4.8 0.3±0.2 0.01 0.0 0.0 0.0 
UV 43.1±1.9 17.9 19.0±2.9 0.27 8.9 11.2 13.4 
UV + 130˚C 80.0±3.0 12.0 9.5±2.3 0.10 3.0 10.5 7.8 
1 % COOH of total C 1s signal 
 
compared to the bottom two thirds of the same channel (112 ± 55 cps). However, this was not observed 
for COC microchannels, which showed both higher oligonucleotide loading based on higher fluorescence 
intensity irrespective of the vertical position along the channel wall (2233 ± 310 cps over entire depth). 
3.3.2 Thermal Effects on UV-Activated Thermoplastics 
Following micro-replication and UV-activation of the micro-structured substrate, a cover plate is 
thermal fusion bonded to the substrate to enclose the fluidic network.158,172,296 In this section, we were 
interested to understand the effects of thermal processing on the accessibility of the functional groups 
resulting from the UV activation step. As such, we examined planar sheets of the appropriate 
thermoplastic with a variety of spectroscopic techniques to determine the surface chemistry resulting 
after thermal treatment. 
The water contact angles (WCAs) for pristine PMMA and COC substrates were 76.4 ± 1.4˚ and 
95.5±1.9˚, respectively. Because COC is composed entirely of saturated hydrocarbons, this polymer is 
more hydrophobic than PMMA, which contains ester moieties producing a lower water contact angle for 
pristine PMMA. Neither of these pristine polymers should generate significant TBO colorimetric signals 
because the positively charged TBO molecules electrostatically bind only to negatively charged functional 
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groups.304,305 At pH = 10.5, only carboxylic acids are deprotonated and thus available for TBO association. 
The small signal (0.2 - 0.3 nmol/cm2) observed for the pristine surfaces (Table 3.1) was most likely due to 
non-specific adsorption to the surface.306 All values discussed henceforth have been corrected for this 
background signal. 
 Upon UV irradiation, activation of the surfaces was apparent as the wettability increased; water 
contact angles decreased by 52.0 ± 1.6% (from 76.4 ± 1.4° to 36.7 ± 0.9° after modification) and 52.8 ± 
2.5% (95.5 ± 1.8° to 43.1 ± 1.9° after modification) for UV-modified PMMA and COC, respectively (Table 
3.1). The TBO signals for these surfaces corresponded to carboxyl functional group densities (see 
calibration curve in Appendix 3.1) of 14.5 ± 2.6 nmol/cm2 and 18.7 ± 2.9 nmol/cm2, respectively. As noted, 
while these TBO signals are indicative of relative changes in the degree of activation through generation 
of carboxyl groups, they cannot be interpreted as absolute surface densities. 
The carboxyl group densities on UV-treated polymers determined by the TBO assay were higher 
than theoretically possible for a carboxylic acid monolayer on either surface (0.83 nmol/cm2).307 This 
anomaly can be explained by scissioning and fragmentation of the surface polymer chains upon UV 
irradiation.289,299 The photo-damaged surface may be porous to the TBO molecules, increasing the 
apparent probed surface area several-fold.289 We provide thorough evidence for this photo-fragmentation 
in Appendix 3.2 including microscopy images of ablated surfaces.  
After the UV-activated PMMA surface was washed with IPA, the RMS roughness decreased by 
90% (Appendix 3.2), and the TBO signal decreased to 1.5 ± 0.5 nmol/cm2, which agreed with previously 
reported values.289 These changes likely occurred due to dissolution and removal of carboxylated surface 
photo-fragments (Appendix 3.2).308 Consequently, these surface fragments can confound the TBO results. 
For example, even though ablation and fragmentation were substantial for UV-irradiated PMMA 
(Appendix 3.3), the UV-COC surface gave the greatest TBO signal (18.7 ± 2.9 nmol/cm2). This signal is likely 
  
106 
due to more efficient carboxylic acid formation rather than increased fragmentation of the UV-activated 
COC surface, which is in accordance with our spectroscopic observations. 
These carboxylated photo-fragments have a lower molecular mass and higher thermal mobility 
than the pristine material, making them critical effectors of thermally-induced changes on the surfaces’ 
carboxyl functional group densities.294 With this in mind, it is not surprising that the UV-activated PMMA 
surfaces would remain porous after heating, as evident by only a slight decrease in its TBO signal, whereas 
the less fragmented UV-activated COC surface showed larger decreases in its TBO signal. Accompanying 
these losses, the water contact angles for these surfaces returned to near their pristine values following 
thermal treatment (Table 3.1), and there was a change in the UV-activated PMMA surface’s morphology 
(see AFM images in Appendix 3.4) that was not observed for the UV-activated COC surface. These 
observations may be attributed to rearrangement of hydrophilic functional groups away from the surface 
due to the interfacial energy with hydrophobic air and thereby becoming inaccessible.290 This 
rearrangement would explain the losses in wettability for the thermally treated UV-activated PMMA and 
COC substrates and should be independent of the starting material’s molecular weight and purity when 
substantial fragmentation occurs (0).  
3.3.3 ATR-FTIR, Raman, and XPS Analyses of Thermally Treated, UV-Activated Polymers 
For the pristine substrates, all spectra agreed with referenced spectra.287,290,309-311 For semi-
quantitative analysis, ATR-FTIR signatures were integrated over the C=O and O-H stretching regions. XPS 
C 1s spectra were deconvoluted to calculate the percent of the C 1s signal from carboxyl groups (see SI). 
The XPS and ATR-FTIR data are presented in Table 3.1, and the C 1s spectra and relevant regions of the 
FTIR spectra are presented in Figure 3.4. Deconvoluted peaks for the pristine and UV-modified polymers 
and a detailed set of deconvoluted C 1s peak percentages are presented in Appendix 3.7. 
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Figure 3.4 (A,B) Carbonyl regions of the ATR-FTIR spectra, (C,D) hydroxyl regions of the same spectra, and 
(E,F) C 1s XP spectra for PMMA and COC, respectively. Shown are spectra for pristine substrates (solid 
grey lines), UV-activated (dotted black lines), and UV/thermal (solid black lines) surfaces. General peak 
positions are labeled on the XP spectra corresponding to deconvoluted functional groups, where R 
generically represents carbon or hydrogen. See Appendix 3.7 for detailed XPS deconvolution methods. 
 
There were changes in the carbonyl region of the UV-activated PMMA ATR-FTIR spectra (Figure 
3.4A). The pristine substrate’s ester C=O stretch at 1719 cm-1 broadened to include stretches with higher 
and lower energy (an increase in peak area of 3.8 au·cm-1 integrated from 1650-1850 cm-1) that 
corresponded to the formation of carboxyls and aldehydes/ketones, which comprised only 1.9% and 7.0% 
of the XPS C 1s signal, respectively.312 Hydroxyl groups were abundant in the XPS data, 8.5% of UV-
activated PMMA’s total C 1s signal (Figure 3.4C, Appendix 3.7). Taken together, these data strongly 
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suggest that carboxyl formation is only a minor product of PMMA’s UV activation, with scissioning and 
aldehyde, ketone, and hydroxyl formation serving as competing reactions. 
Strong signals from carboxyl containing functionalities were observed spectroscopically for UV-
activated COC. Pristine COC did not contain either carbonyl or hydroxyl peaks, but after UV activation, a 
C=O peak at 1711 cm-1 and a 3430 cm-1 hydroxyl peak were observed with relatively large peak areas of 
11.2 au·cm-1 (1520-1850 cm-1) and 13.4 au·cm-1 (3075-3700 cm-1), respectively. In an effort to deconvolute 
the C=O peak and isolate carboxyl formation, we first disproved the supposition that the small shoulder 
at 1637 cm-1 (Figure 3.4B) was due to alkene formation after scissioning of COC’s norbornane ring because 
no changes were observed in the Raman spectra of UV-modified COC (Appendix 3.7). Rather, 
aldehydes/ketones generated this stretch along with 7.1% of the deconvoluted C 1s spectrum, as 
compared to 8.9% carboxyl (Figure 3.4F, Appendix 3.7). These data are the first detailed spectral 
information to be published with regards to the UV/O3 activation of COC and showed that carboxyl groups 
can be directly generated on a COC surface by this simple activation modality.292,313 Moreover, this 
activation method is clearly more efficient at producing carboxyl groups on COC than PMMA.  
Besides quantification of the formation of surface-confined carboxylic acids, of great interest was 
whether the ATR-FTIR and XPS results support or reject the hypothesis that photo-fragments have a 
propensity to thermally rearrange and thus bury carboxyl moieties into the bulk polymer. In general, ATR 
evanescent waves penetrate from hundreds of nanometers to tens of micrometers, but penetration depth 
is linearly dependent on the wavelength of light passing through the ATR crystal and inversely dependent 
on the wavenumber.314 Therefore, hydroxyl peaks are more surface specific, with a penetration depth 
roughly half that of carbonyl signals. Decreases in the UV and thermally treated PMMA and COC surface 




Figure 3.5 Images of Cy3-labeled oligonucleotides immobilized on UV and UV/thermal planar substrates 
for (A,B) PMMA and (C,D) COC, respectively. (E,F) NL493-streptavidin was immobilized on UV and 
UV/thermal COC, respectively. Images of Cy3-labeled oligonucleotides immobilized within UV-modified 
and thermal fusion bonded (G) PMMA and (H) COC microchannels. All fluorescence images of Cy3-labeled 
oligonucleotides are scaled to same intensity. NL493-streptavidin images are scaled independently. 
 
peak areas, 50% and 42%, respectively. Secondly, the carboxyl C 1s signals, which are highly surface 
specific probing only 9 nm to 12 nm into the bulk,300-302 decreased by 47% and 66% after heating UV-
activated PMMA and COC, respectively, and the corresponding decreases in the O/C ratios were 100% 
and 63%. This data supports the generation of hydrophobic surfaces by thermal migration of hydrophilic 
functional groups present on photo-fragments, including carboxylic acids, away from the surface during 
thermal processing. 
3.3.4 Fluorescence Images of Immobilized Cy3-Labeled Oligonucleotides to UV Activated Thermoplastics 
Selection of a polymer for a fluidic device based on efficient coupling of biological 
macromolecules, such as mAbs, to its surface-confined carboxylic acid groups depend on both the degree 
of UV-induced carboxyl formation and fragmentation during UV exposure. Even though carboxyl surface 
densities are generally reduced during thermal processing, we have not shown that this will completely 
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inhibit the coupling of biologics to these functional scaffolds. As an example, biologic monolayers are 
roughly three orders of magnitude less dense than carboxyl monolayer.307 
 To illustrate the consequences of the heating effects detailed above, we covalently tethered Cy3-
labeled oligonucleotides to substrates that were UV-activated and subsequently thermally treated (Figure 
3.5). The background-subtracted fluorescence intensity on UV-activated COC presented higher signal 
(1978 ± 229 cps) compared to UV-activated PMMA (282 ± 98 cps). The oligonucleotide load on UV-
activated COC was ~5 times greater than on UV-activated PMMA and indicated that surface-accessible 
carboxylic acids generated on the UV-activated PMMA surface must be less than an oligonucleotide 
monolayer. After heating the UV-activated PMMA surface, the fluorescence of PMMA’s oligonucleotide 
load decreased substantially (61 ± 98 cps), matching the substantial losses after heating observed in the 
FTIR and XPS data.  
The oligonucleotide load on UV-activated COC increased after thermal treatment (Figure 3.5D). 
However, we speculate that this observation was an artifact of the surface’s increased hydrophobicity 
after heating, which could have improved the kinetics of oligonucleotide immobilization by hydrophobic 
interaction with the partially unfolded oligonucleotide.315,316 This is supported by the fluorescence of 
immobilized NL493-streptavidin on both UV-activated COC and thermally treated UV-activated COC 
surfaces (Figure 3.5E-F), which yielded signals that were not statistically difference at the 95% confidence 
level. 
3.3.5 Polymer Choice and UV-Activation Scheme for Efficient CTC Clinical Recovery and Purity 
Thermoplastics are attractive substrates for in vitro diagnostics, such as CTC selection assays, due 
to the ability to manufacture devices at low cost and in a high production mode, and UV activation is a 




Figure 3.6 (A) Schematic operation of the CTC selection module with 50 parallel, sinusoidal microchannels 
and inlet/outlet channels arranged in the z-configuration. The large arrow indicates sample flow direction 
through the selection channels. (B) SEM of the selection bed showing high-aspect ratio (30 x 150 µm, w x 
d) sinusoidal microchannels and the output channel. (C) Composite fluorescence images of a CTC stained 
with DAPI(+), CK8/19(+), and not with CD45(-). (D) Four WBCs staining positively for DAPI(+) and CD45(+) 
and negatively for CD8/19(-). (E) Fluid dynamics simulation results showing the distribution of flow 
velocities and shear stress in microfluidic selection channels. 
 
such as anti-EpCAM mAbs.76,239  In light of the results discussed above, the choice of thermoplastic (PMMA 
or COC) may be guided by the polymer’s response to UV radiation. In this section, we evaluated UV-
activated and thermally fusion bonded PMMA and COC devices for the positive selection of CTCs. In 
particular, we were interested in comparing clinical yields and purity of the selected CTC fractions from 
undiluted, unfixed, and unfractionated blood.  
The CTC selection device utilized herein employed an array of 50, curvilinear, high-aspect ratio 
microchannels with nominal dimensions similar to ones previously reported by our group (30 µm x 150 
µm x 30.6 mm, w x d x l).158,172 The depth of these channels increased the throughput as well as provided 
reduced pressure drop throughout the selection channels, especially when occupied by captured 
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CTCs.76,158 SEM indicated that the widths of the top and bottom of the channels were 27.8 ± 1.0 µm and 
19.7 ± 0.5 µm, respectively (aspect ratio of ~6.3). On average, the widths of these microchannels are only 
slightly larger than the average CTC diameter (12-25 µm) but much larger than the average leukocyte 
diameter (7-15µm). Channel width plays a critical role in maximizing the probability of cell/wall 
interactions and allows for achieving high CTC yield but lower probability of interactions with smaller 
cells.158 For even smaller cells, such as erythrocytes, the likelihood of approaching the channel wall is very 
limited due in part to the formation of a marginal cell-free layer.317,318  
Fluidic addressing of the microchannel array was achieved using a z-geometry, in which large cross 
section inlet and outlet channels were poised orthogonal to the curvilinear microchannels (Figure 3.6). 
This geometry was recently introduced by our group as a replacement for our previous CTC isolation 
device and offers a smaller overall footprint, retains uniformity of the flow between all selection channels 
thus ensuring optimal recovery throughout the device,158 and demonstrates a reduction in the formation 
and persistence of air bubbles formed during blood infusion. Additionally, the z-geometry addressing is 
easily scalable to isolation beds comprised of larger number of microchannels, which allows for high 
throughput processing of relatively large input volumes (<45 min for 500 selection channels and 7.5 mL 
input volumes).76  
For both PMMA and COC substrates, hot-embossed microfluidic devices and cover plates were 
UV-irradiated and thermal fusion bonded prior to EDC/NHS coupling of mAbs to the microchannel 
surfaces. Between 500 and 850 µL of whole blood, acquired from PDX models that were engrafted with 
tumor tissue biopsied from human patients with metastatic pancreatic ductal adenocarcinoma (PDAC), 




Figure 3.7 Box plots presenting count of CTCs and WBCs selected in UV-PMMA (5 PDX) and UV-COC (4 
PDX) chip from mice blood samples. Data are normalized to 1 mL.  Lower and upper edge of box shows 
25th and 75th percentiles, respectively. Solid line in box represents median, and solid diamond represents 
mean. Error bars show maximum and minimum values. 
 
and rinsing, cells were stained on-chip and counted, and the devices’ figures-of-merits were evaluated. 
White blood cells were scored as DAPI(+) and FITC-CD45(+), but PE-CK8/19(-). CTCs were DAPI(+), PE-
CK8/19(+), and FITC-CD45(-) (Figure 3.6C,D). Purity was defined as the ratio of PE-CK8/19(+) cells to the 
total number of nucleated cells (PE-CK8/19(+) and FITC-CD45(+)) captured within a device.56 Figure 3.7 
provides a summary of the CTC results for PMMA and COC devices. 
COC devices provided higher clinical yields of CTCs compared to PMMA devices. We observed a 
37 ± 20% increase in the number of selected CTCs from PDX models for UV-activated COC versus UV-
activated PMMA devices. For the high aspect ratio channels, higher loads of covalently coupled mAbs 
throughout the channel wall depth were observed for the COC device compared to the PMMA device. In 
the PMMA device, a portion of mAbs may have been physisorbed to the selection surfaces, especially 
towards the bottom of the channel, leading to decreased antigen-binding activity.276 The higher load of 
active mAbs to the COC microchannel surfaces (effective increase of NL in Eq. 3.2) would improve the 
adhesion force of selected CTCs, especially for CTCs with low EpCAM expression that are expected in 
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clinical samples, and provide higher yields consistent with Eq. 3.2.76 Two melanoma and two colorectal 
cancer patients blood were also analyzed using UV-activated and mAb functionalized COC selection 
devices using anti-EpCAM mAbs; we detected an average of 29 ± 17 CTCs and 30 ± 6 CTCs in 2 mL of blood 
(negative control CTCs = 3 ± 3 in 2 mL). 
 We determined the purity level of the selected fractions from PDX mouse model samples and 
found these to be 78.3 ± 19.7% and 98.8 ± 2.4% for the UV-activated PMMA and UV-activated COC devices, 
respectively. Furthermore, the purities of the isolated CTCs from clinical samples were >90%. Studies using 
the CellSearch™ system have reported much lower purities, approximately 0.01 to 0.1%.131  
We are currently in the process of enumerating and analyzing CTCs from other epithelial-based 
cancers, i.e., ovarian, prostate, and pancreatic cancers, using our UV-activated COC CTC devices.76 Side by 
side evaluation of clinical samples using the CellSearch® system along with our technology would provide 
valuable characterization of our device’s performance merits, such as capture efficiency, purity, and ability 
to enrich cells with low EpCAM expression level as some reports suggest that the CellSearch® assay does 
not isolate such CTCs efficiently.29  
The improvement in purity for COC devices can be explained by more efficient surface activation 
and mAb immobilization. Interfering leukocytes can be activated by various properties of a surface, 
including surface polymer chain mobility, surface chemical composition, hydrogen bonding properties, 
charge density, and hydrophobicity/hydrophilicity.319,320 Within short periods of time, a polymer’s 
hydrophobic domain can lead to leukocyte adsorption. Due to less efficient activation, the presence of 
these hydrophobic domains was likely more prevalent in UV-activated and thermally fusion bonded 
PMMA devices as compared to COC devices. 
We conducted three-dimensional, computational simulations of the dynamics of fluid flow 
through the microfluidic selection channels (Figure 3.1) and observed average shear stresses of 3.4 
dynes/cm2 for buffer and 13.3 dynes/cm2 for blood, which matches well with analytic expressions and is 
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approximately an order of magnitude larger than comparable devices.43,87,31,321 In such flow conditions, 
the high shear stress along the high aspect ratio microchannels (Figure 3.6E) can disrupt associations with 
low 𝐹𝐴 (Eq. 3.2). Thus, a high percentage of weakly associated leukocytes should be removed.
31,158 This 
may not be the case for the designs utilizing microposts or herringbones as they possess low velocity 
regions behind posts and within herringbone grooves.44,68 Leukocytes in these regions will likely not 
experience strong shear forces to remove them from the surface. Even though we observed an increase 
in purity of isolated CTC fractions for UV-activated COC devices, the purities for both materials are the 
highest reported for CTC analysis.44,56,96  
3.4 Conclusions 
We have provided evidence elucidating two previously unreported effects that occur during the 
UV-activation of polymer microfluidic devices that are subjected to thermal fusion bonding for assembly 
and are also comprised of high aspect ratio microchannels, especially those applied to CTC analysis. Our 
results indicated that thermal fusion bonding of microfluidic channels reduces carboxylic acid surface 
densities because of photo-fragmentation occurring during UV irradiation. This phenomenon is much 
more pronounced for PMMA as compared to COC. Furthermore, the extent and uniformity of 
microchannel activation was highly dependent on the polymer’s optical properties. For COC, its excellent 
optical properties enabled uniform functional group generation throughout the microchannel’s depth, 
even for high aspect ratio structures, that translated into a more uniform coverage of mAbs attached to 
its walls. We applied this knowledge to guide the choice of proper material for a microfluidic device to 
select CTCs directly from whole blood with high recoveries and purities. The COC-based device provided 
both higher clinical CTC yields and better purity of the selected fractions compared to PMMA.  
    
116 
CHAPTER 4. ENZYMATIC CLEAVAGE OF URACIL-CONTAINING SINGLE-STRANDED DNA LINKERS 
FOR THE EFFICIENT RELEASE OF AFFINITY-SELECTED CIRCULATING TUMOR CELLS 
4.1 Introduction 
The ability to release affinity-selected cells, such as circulating tumor cells (CTCs), from surfaces 
containing selection antibodies (Ab) without perturbing the cells’ morphology, viability, molecular content 
and phenotype has been a major challenge. In spite of the challenge, compelling applications would result 
from the ability to release the selected cells such as securing molecular information from the cells that 
can be used for basic discovery and/or molecular diagnostics. 
The challenges associated with current release strategies include inefficient release or damage 
imposed on the cell by the release process. For example, cell release by shear-based methods155,322 are 
highly dependent on the number of attachment points between the cells’ antigens and surface 
immobilized Abs. Excessively high shear rates are required to release cells with multiple attachment 
points, which can damage them, especially fragile CTCs.323 Synthesis or graft methods are incompatible or 
difficult to apply in microfluidic devices,183  which have proven to be an attractive platform for CTC 
selection due to the high recovery they offer with minimal damage imposed on the cells during selection.  
Thermally responsive materials324-326 have been used to release selected cells with an efficiency 
of ~59% and viability of 90%.324 Polymer brushes on nanostructured surfaces were capable of isolating 
cells at 37°C and releasing 90% of the selected cells after 30 min at 4°C, but the fabrication of the cell 




Figure 4.1 Cell selection and release assay. (A) mAbs immobilized to surfaces using oligonucleotide linkers 
containing a uracil residue are used for the positive selection of target cells. (B) Incubation of the selected 
cells and ssDNA linker with the USER™ enzyme system. (C) Removal of the uracil residue results in release 
of the selected cells. 
 
to isolate and release cells with 90% viability, but the purity of the isolated population was low due to 
non-specific cell adsorption to the hydrogels.181,182 Lectins were reported to isolate and release 
lymphocytes; however, the specificity resulted in low purity of the selected cell population with ~50% 
release efficiency.327 DNA aptamers have also been used for cell isolation; cells could be released using 
DNase (68%) with 66% of the released cells remaining viable.31 Proteolytic digestion of selection Abs has 
been reported, for example using trypsin.74,76,158,253 While efficient cell release was demonstrated, the 
damage of extracellular domains of membrane antigens is possible, thereby limiting the ability to 
immunostain the cells, which is required for phenotypic analysis of selected cells. Light-triggered cell 
release using photocleavable linkers attached to quartz surfaces, which achieved 85% release efficiency, 
has been reported.328 Light-based cell release methods, however, can induce DNA damage in cells that 
can confound diagnostic information.329 
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The work reported herein describes a unique assay (Figure 4.1) for the positive selection of rare 
cells with their subsequent release for post-selection applications, such as the analysis of clinical CTCs, 
flow cytometry (FC) and fluorescence in situ hybridization (FISH). Heterobifunctional linkers (Table 4.1) 
were used to immobilize monoclonal Abs (mAbs) to a UV/O3-activated fluidic surface presenting carboxylic 
acids (-COOH). mAbs were reacted with a sulfo-NHS ester of succinimidyl trans-4 (maleimidylmethyl) 
cyclohexane-1-carboxylate (SMCC), yielding a maleimide-labeled mAb (SMCC-mAb). Once purified, the 
SMCC-mAb could be covalently attached to the reduced 3’-disulfide group (sulfhydryl) of a single-stranded 
oligonucleotide (ssDNA) linker that was immobilized to the activated surface using EDC/NHS coupling of 
the ssDNA linker’s 5’-amino group to the surface-confined COOHs. Incorporating uracil (dU) into the 
ssDNA linker enabled enzymatic nicking by the USER (Uracil-Specific Excision Reagent) system and thus, 
cell release. USER consists of a mixture of Uracil DNA glycosylase (UDG) and DNA glycosylase-lyase 
Endonuclease VIII. UDG catalyzes the excision of dU forming an abasic site. Endonuclease VIII breaks the 
phosphodiester bond of the abasic site, cleaving the ssDNA linker and releasing the selected cell from the 
capture surface. The advantage of ssDNA linkers lies in their stability, low cost, and ease of covalent and 
ordered attachment to a variety of surfaces with a high load.171,330-333 Moreover, USER is active at 
physiological temperatures and in a variety of buffers, such as PBS, both of which can maintain cell 
viability.334,335 
4.2 Experimental Methods 
4.2.1 Materials 
COC surface modification included the following materials: Reagent-grade isopropyl alcohol, 1-ethyl-
3-[3-dimethylaminopropyl] carbodiimide hydrochloride (EDC), N-hydroxysuccinimide (NHS), and 2-(4-
morpholino)-ethane sulfonic acid (MES), PBS buffer (pH 7.4), and bovine serum albumin (BSA 7.5%) in PBS 
buffer, pH 7.4 (Sigma-Aldrich). The monoclonal antibodies used for these studies included rat anti-human 
anti-CD138 (clone 359103, R&D Systems), mouse anti-human anti-CD34 (clone 561, class III epitope from 
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BioLegend), mouse anti-human Fibroblast Activation Protein-α, FAPα (clone 427819, R&D Systems), 
mouse anti-human EpCAM/TROP-1 (clone 158210, R&D Systems), and IgG (R&D Systems). CTCs were 
stained with anti-CD45-FITC (clone HI30, eBioscience), anti-cytokeratin mAbs (CK-PAN-eFluor615, clone 
LP3K, BA17), (eBioscience,) to provide immunophenotyping distinction from infiltrating leukocytes. 
Other reagents used for these studies included sulfosuccinimidyl-4-(N-
maleimidomethyl)cyclohexane-1-carboxylate (sulfo-SMCC, No-Weigh Format) (Thermo-Pierce), Zeba spin 
desalting columns (7K MWCO) from Thermo Scientific, Uracil Specific Excision Reagent USER enzyme 
from New England Biosciences, and the Live/Dead cell viability kit from Life Technologies. All reagents 
were nuclease-free. Nuclease-free microfuge tubes were purchased from Ambion and were used for 
preparation and storage of all samples and reagents.  
4.2.2 Fabrication of the Cell Selection Device 
Hot embossing was used to fabricate the thermoplastic cell selection device as described 
previously.239 Mold masters for hot embossing were prepared in brass using high precision-micromilling 
(KERN 44, KERN Micro- und Feinwerktechnik GmbH & Co.KG; Murnau, Germany) and carbide bits 
(Performance Micro Tool, Janesville, WI).239 Hot embossing of the cell selection devices was performed 
using a HEX03 embossing machine (Jenoptik Optical Systems GmbH, Jena, Germany). The embossing 
conditions consisted of using a temperature of 155°C and 30 kN force for 120 s for the substrate material, 
which was cyclic olefin copolymer, COC; we have shown that COC produces high loads of functional groups 
to its surface following UV/O3 activation with minimal amounts of non-specific adsorption to its surface.75 
4.2.3 Operation of the Cell Selection Device 
Prior to blood sample infusion and following mAb attachment, the selection device was 
thoroughly washed with 1 mL of 0.5% BSA/PBS buffer at a flow rate of 40 µL/min to remove unbound 
mAb from the microchannel walls. Blood specimens collected into BD Vacutainer® tubes were placed on 
a nutator until the blood sample was processed. Two mL of patient blood was transferred into a disposable 
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Luer LockTM syringe (BD Biosciences, Franklin Lakes, NJ) using a BD vacutainer female luer transfer adapter. 
Immediately after transfer, blood samples were processed through the cell selection device. A PHD2000 
syringe pump (Harvard Apparatus, Holliston, MA) was used to hydrodynamically drive the whole blood 
sample through the selection device at the appropriate volumetric flow rate to attain an average linear 
velocity of sample through the sinusoidal microchannels (1.1 mm/s for circulating multiple myeloma cells 
(CMMCs), 2 mm/s for CTCs and KG-1 model leukemic cells).158 Finally, the cell selection device was flushed 
with 2.5 mL of 0.5% BSA/PBS at a linear velocity of 4 mm/s to remove any non-specifically bound cells.  
4.2.4 Heating System 
Temperatures were maintained on-chip using thin film resistive heaters (KHLV-101/10, Omega 
Engineering, Inc., Stamford, CT) under closed-loop PID control (CN77R340, Omega Engineering, Inc., 
Stamford, CT). Temperature feedback was provided through Type K thermocouples (5TC-TT-K-36-36, 
Omega Engineering, Inc., Stamford, CT) mounted between the cover plate and heaters. Double-sided 
thermal tape (Digi-Key) was attached to the cover plate of the cell selection device and the copper block. 
4.2.5 Oligonucleotide Linker Sequences 
Single-stranded oligonucleotide linkers with an internal dU residue were obtained from 
Integrated DNA Technologies (Coralville, IA). The sequences of oligonucleotides that were used as 
cleavable linkers (ssDNA linkers) are summarized in Table 4.1. In principle, the ssDNA linker can contain 
any sequence, however, a string of dTs at the 3’ and 5’ ends were used to eliminate multiple points of 
attachment to the solid surface as dTs do not contain primary amines. The effective footprint for each 
ssDNA linker can be calculated from the radius of gyration Rg for a coil-like ssDNA, where Rg = 0.38N1/2 nm 
and N is the number of nucleotides in the strand.336 It has been reported that the surface coverage 





Table 4.1 Sequences of the ssDNA linkers investigated in this study. 
5’-3’ Oligonucleotide sequence (length) ID Length (nm) 
NH2-C6-T10 GCT ATA TUT T6-C3-SS-C3OH (25 nt) 25dX 9.9 
NH2- C6-T8 UTT TTT TCC GAC ACT TAC GT8-C3-SS-C3OH (34 nt) 34dX 12.9 
NH2-C12-T8 CCC TTC CTC CTC ACT TCC CTT TU T9-C3-SS-C3OH (40 nt) 40dX 15.8 
NH2-C6-(C2H6O2)6-T10 U T10-C3-SS-C3OH (20 nt) 20dT 10.9 
NH2-C6-(C2H6O2)6-T30 U T10-C3-SS-C3OH (40 nt) 40dT 17.5 
 
mAb labeling involved addition of 6 μL (50x excess) of maleimide-crosslinker sulfo-SMCC (10 
mg/mL in nuclease free water) to 0.5 mg mAb in 500 µL of water followed by incubation for 1.5 h at room 
temperature on a rocker. Following reaction, the mAb was purified using a Zeba column (with exchanged 
buffer for PBS pH 7.4) to remove excess non-reacted sulfo-SMCC. mAb-SMCC in PBS pH 7.4 was stored up 
to 3 d at 4°C for cell selection device modification. When non-lyophilized mAbs were used, which 
contained sodium azide, the mAb was purified using a Zeba column prior to SMCC labeling or direct 
attachment.   
4.2.6 Modification of the Cell Selection Chip with Oligonucleotide Linkers 
A UV/O3-activated device was flooded with a solution of 20 mg/mL EDC and 2 mg/mL NHS in 100 
mM MES (pH 4.8) and incubated at room temperature. After 20 min, an air filled syringe was used to 
remove solution from the chip and immediately after that, a 40 µM solution of the ssDNA linker in PBS 
buffer (pH 7.4) was introduced into the device and allowed to incubate for 2 h at room temperature or 




Figure 4.2 Schematic of mAb immobilization onto UV/O3-activated COC thermoplastic substrate using 
cleavable ssDNA linkers. While a COC substrate is shown here, any surface containing functional groups 
can be used for the ssDNA linker attachment with slight modifications of the immobilization chemistry. 
 
After the reaction was complete, the microfluidic chip was rinsed with 100 µL PBS (pH 7.4) at 40 
µL/min  and 300 mM DTT in carbonate buffer (pH 9), which was infused into the microfluidic chip for 20 
min to reduce the 3’-disulfide group into a reactive sulfhydryl moiety (-S-H). The microfluidic chip was 
rinsed with 100 μL PBS (pH 7.4) at 50 µL/min, and immediately an aliquot of the modified mAb-SMCC was 
introduced (~0.5 mg/mL). The reaction proceeded for 2 h on ice or overnight at 4°C (Figure 4.2). 
4.2.7 Cell Release 
The cell selection device was infused with USER enzyme (2U/10μL PBS pH 7.4) and incubated at 
37oC. Immediately after incubation, the released cells were washed from the microfluidic chip at 10-25 
μL/min and collected into a well of a titer plate. When cell staining was required, the microfluidic chips 
were viewed under a microscope before and after release for visual confirmation of the release and the 
released cells were identified in the wells of a titer plate. 
4.2.8 Clinical Samples 
Patients with multiple myeloma and metastatic ovarian cancer were recruited according to a 
protocol approved by the University of North Carolina’s IRB. Blood was collected into BD Vacutainer® 
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(Becton-Dickinson) tubes containing the anticoagulant EDTA and were processed within 6 h of the blood 
draw.  
4.2.9 Cell Cultures 
KG-1 (leukemic, non-adherent) cancer cell lines were cultured in RPMI 1640 with 2.5 mM L-
glutamine supplemented with 10% FBS (GIBCO). Hs578T and SKBR3 (breast cancer, adherent) cell lines 
were grown in 1x MEM/1x NEAA/10%FBS, and 1x McCoy/10%FBS, respectively. The cell lines were 
incubated at 37˚C under a 5% CO2 atmosphere.  
4.2.10 FISH Analysis of CMMCs Isolated from Clinical Samples 
FISH analysis was performed on CMMCs selected from patient samples. CMMCs were selected 
from 1 mL of a multiple myeloma patient’s blood using CD138 mAb for selection. The mAb-modified 
microfluidic chip was washed with PBS pH 7.4/0.5% BSA before analysis and whole blood was infused at 
2 mm/s. Post-selection washing of the microfluidic chip removed remaining blood cells from the chip and 
was performed at 4 mm/s. The chip was then infused and incubated with USER enzyme at 37oC and 
immediately after incubation, cells were washed out and collected into a titer well with 1:1 (v/v) 
methanol:acetic acid. Chips were viewed under a microscope before and after release for visual 
confirmation of release. Cells were spun down for 7 min and supernatant was removed. A 3:1(v/v) 
methanol:acetic acid solution was added with this process repeated twice.  
Cell suspensions in 1:1 (v/v) methanol:acetic acid solution were transferred onto a glass slide. 
Slides were immediately placed on a hot plate at 42oC and left to dry for ~15 min. Cells on the slide were 
treated with 0.05% NP-40 in 2X SSC (Sigma Aldrich, pH 7.3) at 37oC, dehydrated successively in 70%, 85% 
and 100% ethanol at room temperature for 2 min each and dried completely. The DLEU 13q14 Kreatech 
probe with 13qter control probe was used for the FISH assay. A 7.5 µL solution of the probe (DLEU 13q14 
Kreatech probe) was applied to each slide and was covered with a coverslip and sealed with rubber 
cement. Cells with probes were denatured at 75oC for 7 min and hybridized at 37oC overnight in a HYBrite 
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oven. After removal of rubber cement and cover slips, the slides were washed in 0.4X SSC / 0.3% NP-40 at 
73oC for 2 min and then in 2X SCC / 0.1% NP-40 at room temperature for 1 min. Slides were air-dried and 
10 µL (0.1 ng/mL) of DAPI II counterstain (Vysis) was applied to each slide. The cells were analyzed with a 
Zeiss Axioplan 2 Microscope with a 63X or 100X Zeiss oil immersion objective. 
4.3 Results and Discussion 
4.3.1 Validation of Linker Cleavage in a Bench Top Experiment 
The efficiency and specificity of USER cleavage was first tested using a bench top experiment. 
10 pmol of a Cy5-labeled, 34 nt ssDNA substrate containing a single dU residue was nicked with 1 unit of 
USER™ enzyme, which is defined as the amount of enzyme required to nick 10 pmol of a 34 nt 
oligonucleotide with a single uracil residue in a total reaction volume of 10 μL in 15 min at 37°C. The 
experiment was conducted in a microtube using a standard thermo-cycler, and after set times, the 
reaction was stopped with a formamide solution in order to gauge the reaction kinetics. Products were 
separated and quantified using a CEQ 8000 Genetic Analysis System (Beckman Coulter), with the 
appearance of a 26 nt product indicating specific cleavage. 
Electropherograms revealed that the single-stranded oligonucleotides (Figure 4.3B) contained 7-
10% of the nicked oligonucleotide at the dU site prior to the enzymatic reaction as we observed both 26 
and 34 nt fragments. After 5 min of the enzymatic reaction at 37oC, the majority of the 34 nt substrate 




Figure 4.3 Electropherograms of the 26 nt (5’-T6 CCG ACA CTT ACG T8 Cy5-3‘) product generated from 
USER initiated cleavage of 34 nt oligonucleotide containing the following sequence: 5’- NH2-C6-T8 U T6 
CCG ACA CTT ACG T8 Cy5-3‘. The red traces represent the separation of standards (20 nt and 80 nt shown). 
 
min allowed the enzyme to completely nick the substrate (Figure 4.3E). These experiments demonstrated 
that the USER enzyme cleaved the oligonucleotide only at the dU residue as other products were not 
observed in the electropherograms. 
4.3.2 Linker Cleavage in a Microfluidic Device 
To evaluate the ability to select cells and then release the selected cells using ssDNA linkers 
containing a dU residue, a microfluidic device used for cell selection fabricated in cyclic olefin copolymer 
(COC) consisting of an array of sinusoidal channels (25 µm wide, 150 µm deep and 3 cm in length) was 
used as the model system. Using this microfluidic device and direct attachment of the selection mAbs to 
the activated COC surface (i.e., no ssDNA linker used), CTC recoveries of 98% have been noted.76,158 COC 
was used as the material of choice in this study because of its low propensity for showing non-specific 
adsorption artifacts and its high loads of COOH groups following UV/O3 activation.75  The USERTM reaction 




Figure 4.4 Fluorescence images of sinusoidal microchannels (A) before and (B) after 15 min enzymatic 
cleavage of a 3’-Cy3 modified 25 nt oligonucleotide containing a dU residue. The microchannel surfaces 
were activated using UV/O3 exposure and functionalized with 20 mg/mL EDC and 2 mg/mL NHS in 0.1 M 
MES (pH 4.8). After 20 min of the EDC/NHS reaction, a 40 μM solution containing the 3’-Cy3 
oligonucleotide was infused into the device. Before imaging, the device was rinsed with 0.1% SDS and 
nuclease-free water.   
 
To initially evaluate the ability to cleave a ssDNA linker when immobilized to the surface of the 
COC microchannels, the Cy5-labeled and NH2-labeled 34 nt oligonucleotide containing an internal dU 
residue was immobilized to the microchannel surfaces, visualized (Figure 4.4A), and nicked by infusing a 
solution of USER (2 U/10 μL) into the device. Successful oligonucleotide nicking was confirmed by 
microscopy, which indicated a loss of fluorescence within the microchannels (Figure 4.4B) and the 
presence of fluorescence in the effluent. Fluorescence measurements indicated 5.2 ± 0.4 pmol/cm2 of the 
oligonucleotide was cleaved from the surfaces (1.9 × 1013 linkers/device). Based on the size of a 25 nt 
ssDNA with a random sequence,336,337 the theoretical oligonucleotide surface density was estimated to be 
13.2 pmol/cm2, which is close to the measured load of the ssDNA linker. 
 It is important to note that during immobilization, ssDNA linkers can cross-link to the surface with 
multiple points of attachment due to the presence of primary amines on some of the DNA bases. To 
mitigate this, ssDNA linkers were designed (Table 4.1) containing poly dT sequences at the 3’and 5’ ends 
to eliminate crosslinking. A 20dT and 40dT sequence possessing only dT residues lack primary amines that 
could potentially compete with the 5’-amino group of the ssDNA linker during immobilization to the 
microchannel surfaces. These linkers were compared to 34 nt and 40 nt linker sequences with mixed bases 
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(34dX and 40dX). Secondary structures such as homo-dimers and hairpins were unlikely based on the 
sequences of the dX linkers, therefore ensuring accessibility of the linker’s 3’-sulfhydryl with the 
maleimide-labelled Ab. 
4.3.3 Self-Referencing Method for Quantifying Cell Recovery 
We used three cancer cell lines to evaluate the efficiency of cell isolation and release, SKBR3 and 
Hs578T (both adherent), which express EpCAM and FAP, respectively, and acute myeloid leukemia KG-1 
cells (non-adherent) expressing CD34. mAbs directed against these antigens were used for cell isolation 
to determine cell recovery and the efficiency of release.  
Quantifying the number of selected cells recovered is typically accomplished using seeding 
experiments in which a known number of target cells are introduced into a suspension; the seeded cells 
are typically immortalized cell lines, which have a fixed and fairly constant expression level of the selection 
antigen. Unfortunately, this technique does not allow one to determine recovery of target cells present 
in clinical samples because the cell frequency is unknown. Clinical samples also contain target cells with a 
diverse array of selection antigen expression levels, which can dramatically affect cell recovery. In 
addition, seeded cells can undergo damage and/or loss before infusion into devices in an uncontrolled 
fashion, resulting in high levels of variances in the determinations. 
In light of these issues, we developed a “self-referencing” method. Prior knowledge of the number 
of target cells is not required and also, is not affected by cell damage or loss prior to infusion of the sample 
into the selection device. The self-referencing method uses multiple cell selection devices connected in 
series. The number of cells isolated in the first device divided by the total cell count from all devices in the 




Figure 4.5 Accuracy of the self-referencing method for determining recovery of target cells from samples 
in which the expression level of the target would be highly variable and the input cell number is unknown 
or variable. Multiple devices in series deplete the sample of the target cells, allowing for quantification of 
the cell recovery. Over-estimation of recovery is minimized as more devices are used in the series. 
 
high device recovery (70-100%), requiring only two devices in series; the error can be minimized for this 
measurement scheme with three devices in series when the recovery is <60% (<7% error). Thus, the self-
referencing method can accurately measure a device’s recovery from samples and with low standard 





𝐶𝑇𝐶𝑐ℎ𝑖𝑝 1+𝐶𝑇𝐶𝑐ℎ𝑖𝑝 2+⋯𝐶𝑇𝐶𝑐ℎ𝑖𝑝 𝑁
 (4.1) 
In addition to the ability to determine cell recovery from experiments in which the spiking level 
cannot be determined, the self-referencing approach also generates lower standard deviations for 
determinations of recoveries in spiking experiments. For example, in spiking experiments using KG-1 cells 
that were seeded into normal blood samples, the absolute KG-1 cell recoveries calculated using the self-
referencing method (see Eq. 4.1) agreed favorably with the recoveries secured from the KG-1 seeding 
level. However, when relying on the targeted seeding level for efficiency measurements, the relative 
standard deviation for the recovery efficiency was ~35% while that for the self-referencing method was 
only ~6% (data not shown). 
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4.3.4 Cell Recovery using the Cleavable Linkers 
Recoveries using the cleavable ssDNA linkers were compared to a previously reported direct 
attachment approach,76 where mAbs were covalently attached to the UV/O3 activated microchannel 
surfaces that bear COOH groups using EDC/NHS coupling chemistry. The recoveries for direct attachment 
were compared to the recoveries in which the surface attachment of the mAb was accomplished using 
the ssDNA linker. These results are summarized in Appendix 4.1.  
The ssDNA linkers demonstrated similar recoveries for three cell lines investigated when 
compared to the direct attachment protocol. Recoveries were normalized with respect to the anti-EpCAM 
mAb recovery of the SKBR3 cells isolated via the 40dX linkers. Statistically similar results were observed 
for cell recovery via direct attachment when compared to attachment using the ssDNA linkers for SKBR3 
cells, 96 ± 12% (n=4). FAP(+) Hs578T cells were recovered with slightly higher efficiency when mAbs were 
directly attached to the surface, 90 ± 9% (n=8), compared to the 34dX or 40dX linkers, 74 ± 7% (n=3) and 
80 ± 6% (n=5), respectively. Between the ssDNA linkers tested, the data did not indicate a strong 
dependence of recovery on linker length, sequence, or the nature of the chemical group between the 5’-
amino group and the ssDNA linker (C6 for 34dX and C12 for 40dX). The recovery of CD34 KG-1 cells did not 
statistically differ between direct attachment, 81 ± 6% (n=7), and attachment using 40dX, 40dT, or 20dT 
linkers, 76 ± 5% (n=5), 74 ± 7% (n=9), and 77 ± 5% (n=5), respectively. We concluded that the linkers used 
in this study were able to generate accessible mAbs on the microchannel surfaces, irrespective of the 





Figure 4.6 (A) Release efficiency of viable and fixed KG-1 cells isolated with the 20dT and 40dT linkers as 
a function of incubation time with USER™ enzyme. (B) Comparison of the efficiency and rapidity of the 
USER™ enzymatic release process for the three cell lines isolated with 40dX linkers and released in a viable 
state. 
 
4.3.5 Efficiency of Cell Release with the USER™ Enzyme System 
The efficiency of cell release following affinity selection for the three cell lines tested are 
summarized in Appendix 4.1 and illustrated in Figure 4.6. We also evaluated two formats for the cell 
release process within the cell selection device: (i) continuous-flow (CF) of USERTM into the cell selection 
device; and (ii) incubation for a fixed time period after flooding the cell selection device with USERTM. Cells 
were stained after isolation using a LIVE/DEAD assay to determine viability post-selection. Affinity-
selected cells were then released with the USER system to determine release efficiency. To determine 
the viability following release, unstained cells were released and then stained with the LIVE/DEAD assay. 
Lastly, the release efficiency of fixed and DAPI stained cells was evaluated as well.  
We determined that the incubation format provided more efficient release of selected cells using 
the microfluidic device compared to the CF reaction. In the CF reaction, 60 min was required to release 
~84% of the selected cells, while the same release efficiency was achieved within 15 min using the 




Figure 4.7 Release of KG-1 cells isolated using the 40dT linker. Cells stained with (A) Live/Dead™ kit were 
released after (B) 15 min and (C) 30 min USER™ incubation. (D) Cells (eluted at 10 μL/min) were 
enumerated. Live cells generate esterase-dependent Calcein, fluorescing green (ex/em 488/515 nm). 
Dead cells were susceptible to a cell-impermeable, DNA-intercalating dye fluorescing red (ex/em 570 
nm/605 nm). 
 
cells when the selection surface was modified with mAb and the 40dX linker. Additional advantages of the 
incubation format is low enzyme consumption and maintaining the enrichment factor because the cells 
were eluted into a smaller volume; ~10 μL incubation reaction format. Enzymatic release of KG-1 cells 
with USER was carried out on live and fixed cells with mAb attached via 20dT and 40dT ssDNA linkers. 
The release was monitored by enumerating the cells in the effluents with the data collected every 15 min 
(Appendix 4.1). Within 30 min, 80% release efficiency was observed with no significant increases in the 
release efficiency observed for longer incubation times (Figure 4.6).  
Figure 4.7 presents a set of images illustrating the release of viable KG-1 cells. High release 
efficiency was achieved for both viable and fixed cells. Proteolytic (i.e., trypsin) release was not possible 
for paraformaldehyde fixed cells following isolation for direct mAb attachment to the device surface due 
to Ag-Ab crosslinking. Interestingly, the rate of release was faster for the Hs578T and SKBR3 cells 
compared to the KG-1 cells; longer incubation times (30 min) were required for KG-1 cells to achieve the 
same release efficiency (84 ± 4%, see Appendix 4.1 and Figure 4.6B). We believe this result may reflect 





Figure 4.8 Fluorescence images used to quantify cell viability (A, B) after isolation and (C-E) after release. 
Images C-E share the same scale bar. 
 
antigens on KG-1 cells is significantly higher (89x isotype, see Appendix 4.3) compared to FAP on Hs578T 
cells (6x isotype) and EpCAM on SKBR3 cells (15x isotype; data not shown). Thus, the rate of release 
depends on the number of mAbs-antigen associations (i.e., the adhesion force).  
4.3.6 Viability of Released Cells 
Cell viability was analyzed following isolation and also after release. Hs578T, SKBR3, and KG-1 cells 
freshly harvested from culture demonstrated a viability of 93 3%. Following selection, 89 5%, 92 4%, 
and 92 ± 3% viability was found for Hs578T, SKBR3, and KG-1 cells, respectively, which was similar to the 
viability found from culture (Figure 4.8A,B). Post-release viabilities of cell lines were also high, although 
slightly lower than post-isolation values. For example, 80  3%, 82  5% and 84 ± 4% viabilities for Hs578T 
and SKBR3 and KG-1 cells, respectively, were found following USERTM release. The fluorescence images of 
released SKBR3 cells in a titer well are shown in Figure 4.8C-E. In a control experiment, KG-1 cells were 
suspended in PBS (pH 7.4) within a fluidic device containing no mAb or subjected to release; the viability 
was 85 ± 7%, very similar to viabilities observed after enzymatic release. Therefore, the slight decrease in 
cell viability after release does not necessarily reflect enzymatic incubation or fluidic pressures, but is 
partly caused by natural cell viability loss. Clearly, the majority of cells were not damaged by the shear 




Figure 4.9 Flow cytometry analysis of KG-1 cells isolated, stained, and released from the cell selection 
device. 
 
The ability to culture selected and released cells was evaluated as well. Approximately 110 SKBR3 
cells were collected into the well of a 24-well titer plate following selection and release. Media reagents 
were introduced and microscopic observations of cell growth were made in ~24 h intervals (Appendix 
4.1). Cells divided and grew in culture; after 5 d the number of cells doubled. The low seeding density 
caused a slower growth rate of these cells; at higher seeding densities, released SKBR3 cells divided more 
rapidly (data not shown). 
4.3.7 The Efficiency of Immunostaining Cells while Bound to Microfluidic Surfaces 
We performed flow cytometry of KG-1 cells to evaluate the ability to detect and quantify 
expression of immunostained cells following selection, on-chip staining and USERTM release. Histograms 
in Figure 4.9 are shown for 3 antigens, CD33, CD34, and CD117. The expression of CD33, CD34, and CD117 
antigens on the KG-1 cells was evaluated by comparing the positive control’s mean fluorescence intensity 
(MFI) to the isotype control, which takes into account non-specific binding of the mAbs. The three antigens 





Figure 4.10 (A) Composite image of a 7 mm diameter well with DAPI-stained EpCAM+ CTCs isolated from 
a M-OVC patient. (B) Close-up image of a smaller area of the well. (C-E) Fluorescence images of CTCs 
stained with DAPI, CK-TR, and CD45. 
 
is moderately expressed (10x isotype); and (iii) CD117 is weakly expressed (2x isotype). In order to assess 
the efficacy of staining on-chip then releasing, the released cells were compared to the positive control 
cells stained in solution by using the unstained cells as a reference point.  
For all antigens, the released KG-1 cells showed an average MFI that was 54 ± 7% of the positive 
control’s fluorescence intensity. This data likely indicated that when the cells were affinity-selected and 
bound to the cell selection device surfaces during the staining process, only the cells’ surfaces not 
attached to the surface mAb were sterically accessible (i.e., roughly half the cell could be labelled). While 





Figure 4.11 (A) DIC and fluorescence images of M-OVC CTCs isolated using anti-EpCAM antibodies and 
released into a titer well. (B-C) EpCAM+ CTCs were stained with LIVE/DEAD kit after release for viability 
determinations, (B) is green fluorescence signal for viable cells and (C) is red fluorescence signal from 
ethidium homodimer-1 in dead cells. 
 
from unstained cells (see Appendix 4.3). The obvious exception to this statement is when interrogating 
CD117 due to its low expression, which even in positive control only showed 77% positive with an MFI of 
2x the isotype control.  
We considered conducting an experiment where cells would be released, then stained off-chip in 
a traditional test tube as we hypothesized that off-chip staining would result in a higher MFI signal; 
however, we weighted those benefits against the benefits of staining on-chip, which provide a microfluidic 
solid support that prevents sample loss, an especially important factor when dealing with rare CTCs, and 
avoids centrifugation steps that can potentially compromise the cell membrane and viability of an already 
limited cell population. All of these factors will add to the challenge of acquiring high quality phenotypic 
analysis by flow cytometry. For these reasons, we opted to demonstrate that staining on-chip is both 
feasible and still produced reliable phenotypic information even with a reduced MFI signal. 
4.3.8 Releasing Clinical CTCs for Off-Chip Interrogation 
To demonstrate the utility of our assay for the selection and release of clinical CTCs, 2 metastatic 
ovarian cancer (M-OVC) blood samples were processed using anti-EpCAM modified cell selection devices 




Figure 4.12 FISH images with a 13q14 probe of patient CMMCs. Green signal indicates the presence of 
chromosome 13 and red signal indicates absence of the chromosome 13 deletion. The patient sample 
contained a mixture of CMMCs: (A) Cell shows the presence of the deletion and (B) polyploidy cell without 
the deletion. Cells were isolated using an anti-CD138 modified chip. 
 
CD45, DAPI, and Pan-CK, released into wells of a 96 well plate, and enumerated (Figure 4.10). A composite 
micrograph of a 7 mm diameter well with DAPI-stained EpCAM+ CTCs isolated from blood of a M-OVC 
patient is shown in Figure 4.10. Cells were stained with CD45, DAPI, and Pan-CK (Figure 4.10C-E). 
Appendix 4.1 summarizes results secured from M-OVC patient blood samples. The results suggested 
similar cell numbers isolated using microfluidic chips modified via the ssDNA linker and direct attachment 
of the mAb to the activated surface, similar to what we observed for the cell line data.  
With the aid of USER, cells were released following selection and eluted into titer wells where 
they were stained with the LIVE/DEAD™ kit and/or DAPI/CK/CD45 and visualized under a microscope. The 
average viability of CTCs after chip isolation and release was evaluated from M-OVC samples and 
determined to be 93  5% (n=5) for EpCAM+ CTCs. Upon release with USER and based on evaluation of 
multiple areas of the wells in which cells were collected, the viability was determined to be 87 6% for 
EpCAM+ CTCs. Figure 4.11 presents results for EpCAM+ CTCs secured from M-OVC. 
CMMCs were isolated using anti-CD138 mAbs from multiple myeloma (MM) patients, released 
and subsequently tested by FISH for a possible deletion in chromosome 13, which is found in ~86% of MM 
patients. The presence of the deletion is typically associated with poor prognosis and the propensity of 
the disease to progress from an asymptomatic to symptomatic stage.338   
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Both mutated (Figure 4.12A) and wild type (Figure 4.12B) CMMCs were observed in patient’s 
blood. The deletion identified in chromosome 13 in the isolated CMMCs was also present in bone marrow 
from the same patient. Chromosomal analysis of CMMCs selected from whole blood and released 
intact allows for conventional cytogenetic analysis without the need for requiring the patient to 
undergo a bone marrow biopsy, which can provide the ability for more frequent testing. 
4.4 Conclusions 
We have successfully demonstrated the use of ssDNA linkers engineered with a dU residue for 
attaching mAbs to surfaces for selecting clinically relevant cells with high recovery and when using the 
USER™ enzyme system, release the cells both efficiently (~90%) and rapidly (15-30 min) while maintaining 
their viability. Clinical CTCs and CMMCs were selected directly from patients’ peripheral blood then 
released for integration of the cell selection/release assay into existing clinical processing pipelines while 
obviating the need for invasive biopsy procedures. We have demonstrated that the selected cells can be 
fixed, stained, released, and subjected to conventional flow cytometry. The selected/released cells could 
also be successfully subjected to FISH analysis to determine chromosomal abnormalities using 
conventional cytogenetic assays. The USER™ release strategy preserved cell viability making them 
available for cultivation as well. An additional benefit of the ssDNA linkers and the USER™ enzyme system 
was the seamless integration with existing microfluidic devices used for rare cell selection and the general 
attachment chemistry, which can enable the application of these ssDNA linkers to a variety of solid-phase 





CHAPTER 5. MICROFLUIDICS FOR THE LONGITUDINAL TRACKING OF MINIMAL RESIDUAL DISEASE 
IN THE PERIPHERAL BLOOD OF ACUTE MYELOID LEUKEMIA PATIENTS 
5.1 Introduction 
Leukemia is triggered by hematopoietic progenitor cells in the bone marrow that become 
mutated and clonally expand into leukemic blasts that do not fully differentiate into normally functioning 
blood cells.339 Leukemia can be divided into four major types by: (i) the rate of disease progression: acute 
(rapid, within weeks to months) or chronic (slow, within months to years); and (ii) the type of malignant 
cells, either originating from the lymphoid or myeloid lineage. Acute myeloid leukemia (AML) is the most 
common adult leukemia with ~20,000 new cases expected in 2015 with a 5-year survival rate of only 
25%.76 The primary cause of death for AML patients is due to disease relapse.339  
Patients diagnosed with AML are treated with chemotherapy if they are considered fit enough for 
treatment with the goal of inducing complete remission, defined as a normal appearing bone marrow 
biopsy (<5% leukemic cells) and normal circulating blood counts. However, even when the patient is in 
complete remission, low levels of leukemic cells persist that likely have chemotherapy-resistance and 
stem cell properties. This minimal residual disease (MRD) can re-initiate AML within weeks to 
months.339,340 The consequences are significant: Of 1,108 patients in complete remission after therapy, 
60% relapsed of which only 11% survived after 5 years.341 If clinicians can pinpoint when a patient’s MRD 
begins progressing towards the rapid expansion to relapse, preemptive therapies can be taken with better 
patient outcome. Unfortunately, the classification of AML patients by risk according to age, white blood 
cell count, therapy response, and cytogenetic and genotypic abnormalities, if any,341-346 falls short of the 
ability to properly monitor MRD in individual patients. If MRD could be detected with high sensitivity at 
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an early stage, the corresponding assay could assist in guiding therapy to enable precision medicine 
resulting in better patient outcome.342 
A potentially curative therapy for AML is a hematopoietic stem cell transplant (SCT), where a 
donor’s hematopoietic stem cells, either in the peripheral blood or purified bone marrow, are introduced 
into the patient. The donor’s graft transplanted into the recipient’s bone marrow undergoes normal 
hematopoiesis and induces a donor-derived and T cell-mediated anti-leukemia immunity, commonly 
called the graft-versus-leukemia effect. These transplants are typically reserved for patients at high risk of 
disease relapse, because while SCT lowers relapse risk, it is associated with a high treatment related 
mortality (~25%).347,348 Intense chemotherapy is needed to minimize AML relapse prior to grafting. In 
addition, T cell suppression is necessary to reduce graft rejection and graft-versus-host disease. These 
treatments are physically taxing and leave the patient susceptible to a host of foreign and dormant 
infections, hence the SCT’s high rate of morbidity. 
If relapse occurs after SCT, there are interventions that can be curative. A rapid withdrawal of 
immunosuppression and the infusion of donor lymphocytes can instigate an acute graft-versus-leukemia 
response that can result in sustained long term remission.346,349 However, the success of a donor 
lymphocyte infusion is intrinsically dependent upon the level of residual leukemia at the time of 
treatment. Donor lymphocyte infusion was only successful (overall survival >2 years) for 15% of patients 
with active AML, but the treatment was successful in 55% of patients when administered while in 
remission.346 Thus, the ability to detect low but rising levels of MRD that signal the start of relapse is not 
only prognostically important, but can enable clinicians to implement therapy earlier that can improve 
patient outcome.340  
An ideal MRD assay would be sensitive to low MRD levels and suitable for frequent analysis. This 
goal has been hindered by two issues: (i) Unlike other leukemias, AML’s inter-patient heterogeneity is 
immense; there is no characteristic genetic mutation or aberrant protein expression pattern for all AML 
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patients,340 thus complicating the broad applicability of PCR or multi-parameter flow cytometry (MFC) to 
test for MRD. (ii) AML relapse is rapid; it was calculated that long-term 42 day sampling intervals would 
be a minimum frequency to predict 75% of relapses.350 
Assessing MRD from leukemic cells that circulate in a patient’s peripheral blood (circulating 
leukemic cells – CLCs) is a viable option for achieving sensitive MRD detection and monitoring that can be 
done on a frequent basis.340  While PCR-based MRD analyses offer favorable analytical detection limits,351 
ranging from 1 CLC in 104 – 106 normal blood cells, PCR assays are applicable to <50% of all AML patients 
due to AML’s genetic heterogeneity.352,353  
MFC is an approach that identifies aberrant expression of surface proteins (leukemia associated 
phenotypes), on mutated myeloid cells, which are present on almost all (>90%) AML cells.339,340,353 Two 
general leukemic associated phenotype patterns are: (i) Immature, myeloid cells (common normal 
myeloid markers are CD33, CD34, and CD117) with lineage infidelity (abnormal co-expression of a myeloid 
and lymphoid marker, such as CD7); or (ii) asynchronous antigen expression (abnormal co-expression of 
an immature and mature myeloid marker, such as CD56).342 Two main limitations exist regarding MFC 
MRD analysis: (i) The assay requires flow cytometers with >5 colors and highly skilled operators to 
correctly identify a cluster of 20 CLCs amongst 200,000 total bone marrow cells,342 although this detection 
limit varies between operators (bone marrow sensitivity ranges from 10-3 – 10-4).354 (ii) MFC is noise-
limited for rare event analysis355,356 and is significantly affected by peripheral blood cells;342 hence bone 
marrow is generally required unless disease burden is very high. For example, MFC MRD analysis of 
peripheral blood yielded a log reduction in sensitivity compared to a bone marrow biopsy sample340 with 
a considerable number of false negatives below 1% MRD.357 Thus, MFC is only moderately sensitive and 




Microfluidics has demonstrated success for the detection of epithelial solid cancers by isolating 
and interrogating circulating tumor cells (CTCs) that are extremely rare in blood (1-3,000 CTCs per 109 
normal blood cells).25 In particular, we have reported the use of a sinusoidal microfluidic device to isolate 
CTCs in pancreatic,28,75,76 ovarian, colorectal, breast, and prostate cancer.28 The sinusoidal microfluidic 
technology has demonstrated purities >90%,28,30,75,76 >80% CTC recoveries from clinical samples and 80-
100% clinical sensitivity for epithelial cancers when analyzing CTCs.28 
The sinusoidal microfluidic device works on the principle of positive-affinity selection, where 
monoclonal antibodies (mAbs) are bound to a microfluidic device’s surfaces and specifically select target 
antigen-bearing cells (Figure 5.1B,C). In operation, these devices require no sample pre-processing. 
Peripheral blood is hydrodynamically infused into the device that contains 50 parallel microchannels,76,251 
each possessing a 25 µm width and a sinusoidal architecture Figure 5.1A,B) that promote extensive cell 
interactions with mAbs covalently tethered to the microfluidic surfaces (Figure 5.1B).75,87 Antigen-
expressing cells are retained by the mAb-coated surfaces while all other blood components are removed 
from the device by high fluidic shear that disrupts weak, non-specific interactions (Figure 5.1C).30,75,87 
These fluidic shear forces are an order of magnitude higher than in comparable microfluidic 
technologies75,87 and are not present in traditional magnetic bead isolation assays, which generally 
present low purities (0.01-0.1% for the CellSearch™ CTC selection platform)25 that complicate 
immunophenotyping and/or molecular analysis.30,87 After isolation, cells can be immunostained and 
imaged30,75,76 or lysed to analyze mRNA expression,33 gDNA mutations,30 or membrane proteins.251 
Herein, we present an assay and pilot clinical study where AML patients recovering from SCT were 
longitudinally tracked by isolating CD33, CD34, and CD117 expressing CLCs using three sinusoidal 
microfluidic devices, co-staining against a patient-specific aberrant antigen, and immunophenotyping the 




Figure 5.1 (A) Whole blood is processed through three microfluidic devices modified with mAbs specific 
for CD33 (red), CD34 (yellow), and CD117 (blue) expressing cells. Arrows indicate direction of blood flow 
through the device. (B) SEMs of the sinusoidal channel array (50 channels in the array) and the entrance 
of the single channel that addresses all sinusoidal channels. mAb-coated surfaces were false-colored red 
to represent an anti-CD33 mAb device. (C) Schematic of the affinity isolation assay. Antigen expressing 
cells (here CD33(+) cells used as an example) bind to surface-tethered mAbs and are retained in the device 
while other blood components are passed through the device. Selected cells are then immunostained 
against CD45 and the aberrant marker (e.g., with anti-CD7 or anti-CD56 fluorescent mAbs), followed by 
fixation and nuclear staining.  (D) Selected cells are released from the capture surface and carried 
hydrodynamically into flat-bottomed wells, where the cells are imaged by semi-automated fluorescence 
microscopy. CLCs are identified by positive aberrant staining (aberrant(+)) and positive CD45 and DAPI 
staining, whereas other blood components only show CD45 and DAPI staining (aberrant(-)).  
 
required, patients could be sampled frequently compared to a bone marrow biopsy. We compared the 
results from the microfluidic assay to conventional MRD monitoring, which consisted of microscopy, MFC, 
PCR, and FISH analysis of bone marrow biopsy samples and, in cases where the disease burden was high, 
peripheral blood. MRD tracking by microfluidic CLC surveillance matched well with both therapeutic 




5.2 Experimental Methods 
5.2.1 Materials 
Microfluidic devices were fabricated using 6013S-04 COC thermoplastic (TOPAS Advanced Polymers), 
capillary tubing (365 µm OD, 150 µm ID, Polymicro Technologies), reagent-grade isopropyl alcohol, and 
Micro-90® (Sigma-Aldrich). Capillary connectors were fabricated using Inner-Lok™ union capillary 
connectors (Polymicro Technologies) and barbed socket Luer Lock™ fittings (3/32” ID, McMaster-Carr). 
Antibody immobilization reagents included: 1-ethyl-3-[3-dimethylaminopropyl] carbodiimide 
hydrochloride (EDC), N-hydroxysuccinimide (NHS), 2-(4-morpholino)-ethane sulfonic acid (MES) buffer 
(pH 4.8), phosphate buffered saline (PBS) buffer (pH 7.4), and bovine serum albumin (BSA, 7.5%) in PBS 
(Sigma-Aldrich); sodium carbonate anhydrous (EMD Millipore); sodium hydroxide (Fisher Scientific); 
nuclease-free water (BioExpress); DL-1,4-dithithreitol (DTT, molecular biology grade, Acros Organics); 
sulfosuccinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (sulfo-SMCC, No-Weigh Format), 
Zeba spin desalting columns (7K MWCO), and protein stabilizing cocktail (Thermo Scientific); and HPLC-
purified, single-stranded, oligonucleotide linkers with 5’-amino and 3’-disulfide modifications and an 
internal dU residue (5’-NH2-C12-T8-CCC TTC CTC CTC ACT TCC CTT T-U-T9-C3-SS-C3OH, Integrated DNA 
Technologies). Other reagents included formaldehyde (Fisher Scientific), Triton-X100 (Sigma-Aldrich), 
4’,6-diamidino-2-phenylindole (DAPI, eBioscience), and Uracil Specific Excision Reagent (USER, New 
England Biosciences). Nuclease-free microfuge tubes (BioExpress) and centrifuge tubes (Corning) were 
used for preparation and storage of all samples and reagents. 
All antibodies used in this study were monoclonal and mouse anti-human. For cell isolation, anti-
CD33 (clone WM53), anti-CD34 (clone 561, class III epitope), and anti-CD117 (c-kit, clone 104D2) mAbs 
(BioLegend) were used. Direct immunostaining mAbs were anti-CD45-AlexaFluor®647 (clone HI30), anti-
CD7-FITC (clone CD7-6B7), anti-CD38-AlexaFluor®488 (clone HIT2), and anti-CD56-AlexaFluor®488 
(NCAM, clone HCD56) from BioLegend. Indirect immunostaining mAbs were anti-CD7-biotin (clone MG34) 
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and anti-CD33-biotin (clone HIM3-4) from Thermo Scientific and anti-CD34-biotin (clone 581, class III 
epitope), anti-CD56-biotin (NCAM, clone HCD56), and anti-CD117-biotin (c-kit, clone 104D2) from 
BioLegend, all of which were counter-stained with streptavidin-DyLight®550 (Thermo Scientific). 
5.2.2 Cell Selection Device Fabrication 
Hot embossing was used to fabricate the microfluidic device in COC as described previously.163,239 
Mold masters were prepared in brass using high precision-micromilling (KERN 44, KERN Micro- und 
Feinwerktechnik GmbH & Co.KG) and carbide bits (Performance Micro Tool).239 Hot embossing was 
performed using a HEX03 embossing machine (Jenoptik Optical Systems GmbH) and conditions of 155°C 
and 30 kN force for 120 s. Embossed devices were diced, cleaned with 10% Micro-90®, IPA, and DI water, 
assembled with capillary tubing and coverslip, clamped between glass plates, and thermal fusion bonded 
at 130°C for 60 min or 133°C for 30 min. 
Immediately prior to oligonucleotide immobilization, bonded devices were UV/O3 activated (22 
mW/cm2, 15 min) in a home-built activation chamber equipped with a quartz, low pressure Hg lamp to 
generate COOH groups on the microfluidic surfaces,75 and the spacing between the capillaries and 
coverslip were sealed with epoxy. To react the oligonucleotide’s 5’-amino group with the activated 
surfaces, devices were incubated for 15 min at room temperature with a solution of 20 mg/mL EDC and 2 
mg/mL NHS in 100 mM MES buffer, after which devices were dried with an air-filled syringe and incubated 
overnight at 4 °C with 40 µM oligonucleotide in PBS buffer.  
For Ab immobilization, the device was air-dried, washed with 100 µL PBS (50 µL/min), and the 3’-
disulfide group was using 300 mM DTT in 200 mM carbonate buffer adjusted to pH 9 (400 µL, 20 µL/min) 
to produce maleimide-reactive sulfhydryl groups. Devices were then immediately air-dried, washed with 
100 µL PBS (50 µL/min), air-dried, flooded with freshly prepared maleimide-labelled mAbs, and incubated 
overnight at 4°C or 2 h at 25 °C. As described previously30, all mAbs (0.5 mg/mL) were azide-purified with 
a Zeba column, reacted with sulfo-SMCC at 80X molar excess for 45 min, and again purified with a Zeba 
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column. Prepared devices were either used within 48 h or air-dried, flooded with 2X protein stabilizing 
cocktail in PBS, and used within 3 weeks. The long term stability and reproducibility of this procedure was 
evaluated with the devices showing consistent performance for cell recovery even after 35 days cold 
storage (see Appendix 5.5) 
5.2.3 CD33, CD34, and CD117 Antigen Co-expression in AML Cell Lines 
Three AML cell lines were analyzed by MFC to determine co-expression of the CD33, CD34, and 
CD117 isolation antigens. The U937 cell line358 was a gift from Dr. Gregory Lizee at MD Anderson, and the 
Kasumi-1 cell line359 was a gift from Dr. Douglas Graham at the University of Colorado at Denver. The 
HL60360 and KG-1361 cell lines were purchased from the American Type Culture Collection (ATCC) through 
the Tissue Culture Facility at UNC. The cell lines were immunostained with anti-CD33-APC, anti-CD34-PE-
Cy7, anti-CD117-PE antibodies (BD Biosciences) and analyzed by MFC using a MACSQuant Analyzer 
(Miltenyi Biotec GmbH). Data was analyzed using FlowJo (FlowJo, LLC). 
5.2.4 Processing Clinical Samples with the Cell Selection Device 
AML patients being prepared for allogeneic SCT were recruited according to a clinical protocol 
approved by the University of North Carolina’s Institutional Review Board (IRB). Blood specimens were 
collected into BD Vacutainer® EDTA tubes and remained on a nutator until processing (within 4 h). First, 
devices were thoroughly washed with >1 mL 0.5% BSA/PBS buffer (50 µL/min) to remove unbound mAb 
and passivate microchannel surfaces. Blood was transferred into disposable Luer Lock™ syringes (BD 
Biosciences) using a BD vacutainer female Luer transfer adapter. Filled syringes were connected to the 
devices via capillary connectors and processed through the microfluidic devices at 25 µL/min (2 
mm/s).75,158 Immediately thereafter, devices were rinsed with >1 mL 0.5% BSA/PBS (50 µL/min, 4 mm/s) 
to remove any non-specifically bound cells. 
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5.2.5 Immunostaining, Cell Release, and Imaging 
After blood processing and rinsing, isolated cells were incubated at 4 °C for 30 min with a cocktail 
of anti-CD45-Cy5 mAb and mAbs targeting the aberrant marker (CD7 or CD56) either conjugated to FITC 
or biotin. In some cases, the devices were stained with biotinylated mAbs targeting the isolation marker 
(i.e., anti-CD33-biotin on the CD33 cell isolation device). All biotinylated Abs were indirectly stained via 
streptavidin-Cy3 incubation (4°C, 30 min). After mAb incubation, cells were rinsed with 250 µL PBS (50 
µL/min), sequentially fixed, porated, and nuclear-stained via 10 min incubations with 2% formaldehyde, 
0.1% Triton-X100, and 1 µg/mL DAPI, respectively. The devices were washed with 250 µL PBS (50 µL/min) 
and released by incubation with the USER™ enzyme (4U/10µL PBS) for 45 min at 37 °C to clip the 
oligonucleotide linkers anchoring the cells to the microfluidic surfaces.30 Cells were then washed off-chip 
with PBS (50 µL/min) while periodically gently tapping the device with forceps.  
The released different subpopulations of cells were collected in separate wells of a flat-bottom 
96 well plate (Argos Technologies) sealed with an optically clear Microseal® B adhesive film (Bio-Rad 
Laboratories), which was punctured just prior to release so that the device’s capillary could be fed into 
the well. Before visualization, the wells were centrifuged for 7 min at 250 rcf and were imaged using a 
Zeiss Axiovert 200M microscope equipped with a 20X objective (0.4 NA, EC Plan NeoFluar®), an XBO 75 
lamp, DAPI/FITC/Cy3/Cy5 filter sets (Omega Optical), a Cascade 1K EMCCD camera (Photometrics), and a 
MAC 5000 stage (Ludl Electronic Products), all of which were computer-controlled via Micro-Manager.362 
DAPI, FITC, Cy3, and Cy5 exposure times were 50, 1000, 2500, and 3500 ms, respectively, with Cy3 and 
Cy5 exposures employing EM gain. Each well was imaged in its entirety via Micro-Manager’s grid collection 
software, and the image sets were stitched and analyzed via a custom ImageJ macro, which identified 
nuclei and displayed fluorescence panels for phenotyping. FITC-labeled calibration beads were imaged 
under the same conditions, and beads differing in antibody binding capacities were identified by surveying 
fluorescence intensities on the FITC channel. 
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5.3 Results and Discussion 
5.3.1 Sample Processing 
The microfluidic assay used a minimally invasive blood sample that permitted frequent, which for 
this study consisted of biweekly or less MRD testing through the first 100 days of post-SCT and monthly 
thereafter. For most samples, ~3 mL of peripheral blood was processed with 1 mL sent through one of 
three 50-channel, sinusoidal microfluidic devices that were modified with mAbs targeting CD33, CD34, 
and CD117 (Figure 5.1). The blood sample, which was not fixed, fractionated, or diluted, was processed 
through each chip over the course of 40 min; although this time frame is flexible because the processing 
time can be reduced by scaling to >250 sinusoidal channels in each device.76,251 Isolated CLCs were then 
identified by staining against the aberrant marker (i.e., CD7 or CD56) and leukocyte specific antigen CD45. 
CD45 staining precluded non-hematopoietic cell types such as CD34(+) circulating endothelial cells.363 
Isolated cells were then fixed and DAPI-stained, and each subpopulation (CD33, CD34 or CD117) was 
released for imaging into separate wells of a flat-bottom titer plate. Cell release was enabled by 
enzymatically cleaving DNA oligonucleotide linkers containing a uracil residue that anchored mAbs to the 
microfluidic surfaces. We have recently optimized and validated the entirety of this process for several 
cell lines and clinical samples, including the CD34(+) KG-1 AML cell line for which the assay achieved 65% 
recovery by CD34 selection from buffer and >80% release efficiency after fixation.30 
Fluorescence microscopy was chosen for immunophenotyping the selected cells because the CLC 
abundance was very low (<20/mL) in some cases, making it difficult to secure reliable results using flow 
cytometry. The microscope imaging was semi-automated; the microscope objective was computer- 
controlled to automatically capture images of the wells for all fluorescence color channels; custom image- 
processing macros were built to stitch the images together, identify nuclei and display fluorescence 




Figure 5.2 Immunophenotyping of aberrant(+) CLCs and aberrant(-) cells isolated by targeting (A,B) CD33, 
(C,D) CD34, and (E,F) CD117, respectively. All cells were DAPI(+)/CD45(+) and positive for at least one of 
the isolation markers (CD33, CD34, or CD117). All images were taken from Pt #1 (CD7 aberrant marker) 
85 days post-SCT. The cells in this panel were stained using DAPI (nucleus), and mAbs directed against CD7 
(FITC), CD45 (Cy5) and finally, the selection marker (CD33, CD34, CD117; Cy3). 
 
that stained DAPI(+) and CD45(+) were identified as CLCs if they stained aberrant(+) (Figure 5.2). CLC size 
(10-30 µm) and high nuclear-to-cytoplasm ratio were not regarded as absolute criteria. Conventional 
microscopic preparation flattens and enlarges cells when plating the coverslip.62,63 In general, CLCs were 
~10-15 µm in diameter, similar to KG1 cells.30 
The three devices were arranged in parallel rather than a serial configuration because co-
expression of the isolation markers was observed for some AML cell lines (Appendix 5.1) and was 




Figure 5.3 (A) FITC fluorescence, (B) brightfield, and (C) overlay images of calibration beads with different 
antigen binding capacity levels (see (C) annotations for the approximate load of the fluorescent antibodies 
per bead). Image contrast settings were selected to highlight low intensity fluorescence; brightly 
fluorescent beads were not saturating the CCD. FITC exposure times were identical to those used for CLC 
identification. 
 
device in the series with a large number of cells in the first device of the series while depleting target cells 
from devices positioned downstream. The parallel arrangement can also enable separate interrogation of 
the CLC subpopulations to determine drug resistance for each subpopulation resulting from 
chemotherapy and other factors.364,365 For example, circulating leukemic stem cells, which are the only 
leukemic cells capable of propagating AML,364 would be isolated in the anti-CD34 and/or anti-CD33 device. 
These stem cells could be phenotypically identified by CD38 and CLL-1 expression364,366 and further 
interrogated while simultaneously monitoring the leukemic blast progeny and normal blood cells. 
5.3.2 Microfluidic Affinity Selection Sensitivity and Specificity 
We assessed specificity of the microfluidic selection process by co-staining against the isolation 
marker, either CD33, CD34, or CD117 (Figure 5.2). The observed specificity (count of cells staining positive 
for the isolation marker divided by the total cell count) was 88-99% with 2-33 cells/mL not showing 
discernable expression of the selection antigen. These results agree with our previous reports using this 
microfluidic in terms of the selection of CTCs in whole blood samples.  
The efficiency of affinity selection depends on the cell’s antigen expression and the density of 
surface-confined mAbs.28,87 Also, as the cell rolls along the microfluidic surfaces, the probability that a 
moving antigen will bind to the surface-confined mAb depends on the cell’s forward velocity, the 
associated residence time of the mAb and antigen in the reaction radius, the Ab-antigen binding 
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kinetics,147 and the steric likelihood that the mAb interacts with the targeted epitope (analogous to a steric 
factor in collision theory).  
The overall probability of cell recovery can be improved by accumulating a large number of 
binding events for a single cell. In the sinusoidal microfluidic device, this accumulation is engineered into 
the device by using continuous sinusoidal channels that offer rolling distances >250 µm as opposed to 
discrete surfaces provided by micropillars.28 For example, assuming a monolayer of mAbs on the surface, 
a cell rolling for 250 µm would encounter in excess of 16,000 mAb collisions. Because the number of 
binding events also scales with the number of antigens, recovery is dependent on the expression of the 
antigen and the target cell’s antigen density. This has been empirically observed by several groups using 
cell lines with variable antigen expression.65  
There is a fundamental lower limit to antigen expression for cell recovery, which is set by an 
insufficient number of mAb-antigen complexes to hold the cell to the surface against the blood’s fluidic 
shear force. Bell367 provided a theoretical framework to assess the critical force at which a cell will detach 
from a surface (𝐹𝑐) when it is bound by 𝑁𝑏  bonds, each with a critical force of 𝐹𝑏  and an equilibrium 
constant 𝐾 (taken as 106 M-1) given by; 
𝐹𝐶 = 𝑁𝑏𝐹𝑏 = 𝑁𝑏0.7
𝑘𝑇
𝑟0
ln (𝐾𝑁𝑏) (6.1) 
where 𝑘 is Boltzmann’s constant; 𝑇 is temperature (293.15 K); and 𝑟0 is the distance (assumed 0.5 nm) at 
which a bond ruptures. We set this total critical force equal to the shear force of blood flow in the 
sinusoidal device, which we have shown via fluid dynamics simulations to be on average 14 dynes/cm2 
and herein used the highest local shear force of 40 dynes/cm2.75 We then solved for 𝑁𝑏, by assuming that 
the cell was flattened against the microfluidic surface but did not compress the fluid flow. Using these 
assumptions, we determined that 1.6 mAb/antigen bonds/µm2 could retain the cell against the shear 
force exerted by the blood flow through the device. 
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For a 12 µm diameter cell with a surface area of ~450 µm2, the recovery limit for antigen 
expression is approximately 700 antigens per cell. In contrast, it is technically difficult to detect cells with 
only 700 antigens by immunofluorescence without a highly sensitive microscope. For example, we imaged 
~12 µm beads that were coated with different levels of anti-IgG antibodies and functionalized with IgG-
FITC, ranging in antigen binding capacity from 940 to 259,000 (Figure 5.3). Beads with an antigen binding 
capacity of 7,000 were detected but with weak signal. Beads with an antigen binding capacity of 940 could 
not reliably be detected from background.  
Thus, it is possible to physically isolate a cell by positive-affinity selection but incorrectly classify 
the cell as negative for the marker by immunofluorescence (albeit, we did not consider the efficiency of 
isolation, which we discuss elsewhere28,87). Close inspection of the top left cell in Figure 5.2F (FITC panel) 
shows extremely faint fluorescence signal similar to the 940 antigen binding capacity beads in Figure 5.3, 
but this was not counted as a CLC. Also, the specificity reported, which is based on staining for the isolation 
marker with good results (88-99% with 2-33 non-target cells/mL), does not contradict previously reported 
purities for CTC isolation (3.2 ± 3.4 non-specific leukocytes/mL blood, averaged from 66 samples) that 
identified non-specific leukocytes by CD45 staining (~200,000 molecules per cell).30,75,76,368 
5.3.3 Patient Characteristics 
Five AML patients (Pts #1-5) undergoing allogeneic SCT were recruited for post-SCT microfluidic 
MRD monitoring. Characteristics of the patients, such as cytogenetic/molecular risk, leukemic associated 
phenotype aberrant marker, and pre-SCT characteristics regarding disease burden are available in Table 
5.1 and are discussed in detail in Appendix 5.1. Full leukemic associated phenotype panels and aberrant 
markers that were identified by MFC are provided in Appendix 5.2. An optimal aberrant marker that was 
expressed on a significant portion of the patient’s leukemic blasts and not on normal blood cells was 




Table 5.1 Patient characteristics for Pts #1-5. 
Characteristic Pt 1 Pt 2 Pt 3 Pt 4 Pt 5 
Age 52 / Female 36 / Female 68 / Female 67 / Male 54 / Female 









Risk (ELN) Intermediate-I Intermediate-I Favorable Adverse Favorable 
Aberrant 
marker 
CD7 (51%) CD7 (50%) CD7 (na) CD56 (34%) CD56 (52%) 
Conditioning MAC Bu/Flu/ATG MAC Bu/Cy/ATG RIC Bu/Flu/ATG RIC Bu/Flu/ATG MAC Bu/Flu/ATG 


















De novo AML,  
CR 
De novo AML,  
CR 
Donor gender Male Male Male Female Female 
HLA match 10/10 10/10 10/10 10/10 10/10 
*Percentages are the proportion of leukemic blasts positive for the marker by MFC. ELN (European LeukemiaNew Risk); na (not 
available); MAC (myeloablative conditioning); RIC (reduced-intensity conditioning); Bu (busulfan); Flu (fludarabine); ATG (anti-
thymocyte globulin); Cy (cyclophosphoamide); CR (complete remission); CR(p) (CR but incomplete recovery of platelet counts). 
 
to accommodate any aberrant marker; however, the five patients enrolled in this study expressed either 
CD7 or CD56. It is possible that the leukemic associated phenotype could change during progression, 
which most often involves up-regulation of the isolation markers (CD33, CD34, CD117)339,369 that may 
improve assay recovery.28 However, CLCs may also lose or change the aberrant marker (i.e., CD7 or 
CD56).369 Thus, cells that stain aberrant(+) are referred to as CLCs while aberrant(-) cells are regarded as 
cells that include normal blood cells and potentially other leukemic cells even if they express the selection 
antigen (CD33, CD34 or CD117). In future studies, loss of the aberrant marker can be accommodated by 
employing wider staining panels that target all aberrant antigens (Appendix 5.2) to provide more 
complete AML coverage.369 Lastly, the rare presence of normal, immature CD34(+) cells that co-express 
CD7 has been noted during marrow regeneration and T-lymphopoiesis.370 These cells are unlikely to be 
present in peripheral blood after full engraftment (~14 days post-SCT) and thus unlikely to affect CLC 
identification by the microfluidic assay. The presence of either CD33(+) or CD117(+) cells that co-express 




Table 5.2 Heat maps are the percent change of the total count relative to the previous sample. If MRD(+), 
the patient’s MRD burden was assigned using the quartiles of total CLC counts accumulated from all 
patients. MRD burden was assigned as low (<29 CLCs/mL), mid (≥29 and <90 CLCs/mL), high (≥90 and <405 
CLCs/mL) and very high (≥405 CLCs/mL). na = not available. 
 
Total CD33 CD34 CD117 Total CD33 CD34 CD117
Pt #1 CD7(+) CD7(-)
28 Mid 81 0 0 81 403 232 12 159
45 High 90 1 26 63 558 189 28 341
57 High 221 104 14 103 129 72 13 44
71 High 348 72 20 256 207 69 12 126
85 Very high 1761 469 48 1244 152 54 5 93
95
Pt #2 CD7(+) CD7(-)
-7 Low 18 8 0 10 458 283 80 95
14 Very high 566 238 77 251 2812 764 177 1871
28 Very high 1066 86 116 864 2470 740 1166 564
40 Low 22 2 12 8 98 38 38 22
54 High 102 12 28 62 154 24 80 50
70 High 140 2 1 137 271 22 25 224
84 High 314 99 0 215 89492 88716 134 642
98 Very high 443 51 372 20 249 55 156 38
118
Pt #3 CD7(+) CD7(-)
-7 Low 15 0 11 4 47 0 16 31
13 None 1 0 0 1 67 22 17 28
30 Very high 1430 1416 13 1 1301 1270 31 0
44 na na na 11 12 na na 39 319 na na
55 Very high 1691 1640 0 51 1350 1021 0 329
69 Mid 69 31 0 38 109 21 1 87
90 None 0 0 0 0 4 3 1 0
107 Mid 29 28 1 0 29 24 5 0
121 None 4 4 0 0 0 0 0 0
137
Pt #4 CD56(+) CD56(-)
43 na na 0 na na na 1573 na na
57 Mid 29 0 0 29 2528 2038 9 481
71 Low 11 0 0 11 426 238 52 136
81 None 5 0 0 5 285 125 57 103
95 Mid 30 9 21 0 180 53 69 58
144 Mid 57 56 0 1 230 210 6 14
186 Mid 31 31 0 0 81 77 2 2
214 Low 27 0 18 9 597 275 225 97
246 Very high 405 405 0 0 7 7 0 0
254
Pt #5 CD56(+) CD56(-)
-5 None 0 0 0 0 68 54 4 10
12 Mid 29 12 0 17 39 33 0 6
28 None 5 0 1 4 146 115 27 4
40 None 2 0 0 2 489 274 175 40
68 High 174 153 10 11 291 262 5 24
85 Very high 2684 2663 10 11 1454 1310 138 6
118 Low 21 19 0 2 64 44 3 17


















-100%   0%   500% 
  
154 
5.3.4 CLCs in Clinical Samples and Early Signs of Impending Relapse by Microfluidic MRD Surveillance 
All data for each patient sample including CLC and aberrant(-) cell counts for each device are 
provided in Table 5.2. The five AML patients were sampled 39 times by the microfluidic assay; in 
comparison, only eight microscopy, FISH, PCR and/or MFC tests were administered over the same 
sampling interval because of the need for requiring the patient’s bone marrow in most cases. Three 
healthy donors were also analyzed (Appendix 5.4). An average of 151 ± 89, 19 ± 13, and 108 ± 103 
aberrant(-) cells/mL blood and 2 ± 2, 0 ± 1, and 1 ± 1 cells non-specifically stained aberrant(+)were isolated 
in the CD33, CD34, and CD117 devices, respectively. Based on a 99% confidence limit (3X the standard 
deviation), we established a threshold of 8, 3, and 5 aberrant(+) cells for MRD positivity in the CD33, CD34, 
and CD117 subpopulations, respectively. 
At 137, 254, and 178 days post-SCT, Pts #3, #4, and #5, respectively, were alive and had not 
relapsed. Pts #1 and #2 relapsed and died 95 and 118 days post-SCT, respectively. For both patients that 
relapsed, the microfluidic assay detected MRD well before PCR, MFC, microscopic, or FISH-based MRD 
testing performed on the same patient. However, the MRD assessments made by the microfluidic assay 
agreed to the results secured using PCR when these tests were performed on the patients. We observed 
that the microfluidic assay detected patterns of MRD progression that may have indicated an onset of 
relapse (see Table 5.2 and the associated heat map). Tracked MRD progressions are shown in Figure 5.4 
and Figure 5.5 for Pt #1 and Pts #2-5, respectively, with annotations of MRD test results and antiviral 
treatments given in the figure. 
Active cytomegalovirus (CMV) infections are common in SCT patients as the regulating lymphoid 
immune system remains suppressed to avoid graft-versus-host disease. In this study, Pts #1-4 experienced 
CMV activation as detected by weekly PCR surveillance. These Pts were treated with antivirals (oral 
valgancyclovir or intravenous ganciclovir), which are known to cause myelosuppression, until CMV was 
cleared. CMV replicates in myeloid cells and is in effect myelosuppressive, which is why it has been 
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suggested that early CMV infections can aid in long term remission. CMV may be cytotoxic to the MRD 
(virus-versus-leukemia effect) and/or cause myeloid cells to present antigens that induce a T cell and/or 
natural killer cell attack (another graft-versus-leukemia mechanism).371 
Figure 5.4A shows Pt #1’s total cell counts for days 28 through 85 as determined by the 
microfluidic assay and Figure 5.4B distinguishes these counts by aberrant staining. The microfluidic assay 
detected 17% CLCs for Pt #1 on day 28, whereas the NPM1 PCR assay of a bone marrow biopsy three days 
later was MRD(-) (Figure 5.4D). The PCR assay’s negative result indicated that the residual leukemic cells, 
, at least those with the NPM1 mutation, were below the assay’s detection limit (1 mutated gene in 10,000  
background copies). In the microfluidic MRD assay, aberrant(-) cells, which included normal donor cells, 
increased by ~40% 17 days later while CLC levels remained approximately constant. In addition, the 
presence of aberrant marker (CD7) for the CD34 subpopulation was observed 45 days post-SCT. However, 
the total cell count decreased at day 57, perhaps due to CMV activation (Figure 5.4A), but CLC percentages 
rose to 63% with the observation of aberrant(+) cells in the CD33 subpopulation (Figure 5.4B).  
CLC counts were high after day 57 and spiked to 92% at day 85. Relapse was confirmed by a 
peripheral blood smear at day 81. Unfortunately, the disease burden was already high (10% of the bone 
marrow) and the AML burden approximately doubled every two days (Figure 5.4D,E). Pt #1 died 95 days 
post-SCT. Considering myelosuppressive antiviral treatment from days 58 to 82, it may be suggested that 
the antiviral treatment delayed the rapid relapse progression that was observed after day 81 by 
microscopy (Figure 5.4D). We retrospectively highlight the microfluidic assay’s results at day 57 as a 
potential indicator of impending relapse for this patient characterized by increasing CLC levels and 
receding aberrant(-) cell numbers. Thus, the microfluidic assay was able to detect MRD 28 days following 
SCT and impending relapse 57 days following SCT, while microscopy detected relapse in a bone marrow 




Figure 5.4 (A-C) Microfluidic monitoring of Pt #1 from 28 to 85 days post-SCT. (A) Total cell count, which 
represents the cumulative number of cells counted from all three subpopulations (CD33, CD34 and CD117) 
selected in the three separate microfluidic devices and all phenotypes (aberrant(+) and aberrant(-)). (B) 
Cell counts of aberrant(+) and aberrant(-) phenotypes but cumulative for all microfluidic devices used in 
the assay. (C) Cell counts of aberrant(+) and aberrant(-) cells discerned by each isolation antigen (CD33, 
CD34, or CD117). (D) Results for PCR (NPM1 gene) and peripheral blood smear MRD assays. Relapse was 
confirmed on day 81 by a peripheral blood smear test (dagger mark). This patient died 95 days post-SCT. 
(E) An image of the Wright-Giemsa stained peripheral blood smear from day 85, which showed two blasts 
with open chromatin and weak intensity from the cytoplasm (magnification was 100x). PB = Peripheral 
Blood; NA = not applicable. 
 
Pt #2’s MRD progression (Figure 5.5A,B) from days 7 to 28 post-SCT was very similar to Pt #1’s 




Figure 5.5 CLC counts and aberrant(-) cells for (A,B) Pt #2, (C,D) Pt #3, (E,F) Pt #4 and (G,H) Pt #5. Cell 
counts are color coded according to the targeted marker used for CLC selection. Results from FISH, PCR, 
blood smear and MFC MRD diagnostics, which used bone marrow biopsies unless noted otherwise, and 
the time frames for antiviral therapy are shown in the figures. Linear connections between events are for 
visualization purposes only 
 
analysis was MRD(-) at day 30, and the microfluidic assay’s cell counts dropped precipitously at day 40. Pt 
#2 was treated with antivirals for an active cytomegalovirus infection from days 41 to 69. During 
treatment, all cell counts recovered slowly and after lifting treatment, a surge of CD33(+)/aberrant(-) cells 
was observed at day 84 (Figure 5.6) that may be attributed to a “left shift” immune response to late-onset 
cytomegalovirus disease or severe physiological burden, where the marrow is stimulated to produce 
immature CD33(+)/aberrant(-) cells that spill into the peripheral blood (also supported by MFC analysis of 
peripheral blood on day 79 that indicated the presence of <1% immature cells). Regardless, CLC counts 
increased steadily, and the last sample for microfluidic analysis (day 98) was characterized by a low 
aberrant(-) cell count and high CLC count, most notably with CD34(+)/aberrant(+) CLCs comprising 54% of 




Figure 5.6 Fluorescence images of the cells isolated using the anti-CD33 device for Pt #2’s day 84 sample. 
Particle analysis of the DAPI image indicated the well contained 89,492 cells, which showed high 
agreement with CD45-Cy5 staining. This cell count is likely to be an under-approximation of the true cell 
count due to imperfect particle analysis. The entire well was scanned to identify CLCs that expressed the 
CD7-FITC aberrant marker, 99 of which were identified. (A,B) DAPI and CD45-Cy5 fluorescence images. 
These images were stitched from 225 individual images acquired with a 20X objective. The apparently 
dark portion in the bottom, left corner of panel (B) is an artifact of background subtraction used to 
produce this figure, but was not present during the identification of aberrant cells. (C-G) Zoomed 
fluorescence panel of a single aberrant, CD7-FITC(+) CLC amidst a large background of aberrant(-) cells. A 
Cy3-labeled Ab was not used (autofluorescence channel). 
 
leukemic blasts, which are sometimes observed in regenerating marrow;370 however, there were relatively 
few CD34(+)/CD7(+) cells at day 14, when the marrow may have been regenerating from initial 
engraftment, and so we would expect the CD34(+)/CD7(+) subpopulation at day 98 to contain CLCs. 
Further, CD33(+) and CD117(+) cells aberrantly expressing CD7 (a T cell antigen) should never be observed 
in normal marrow, regenerating or otherwise, all of which suggested persistent leukemic MRD. 
Subsequent sampling of this patient was not possible as this patient died 118 days post-SCT. 
Pt #3 had the most acute MRD progression with 1,430 CLCs/mL (50% CLCs) developing at day 30 
even though the patient was MRD(-) at day 13 (Figure 5.5C,D). This may reflect the patient’s pre-SCT 
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chemotherapy regimen, which was less intense than Pts #1 and #2 due to Pt #3’s age (Table 5.1, Appendix 
5.1). During antiviral treatment from days 41 to 69, the cell counts remained approximately the same as 
the day 30 results until day 69, when both CLC and aberrant(-) counts slowly declined. At 90 and 121 days 
post-SCT, Pt #3’s samples were MRD(-) as was microscopic analysis at day 89. 
Pt #4’s MRD profile is rather unique, remaining MRD(+) but with low CLC counts (11-57 CLCs/mL) 
for 157 days except for one MRD(-) result at 81 days post-SCT (Figure 5.5E,F). During this time, Pt #4’s 
MRD was just detectable by FISH at day 88 but was not detected by several tests at day 145. Pt #4 incurred  
cytomegalovirus activation and was treated between days 174 and 214, and there was a notable increase 
in aberrant(-) cell counts at day 214. However, the next sample at day 246 showed a spike of CD33(+) CLCs 
and low aberrant(-) cell counts.  
Pt #5 is the only patient that did not test positive for a cytomegalovirus infection during tracking 
for 146 days (Figure 5.5H). Pt #5 had been consistently MRD(+) by NPM1-PCR, but with low disease 
burden. The microfluidic assay indicated consistently MRD(+) with CLC levels spiking at days 68 and 85 
post-SCT but then sharply declining at day 118 (Figure 5.5G). The microfluidic assay at day 146 was MRD(-
), as was NPM1 PCR at day 132. The aberrant(-) cell counts correlated with the CLC counts (Figure 5.5H); 
we speculate a graft-versus-leukemia response occurred.  
In summary, Pts #1-3 had very high CLC counts and experienced the same viral activation within 
a few months post-SCT. These patients represent three divergent scenarios. Pt #1 rapidly progressed 
towards relapse; Pt #2 experienced a recession of all myeloid counts, presumably due to cytomegalovirus 
activation, but then relapsed; and Pt #3 CLC counts receded almost entirely and is currently in complete 
remission. While we sampled the patients at a sufficient frequency to observe the reported trends, we 
still have limited data for each sample to confidently determine the nature of these trends. However, we 
can speculate that virus-versus-leukemia effects played a role in the progression of Pts #2 and #3. Pt #5 
was similar in progression to Pt #3 yet did not experience a viral infection. It is possible that the recession 
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of Pt #5’s MRD was due to graft-versus-leukemia effects that acted similarly to the proposed virus-versus-
leukemia mechanism.371 Lastly, Pt #4 was anomalous to the other patients, progressing to high CLC counts 
and experiencing a viral infection far later (>six months post-SCT). 
5.3.5 Shifts in CLC Subpopulations through Relapse 
Frequent monitoring of CLC subpopulations can provide a real time insight into patient-specific 
MRD progression. It has been observed that both genetic364,365 and phenotypic339,369 evolution occurs as 
residual leukemic cells experience selective pressures, which range from chemotherapy to nutrient, 
oxygen, and space deprivation364 and likely from interplays between residual leukemia, the grafted 
immune system, infections, and clinical treatments. All of these variables contribute to extremely 
heterogeneous clonal subpopulations that compete towards forming dominant AML clone(s) that are, in 
effect, relapse.364 Previous methods have been limited for retrospective comparisons of the primary and 
relapsed tumors. But, with the microfluidic assay and its high sensitivity even when sampling peripheral 
blood, it may be possible to monitor acute clonal responses to selective pressures. 
For this reason, the CLC and aberrant(-) subpopulations (differing by the target isolation antigen: CD33, 
CD34, or CD117) were independently analyzed by selecting them in different devices. While it is unlikely 
all CLC subpopulations are mutually exclusive due to co-expression of the targeted antigen, there may be 
CLC subpopulations that solely express one antigen or have very weak expression of the other antigens 
(Appendix 5.1). One case in point is Pt #1 (Figure 5.4C): from days 45 to 85, the CD34(+) CLCs remain fairly 
constant at 3-4%; CD117(+) CLCs steadily increased from 10% to 65%; and CD33(+) CLCs appeared at day 
57 but their number density fluctuated thereafter. Similar patterns were not observed in the aberrant(-) 
subpopulations (Figure 5.7), which were isolated in the same devices as the CLC subpopulations. Thus, it 
is most likely that we have observed genetically distinct CLC clonal subpopulations or that the gene 




Figure 5.7 The percent change between samples in the (top) aberrant (+) and (bottom) aberrant(-) cells. 
All changes are calculated relative to the previous measurement. Patient data was separated by shading 
and the x-axis arbitrarily represents subsequent sampling (not scaled with time). We did not observe any 
apparent trend between the aberrant(+) and the aberrant(-) sets. The maximum decrease in any set was 
-100% and corresponded to complete loss of cells associated with that set. There is no fundamental limit 
to increases in the aberrant(+) or aberrant(-) cells, but we did limit the y-axis to +1000% for visualization 
purposes. Lastly, if a set of cells was present in a sample but was not observed on the previous sample, a 
change of +100% was assigned. 
 
The CLC subpopulations in each patient’s MRD presented a unique profile. We also found no clear 
pattern in the progression of any CLC or aberrant(-) subpopulation between patients (Figure 5.7). While 
there are cases where the progression of the CLC subpopulations is mirrored by the aberrant(-) 
subpopulations, which may reflect physiological pressures on the bone marrow environment, there are 
many cases where progression of the CLC and aberrant(-) subpopulations are extremely dissimilar. These 
results may reflect AML’s inter- and intra-patient heterogeneity.364 To explore the significance of these 
subpopulations as the AML evolves post-SCT, we plan future studies that will gather more information 





This study represents the first microfluidic endeavor for monitoring AML patients following stem 
cell transplantation. The microfluidic assay was able to isolate and phenotypically identify leukemic cells 
circulating in a patient’s peripheral blood. In this pilot clinical study, we monitored five AML patients 
following SCT. Because the assay required peripheral blood and not a bone marrow biopsy, 39 microfluidic 
tests could be carried out compared to only eight PCR, MFC, FISH, and/or microscopy tests, because they 
required highly invasive bone marrow biopsies in most cases. Because we were able to frequently test 
and observe changes in MRD levels, we identified signs of impending relapse earlier than bone marrow-
based tests, which could enable therapeutic interventions at low disease burden and result in better 
outcomes for the patients. We also observed a case where late PCR detection of a patient’s MRD 
translated to rapid relapse with the tumor doubling every two days and patient death shortly thereafter. 
We also observed the heterogeneity in AML; the CLCs and non-aberrant cells progressed variably, 
unpredictably, and, as we suspect, in response to graft- and virus-versus-leukemia effects as the bone 
marrow replenished. We are now developing a multifaceted microfluidic system capable of quantitative 
and in-line microfluidic flow cytometry with integrated flow sorting for additional gene expression and 
gene mutation analysis of the CLCs as well as surveying the lymphoid system33 for its graft-versus-leukemia 
capability. 
The microfluidic assay demonstrated herein the ability to track response to therapy in a minimally 
invasive fashion. The assay could also be used to provide a venue for the detailed management of a 
particular patient’s cancer, especially in monitoring a patient’s response to initial chemotherapy regimens, 
as well as long term monitoring for disease recurrence. This microfluidic assay could also be adapted to 
manage chronic lymphocytic leukemia (CLL), B cell lymphomas,372 and Hodgkin’s lymphoma373 by 
programming into the chips the appropriate selection mAbs and aberrant markers. In addition, the 
presented microfluidic assay could also be envisaged as a companion diagnostic for the discovery of new 
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therapies for various leukemic diseases. With these observations and the data presented in this 







CHAPTER 6. FUTURE DIRECTIONS 
6.1 Introduction 
Future research will be directed towards further improvement of the assays detailed throughout 
this dissertation, then mobilizing the technologies to impact patient care. These endeavors involve: (i) 
injection molding microfluidic devices for increased production rates with reduced cost; (ii) integration of 
the cell isolation device with downstream devices for cell analysis; (iii) systems for fully automated 
analysis; and (iv) technologies for cell analysis, including microfluidic multi-parameter flow cytometry 
(µMFC). Some of these objective are being realized in a system that is targeted towards the isolation and 
immunostaining of CTCs, which is being developed by Biofluidica, Inc., a startup company originating from 
the Soper group. Thus, we detail not only future technologies, but staged pathways to commercialization 
that offer both short-term and long-term product development and are geared towards rapidly and 
iteratively expanding the sinusoidal technology’s clinical impact. 
6.2 Modular Microfluidic Systems for Integration Cell Isolation and Analysis 
The cleavable linker bioassay detailed in Chapter 4 has enabled the use of additional 
instrumentation for downstream cell analysis, such as label-less impedance detection of the cells, 
automated fluorescence microscopy for immunophenotyping, and microfluidic flow cytometry. All 
laboratory-based demonstrations thus far have relied on manually mating these technologies; however, 
it is highly advantageous to couple devices into a single microfluidic platform, where all sample transfer 
is self-contained and the mechanisms to direct transfers are automated without user intervention. This 
adds several advantages, including the elimination of sample loss, which could incur false negatives, 
and/or sample contamination that could give rise to false positives. 
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Fluidic motherboards provide a platform to which task-specific microfluidic modules, such as 
those for cell isolation, can be attached, thereby providing a central element around which full automated 
analyses can be realized. This strategy also endows flexibility in fabrication methods. For example, the cell 
isolation module may be rapidly produced by injection molding, whereas the impedance detection 
module, which relies on thin film gold electrodes to measure each cell, may be fabricated by lithography 
based methods without over-complicating the fabrication of the entire system. Furthermore, the 
motherboard and the majority of components can be fabricated by mass-production methods with 
inexpensive materials so that the entire system can be packaged as a single, disposable consumable, which 
avoids potential cross-contamination issues when implementing in a clinical setting. 
 In general, the fluidic motherboard can perform the following functions: (i) Serves as a structural 
element to which all task-specific modules are connected; (ii) provides a fluidic path connecting different 
task-specific modules and interconnects them with the instrument; (iii) provides reservoirs for loading 
reagents and buffers for each analysis; and (iv) contains the valving structures for directing fluid flow 
through the fluidic system. These fundamental processes are easily adapted to many configurations of 
task-specific modules; thus, research and development for relatively simple analyses can be easily 
translated to more complicated configurations with many modules, and vice versa. 
Figure 6.1A,B shows the design of a thermoplastic-based motherboard that is catered to CTC 
analysis, which selects cells either by EpCAM or FAPα markers then passes these cells into an impedance 
module for cell counting and an imaging module for automated immunophenotyping of the selected cells. 
The motherboard, which is pre-assembled with the task-specific modules, is slides into cartridge decks of 




Figure 6.1 (A) Schematic of the module fluidic system for the comprehensive analysis of CTCs. The system 
consists of 3 modules and 13 membrane valves that are resident on the motherboard. The modules are 
used for CTC affinity selection, impedance sensing, and imaging of the selected cells following their 
staining. The system also contains reservoirs for the sample and reagents used for the assay. (B) Prototype 
of the modular fluidic system. (C) Front side view of the peripheral instrumentation showing two fluidic 
motherboards. (D) Back side view of the electronics including USB hub, impedance data acquisition board; 
impedance detection electronics, analog signal output board, control board for operation of up to 4 
motherboards (pumps, solenoid valves, and heaters), and robot control board. Microscope control 
electronics are located inside microscope enclosure shown in (C) along with optical components. 
 
peristaltic pumping, dispensing blood, collecting waste, and reservoirs for all reagents and buffers, such 
as enzymes for cell release, antibodies for immunostaining, and formaldehyde for fixing the CTCs. The 
backside of the motherboard contains a network of microfluidic channels that connect the various 
modules together as well as membrane microvalves that allow control of the fluid flow between the 
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modules. The rest of the system contains all necessary peripheral instrumentation for fluidic pumping, 
electronic readout, and image collection and processing for cell phenotyping.  
6.3 Paths to Commercialization 
For future research, we have preliminarily outlined three paths (Figure 6.2) to generate 
commercial products driven for either research- of clinical-based CTC analysis. The three proposed paths 
share similar instrumentation but cater to different levels of analysis varying in complexity, and thereby 
the amount of research and development necessary to generate working prototypes and technical 
feedback for iterative design improvement.  
Product 1 (Figure 6.2A) is semi-automated and relies on the sinusoidal technology’s state-of-the-
art purity to identify CTCs by label-less impedance detection, which can then be dispensed into a standard 
microfuge for laboratory testing as desired by the operator. As peripheral instrumentation is minimal and 
very simple device designs are plausible, the pathway to Product 1 is likely the quickest path to a 
commercial product and generating feedback from clinical testing (both control patients with non-
malignant disease and cancer patients) over large demographics. 
The second product (Figure 6.2B) is designed to conduct fully-automated CTC analysis (essentially 
the prototype shown in Figure 6.1), including phenotypic identification and potentially cytogenetic 
analysis. This pathway, which can be conducted in parallel or driven by the iterative developments from 
Product 1, requires a higher degree of research and development in fluid control, automated microscopy 
instrumentation, and image recognition software, and thus will take a longer time frame and financial 
investment to commercialize. 
Thirdly, we have outlined future products (Figure 6.2C) that utilize microfluidic MFC to full-





Figure 6.2 Strategic path for commercializing the CTC technology. (A) Rapid generation of a low cost 
system that purifies, counts, and tests the viability of CTCs. CTCs are then dispensed for laboratory 
analysis. (B) A fully automated CTC test, including CTC phenotyping. (C) Future research and development 
to explore microfluidic MFC to sort CTC sub-types for separate testing (molecular profile/drug resistance), 
either by laboratory technicians or within an integrated microfluidic system.  
 
especially appealing to research-based, cancer discovery applications, but the path to commercialization 
is less clear as more research and development is necessary to explore the benefits and drawbacks of the 
MFC instrumentation, which could significantly range in complexity/cost depending on future results.   




Figure 6.3 Injection molding of high aspect ratio fluidic microchannels (25 µm wide and 150 µm deep) 
used in the CTC isolation module. (A) Design of “split” CTC isolation channels; red circles show the position 
of the ejector pins. (B) SEM of injection molded sinusoidal microchannels with ejector pins and (C) 
injection molded sinusoidal channels with no ejector pins. Simulations of (D) velocity through the parallel 
channels and (E) shear stress in the inlet and outlet channels using straight or tapered addressing 
channels. 
 
development: Modifications to the cell isolation unit to enable mass-production, low-cost injection 
molding; valving components that control fluid delivery in the integrated system and enable automated 
operation; and instrumentation for downstream CTC analysis, including impedance measurements, 
automated microscopy, microfluidic MFC systems for rare cell identification and flow-based sorting, and 
eventually, the molecular profiling of CTCs for clinically actionable oncogenes. 
6.4 Injection Molding the Z-Configuration Cell Isolation Modules 
All cell isolation devices used to date have been fabricated by hot embossing, a technique that is 
perfectly suited for laboratory use, but for commercial production, Injection molding offers higher scaling 
(~4-fold increase in production rate) and a substantial decrease cost per device (nearly 10-fold lower per 
part compared to hot embossing).374 Many practical considerations (materials, mold fabrication, etc.) are 




be addressed. Ejector pins, which physically push the molded device out of the mold cavity, must be 
placed in close proximity to the smallest microstructures to ensure high replication fidelity.  
“Empty” space must be incorporated within each microfluidic bed (Figure 6.3A) to allow for the 
inclusion of ejection pins, which enables accurate replication of the mold (Figure 6.3B) and avoids polymer 
pullout (Figure 6.3C) that prevents subsequent device assembly. The “empty” spaces are accommodated 
by periodically elongating (by approximately 10-fold) segments of the inlet and outlet channels, which 
increases fluidic resistance in these segments substantially. In consequence, non-uniformity in blood 
delivery between the sinusoidal channels (detailed in Chapter 2) develops between each subsection of 
the microfluidic bed (Figure 6.3D) that can adversely affect cell isolation147,158 and purity of the isolate.75 
By adapting our numerical optimization strategy88 to this specific problem, we have engineered 
designs for the cell isolation unit that will open the door for the inclusion of ejector pins and injection 
molding, even for high throughput devices. These new microfluidic geometries utilize subtle tapering of 
the inlet and outlet channels to not only correct non-uniformity in blood distribution due to the ejector 
pins (Figure 6.3D) but also control fluid shear stress (<10 dynes/cm2) (Figure 6.3E) throughout the device 
to preserve CTC viability.75 
6.5  Microvalving Systems for Automated CTC Analysis 
Automated analysis drastically simplifies user interaction with the CTC technology, thereby 
mitigating sample loss or contamination and ensuring reproducibility in the assay. Because multiple 
operations are conducted per assay (blood delivery, sample washing, incubation of the enzymatic release 
agent, CTC release, immunostaining procedures, and imaging), automation requires tight control over 
where fluid is delivered (which module) and the timing of the operations. We have developed membrane 




Figure 6.4 (A) Schematic operation of membrane microvalve with direct solenoid actuation. (B) 
Preparation and assembly membrane valve using a pressure sensitive adhesive tape. (C) Picture of 
assembled test valve for evaluation of valve performance. (D) Results of pressure test of the membrane 
microvalves. (E) Schematic representation of self-aligning fluidic interconnects for attaching modules to a 
fluidic motherboard with minimal unswept volumes based on conical receiving ports molded into modules 
and motherboard and a semi-rigid TefzelTM tubing (1) permanently bonded with adhesive (2). (F) Picture 
of assembled units with interconnects shown in (E). 
 
The operation of the on-chip microvalves is controlled by direct solenoid actuation and is 
conceptualized in Figure 6.4A. In this very straightforward setup, a solenoid piston is poised directly over 
the valve membrane. The solenoid is not energized in the open position and does not impose any force 
on the membrane. Fluid can freely flow from the bottom layer containing the microfluidic network 
through the valve in the top layer and return back to the bottom layer. To close the valve, the solenoid is 




Figure 6.5 (A) Impedance trace of SKBR3 cells. SKBR3 cells recovered from the impedance sensor in (A) 
and subjected to (B) Eth-HD1 staining and (C) calcein AM staining. (D) SKBR3 cells that were subjected to 
FA and Triton-X100 and then allowed to hydrodynamically flow through the impedance sensor module. 
SKBR3 cells recovered from the impedance sensor in (D) and subjected to (E) Eth-HD1 staining and (F) 
calcein AM staining. (G-H) Diagram explaining the origin of higher then buffer-only resistance registered 
for intact cells (A) and drop in resistance for cells containing membranes that are compromised (D). R
cell
 – 
resistance of cell, R
sol
 – resistance of volume of solution equal to volume of cell. Impedance traces were 
collected for cells suspended in 1X TG buffer. The impedance was measured at a frequency of 40 KHz. 
 
These microvalves employ a pressure sensitive adhesive tape for the valve membrane because 
these inexpensive tapes ensure biocompatibility and are easily deformed. However, the solenoid provides 
a considerable amount of force, and without modification, the tape would adhere to the valve seat the 
first time the valve was closed. We found a simple method to locally “deactivate” the tape (UV/O3 or O2 
plasma exposure) allows the valve to be opened and closed reversibly while also ensuring that the 
microvalve assembly can resist fluid pressures (Figure 6.4D) that are an order of magnitude higher than 
necessary to operate the motherboard.  
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6.6 Cell Enumeration and Viability Testing by Impedance Sensing 
Impedance sensing is a label-less strategy to reliably detect single cells.158 A pair of electrodes is 
positioned across a fluidic channel, and cells are hydrodynamically infused past the electrode pair. At low 
frequencies (<100 kHz), capacitance formed at the cell membrane impedes current flow between the 
electrodes, and each cell generates a voltage spike that is proportion to the cell size (displaced volume of 
buffer).375,376 Using an impedance sensor detailed elsewhere,146 we have observed that the impedance 
sensing can also determine cell viability.  
Figure 6.5A shows impedance traces for viable SKBR3 breast cancer cells, and Figure 6.5D shows 
data for non-viable cells, which were subjected to fixation and poration of the cell membrane. The polarity 
of the impedance response was positive when the cells were not treated, indicating an increase in 
resistance due to an intact cell membrane, but was negative when the cell was porated, indicating that 
the non-viable cell’s cytosolic protein structure was more conductive than the carrier buffer (Figure 6.5G-
H). Indeed, after collecting the cells exiting the impedance sensor and staining to test viability (see Chapter 
4 for assay description), the majority of cells generating positive voltage signals were live (calcein AM-
positive, Figure 6.5C) and the non-viable, porated cells were in fact dead and stained positive by the 
intercalating ethidium homodimer 1 dye (Eth-HD1, Figure 6.5E).146 
These results are very promising for simultaneously enumerating and determining the viability of 
released CTCs, which could be used to sort cells by viability for separate molecular profiling. Yet research 
is needed to mate viability measurements with the USER™ enzyme system that is used to release cells, 
the activity of which was optimized in PBS. Operating the impedance detector in PBS will generate a much 
lower background voltage that is likely to be similar to the porated non-viable cells because PBS is a 
physiological saline. That is, while viable cells would be detected, non-viable cells in PBS would likely be 
missed. Thus, it will be necessary to demonstrate high enzymatic activity of the USER™ system in the 
impedance sensing buffer or find an optimal buffer that caters to both systems. 
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6.7 Microfluidic MFC for In-Line Immunophenotyping and Cell Sorting 
While scanning-based microscopy imaging is suitable for immunophenotyping cells, the cells 
cannot be sorted by sub-type for further analysis, which would be useful for AML applications.364 To 
address this limitation, microfluidic MFC systems can be used to immunophenotype cells in a flow through 
device, and then, incorporate microfluidic architectures for in-line cell sorting based on the MFC response 
for a particular cell type. Currently, two microfluidic flow cytometers are being investigated. The first 
system has been constructed and evaluated by the GE Global Research Center (GRC). The GRC MFC system 
(Appendix 6.2) is similar to conventional MFC systems and consists of a three channel, epifluorescence 
system that uses photomultiplier tubes (PMTs). In parallel, we have built and are in the process of testing 
a novel MFC system (Figure 6.6) that is comprised of a CCD-based spectral flow cytometer employing 
time-delayed integration (TDI; TDI-Spectral MFC). The main advantages of the TDI-Spectral MFC system 
are a ~100% duty cycle with improved signal-to-noise ratios compared to PMT-based system,377 flexibility 
in the type and number of fluorescent dyes that can be used because emission is spectrally sorted rather 
than passed via filters, and contains a simplified optical train with less optical components compared to 
multiplexed MFC systems, which is more easily packaged alongside a microfluidic system. 
The TDI-Spectral MFC system uses a single excitation laser (488 nm) to excite several fluorophores 
(e.g., FITC, PE, PE-Cy5, PE-Cy7), but rather than using band pass filters to select fluorophore-specific 
wavelengths, the emission spectrum is dispersed using by a spectrograph onto one axis of a CCD array 
(Figure 6.6B). Because the CCD reads an immunostained cell’s entire fluorescence emission spectrum with 
high resolution (Figure 6.6C), immunostaining dyes that spectrally overlap can be resolved by classic least 
squares unmixing deconvolution.378 Our custom software was consistently capable of resolving mixtures 
of 4 dyes with overlapping emission spectra (Figure 6.6D,E). The optical system was even capable of 
resolving PE-Cy5 and PerCP-Cy5.5, which overlap considerably with maximum emission wavelengths of 
670 nm and 690 nm, respectively (Figure 6.6D).  
  
175 
Figure 6.6 (A) Picture of the assembled TDI-Spectral MFC system. (B) Optical schematic. The system uses 
epi-illumination and a grating to spectral sort the emission, which is detected using a single CCD camera 
operated in TDI mode. (C) Wavelength calibration from 500 to 1000 nm of the grating-CCD combination. 
(D) Deconvolution of a mixture of 5 dyes with overlapping emission spectra. (E) Deconvolution of different 
mixtures of a 4 dye system (F = FITC; P = PE; 5 = PE-Cy5; 7 = PE-Cy7). A box with color indicates that the 
program detected the dye in the mixture. All dye combinations were successfully deconvoluted by classic 
least squares unmixing, which fits a linear combination of reference spectra to the measured spectrum. 
 
While the TDI-Spectral MFC system uses a spectral MFC format,378 it is considerably unique in its 
operation. Typically, high gain EM-CCDs acquire spectra over very short exposure time (10 µs), but due to 
the much longer readout time (10 ms), the effective duty cycle is low (0.1%). Signal events must occur on 
the order of 100 events/s, and a technician must dilute cells below 30 cells/10 µL,379 otherwise events 
would occur during spectral read-out and would be missed. However, cells released from the microfluidic 
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cell isolation device (internal volume of ~10 µL) can be concentrated and thereby require high duty cycles 
to ensure each cell is imaged; the TDI-Spectral MFC system provides nearly 100% duty cycle due to the 
time-delayed integration (TDI) mode of operation of the CCD camera. 
We have designed our spectral MFC system to operate in TDI mode (Appendix 6.1).377 A cell’s 
fluorescence spectrum is collected on a few rows of the CCD, and as the cell moves through the field of 
view, the CCD transfers the collected photoelectrons to the next row of pixels at the same time as which 
the cell moves. Thus, fluorescence is integrated throughout exposure and is contained is just a few read-
outs of the serial register, thereby increasing signal-to-noise as well as the duty cycle.377 Most importantly, 
multiple cells can occupy the CCD’s field of view, because they will remain resolved as they’re spectral 
information is separated during readout. 
TDI imaging emplaces certain restrictions on the system: (i) the cell’s linear velocity must be nearly 
constant to match the CCD’s fixed clocking rate; and (ii) the cell’s maximum linear velocity is limited by 
the CCD’s readout time. We have approximated the maximum linear velocity to be on the order of 1 mm/s, 
which would typically require extremely low elution flow rates for cell release. Thus, we have outlined in 
Appendix 6.1 a unique flow cell to: (i) Focus released cells using an effective sheathing system; and (ii) 
rapidly decrease the cell’s linear velocity to the targeted value of 1 mm/s while retaining the tightly 
focused position of the cells.  
6.8 Concluding Remarks 
In this dissertation, many facets of the sinusoidal technology for cell isolation have been detailed. 
Empirical evidence and theoretical physics have been geared towards demonstrating that the sinusoidal 
technology can isolate rare cells from undiluted, unfixed, and unfractionated blood with very good 
recovery and state-of-the-art purity. We have extensively characterized the efficiency of conducting 
bioassays in thermoplastic-based microfluidic devices with the purpose of employing mass-production 
fabrication modes such as injection molding, which reduces the cost of the disposable device. We have 
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also advanced the bioassay design to enable the isolation and release of rare cells, thereby opening the 
door to several downstream technologies to analyze the cells. We have demonstrated the technology’s 
clinical sensitivity and utility in several applications, namely epithelial cancers and AML. All of these 
developments feed directly into commercialization, for which we have proposed several paths to translate 
these academic discoveries into point-of-care systems that can provide inexpensive and routine cancer 





 DERIVATION OF THE Z-CONFIGURATION GEOMETRY OPTIMIZATION STRATEGY AND 
APPLICATION AND VALIDATION FOR CONSTRUCTING HIGH POWER HYDROGEN FUEL CELLS 
A2.1.1 Derivation of Z-Configuration Optimization Strategy 
To optimize a Z-type parallel configuration of a fuel cell for flow uniformity, we must make a few 
assumptions. First, we assume that the flow is perfectly distributed through the parallel channels, i.e.,  





and the mass-balance equations in Eqs. 2.11c-g imply that 
𝑉𝑁𝐴𝑁 = 𝑣𝑃𝑎𝑃 (A2.1.1b) 
𝑉𝑁−1𝐴𝑁−1 = 𝑉𝑁𝐴𝑁 + 𝑣𝑝𝑎𝑃 = 2𝑣𝑃𝑎𝑃 (A2.1.1c) 
which can be generalized for the 𝑖th inlet header by 




 We now make a second assumption that the entire Z-configuration is symmetric (symmetry plane 
shown in Figure 2.12A). Here, the geometry of the 𝑖th inlet header is identical to the (𝑁 − 𝑖)th outlet 
header. For the geometry in Figure 2.12, this means that 𝐴1 = 𝐴3′ and 𝐴1
′ = 𝐴3, which is also true for 
widths, heights, resistances, and average velocities. By Eq. A2.1.1a, this constraint immediately leads to a 
universal set of solutions by relating the 𝑖th and (𝑁 + 1 − 𝑖)th inlet headers; 
𝑉𝑖𝑅𝑖 = 𝑉𝑖
′𝑅𝑖′ = 𝑉𝑁+1−𝑖𝑅𝑁+1−𝑖  (A2.1.1e) 
 We then substitute Eq. A2.1.1d on both sides of Eq. A2.1.1e to give; 
















  (A2.1.3) 
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assuming that the segment’s aspect ratio is given by 𝑊/𝐻, i.e., 𝑊/𝐻 ≥ 1. 
 Eq. A2.1.3 is the key to our optimization method because it relates the first 1…𝑁/2 inlet headers 
to the last 𝑁/2…𝑁 − 1 inlet headers. Practically, we can change the dimensions of the 1…𝑁/2 inlet 
headers with respect to the 𝑁/2… 𝑁 − 1 inlet headers to satisfy Eq. A2.1.3. For several reasons outlined 
elsewhere,88 we chose to alter the headers’ widths to satisfy Eq. A2.1.3. 
There are infinite solutions to the outlined 𝑅/𝐴 relationships; some constraint must be emplaced 
to arrive at a unique solution, which we arbitrarily assigned as a minimized footprint in this appendix. 
Thus, we begin by setting the widths of the 𝑁/2…𝑁 − 1 headers with the same dimensions as the parallel 
channels, which propagates to an optimized geometry with a minimal footprint, unless the 𝑁/2…𝑁 − 1 
headers are narrowed further. It should be noted that if the widths of the 𝑁/2…𝑁 − 1 headers are 
increased, all widths will increase, and this technique can be used for fuel cells as a tool to reduce Reynolds 
numbers throughout the headers and the corresponding minor losses, distribution asymmetry, and 
parasitic pressure drops. In other applications, we have written algorithms to limit parameters such as 
fluidic shear stress throughout the header channels by stipulating that Eq. A2.1.3 must be satisfied and 
flow through all header satisfies the secondary condition. Practically, this is implemented by wrapping the 
width optimization algorithm detailed later in this section by a similar algorithm stipulating the secondary 
condition. These applications were equally successful and resulted in approximately linear header shapes 
unique to these restrictions. 
Next, the geometries of the first 1…𝑁/2 inlet headers are set to satisfy the relation in Eq. 
(A2.1.3), which involves increasing their width and/or height relative to the last 𝑁/2…𝑁 − 1 inlet 
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headers. Note that if there are an odd number of parallel channels, the middle 𝑁/2 inlet header, which is 
not related to any other, is simply assigned the geometry of the last 𝑁/2 + 1 inlet header.  
Since Eq. A2.1.4 is far from a simple expression relating 𝑊 to 𝑅/𝐴, it is not trivial to fit a universal 
expression to approximate the set of 𝑊𝑖 for any geometry since there are also dependencies on channel 
height and length. Rather, we wrote a simple search algorithm to find 𝑊𝑖 for the first 1…𝑁/2 inlet 
headers by the following operations: 
(1) For the 
𝑁
2
…𝑁 − 1 inlet headers, calculate the 𝑅/𝐴 ratios, and set the target 𝑅/𝐴 ratios for the 
1…𝑁/2 inlet headers by Eq. A2.1.3. All subsequent steps regard the 1…𝑁/2 inlet headers. 
(2) Set 𝑊𝑖 equal to zero, and an initial step size of 1 mm. 
(3) Add a step to the initial 𝑊𝑖 and recalculate 𝑅𝑖/𝐴𝑖 via Eq. A2.1.4. 
(4) If the new 𝑅𝑖/𝐴𝑖 is greater than the result from step (1), add another step increment and repeat 
step (2).  
(5) If the new 𝑅𝑖/𝐴𝑖 is less than the target from step (1), take one step back and decrease the step 
size by a factor of 10. Proceed with step (2) unless the new step size is less than a specified 
tolerance increment. If the tolerance limit has been reached, compare 𝑅𝑖/𝐴𝑖  as is to 𝑅𝑖/𝐴𝑖 with 
an added tolerance step, and choose the value closest to the target. In this appendix, we specified 
the tolerance increment at 0.01 mm to reflect fabrication limits for fuel cells.380 
(6) Set the 𝑖th outlet header width equal to the (𝑁 + 1 − 𝑖)th inlet header width. 
We modified the FORTRAN program used to solve Eq. 2.12a-d to include this search algorithm and 
solve for both the initial and optimized flow profiles. We analyzed a 175 channel Z-configuration with an 
Intel i7-3517U CPU in only 2.625 s CPU time. Moreover, with UNC-Chapel Hill’s KillDevil supercomputing 




A2.1.2 Validation of the Optimization Strategy using Computational Fluid Dynamics Simulations 
As a matter of validation, we used COMSOL Multiphysics® 4.3a to conduct CFD simulations of both 
air and hydrogen flow distributions through Z-type configuration designs of fuel cells. Geometries were 
constructed within COMSOL as two-dimensional to ensure numerical tractability. To account for this 
approximation, a volumetric drag term was added to the velocity field (𝒖), 𝐹𝜇 = −12𝜇𝒖/𝐻
2 . The validity 
of this volumetric drag term was affirmed by comparison with a three-dimensional model of geometry I 
defined below (data not shown). Elongated inlets and outlets were used to stabilize flow profiles prior to 
flow encountering the parallel channels. 
A faux internal boundary was drawn across the middle of the parallel channels. This boundary had 
no effect except to ensure that the meshing algorithm assigned data points along this boundary in each 
channel, which were used to construct velocity line plots. Solutions were obtained via meshing and solving 
with custom settings within COMSOL. The maximum element size, minimum element size, and maximum 
element growth rate were 0.25 mm, 10.3 µm, and 1.04, respectively; the resolutions of curvature and 
narrow regions were 0.1 and 16, respectively. The geometries presented herein consisted of 
approximately 150,000 to 600,000 elements. Systems were solved using the PARDISO algorithm, the 
Double-Dogleg nonlinear solver, automatic pseudo-time stepping, and a relative tolerance that was 
minimized for each geometry to ensure convergence to a unique solution in all cases. For the largest 25-
channel geometry, it took 4,111 s of CPU time using an Intel i7-3770K processor. Excluding points that 
defined the wall, data was averaged to generate the linear velocity through a parallel channel. To account 
for small deviations caused by extracting the 𝑣𝑖 data in this manner, sets of 𝑣𝑖 from both discrete and CFD 
solutions were normalized with respect to the average linear velocity over all 𝑣𝑖. Pressure drops were 
calculated using two lines across the inlet and outlet channels, which were directly adjacent to the first 
and last parallel channel, respectively, to account for the elongated inlets and outlets. The maximum 
pressure of the inlet line was subtracted from the minimum of the outlet line. 
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 Optimized geometries from the network analysis program were constructed within COMSOL by 
fitting cubic functions through each header segment at the branching tee junctions. This resulted in a 
smooth transition between the widths, thereby avoiding abrupt changes in fluid flow and minor losses 
due to sudden contractions. It must be noted that while the cubic function resulted in well distributed 
flow (see below), this adaptation was empirical. It is entirely plausible that there are alternative methods 
of fitting the sets of header widths that better match the network analysis optimization results. Moreover, 
potential deviations in the fabrication of these curvatures and their impact on flow distribution warrant 
future experimental validation.  
A2.1.3 Application and Validation for High Power Fuel Cells 
 Using both network analysis and CFD models, we assessed air flow distributions for three Z-
configuration geometries.254,381 For comparability, all inlet velocities were set so that the average parallel 
channel velocity should be 0.1 m/s381 if perfectly distributed, i.e., 𝑉𝑖𝑛 = (∑ 𝑎𝑖
𝑁
𝑖=1 )/𝐴𝑖𝑛  ∙ 0.1 𝑚/𝑠 
(stoichiometry ratio of 1.3 and 3.3 for air and hydrogen, respectively, at a current density of 0.3 A cm-2). 
Flow distributions and CFD velocity surfaces of geometries I-III are shown below. Flow non-uniformity was 





In the case of perfectly uniform distribution, 𝐹1 = 0, and 𝐹1 → 1 as flow non-uniformity becomes 
increasingly severe. 𝐹1 parameters were nearly identical between network analysis and CFD results. 
Additionally, these results coincide with previously published results,254,381 all of which validates the 





Air flow distributions in (A) initial and (B) optimized geometries I-III calculated via (green) network analysis 
and (red) CFD methods. Dashed lines represent perfectly distributed profiles. 
 





Network analysis F1 parameters for optimizations of geometry III using various percentages of the optimal 
header widths. The line connecting data points is for illustration only. 
 
We applied the network analysis optimization code to geometries I-III and adapted the resultant 
inlet and outlet header widths to the CFD simulations. The optimized flow profiles from network analysis 
and CFD solutions are shown above. After optimization, we have significantly reduced flow non-uniformity 
in geometries I-III, where the air flow 𝐹1 parameters decreased by 86% on average. Additionally, the 
parasitic pressure required to drive these optimized geometries is either slightly reduced or essentially 
unaffected.  
To confirm that these geometries are indeed optimized, we altered the header tapering of 
geometry III by different percentages of the optimal widths given by Eq. A2.1.3. The network analysis 
results from applying various percentages of the optimal widths to geometry III are shown below. Note 
that these percentages regard the increases in widths of the 1…𝑁/2 headers relative to the widths of 
the 𝑁/2…𝑁 − 1 headers. Applying 80% of the optimal widths increased the 𝐹1 parameter from 0.01 to 
0.21, but applying 90% resulted in an 𝐹1 of 0.11, which is within the ± 5% deviation that has been 
previously defined as an acceptable tolerance for flow non-uniformity.383 
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We have demonstrated that this optimization method is effective, simply devised for any given 
system via the relations in Eq. A2.1.3, does not change any geometric parameters of the parallel channels 
that could affect reaction efficiencies, and offers improved scalability over previous optimization 
methods,384,385 which is immediately evident from the CPU times that were required to solve for velocity 
fields and would be further improved by more advanced algorithms than the simplified search algorithm.  
For the purpose of simulating hydrogen fuel cells, we recognize that the single-phase, steady-
state models employed for geometry optimization are limited in scope and do not describe dynamic 
processes, such as the generation of water droplets/slugs and water purging via hydrodynamic force, that 
create time-dependent fluctuations in pressure and flow distributions during device operation. Fuel cell 
flooding remains a critical limitation of parallel systems, such as Z-type geometries, primarily since flow 
velocities and hydrodynamic forces are significantly reduced (relative to single, serpentine channels) when 
stoichiometry is conserved.386-389 The uniform steady-state flow fields illustrated in this appendix are also 
necessary to provide uniform hydrodynamic forces for water removal across the entire electroactive 
surface. As such, the model presented herein functions as a necessary initial step in the development of 
more complex multi-phase models describing water removal dynamics. In alternative fields of study, such 
as microfluidics, where large scale Z-configuration networks are needed for liquid delivery,75,76,158 this 





 CHANG-HAMMER MODEL – PARAMETERS AND FULL EXPRESSIONS 
Physical parameters used for the majority of Chang-Hammer calculations. 
Parameter Value Unit Description Reference 
kin 2.5 × 104 M-1 s-1 Ab-EpCAM binding kinetics 390 
a 2 nm Encounter radius 391 
D 7× 10-15 m2 s-1 Receptor diffusivity 392 
R 8 µm Cell radius - 
Nr  
400,000 - MCF7 EpCAM expression 
252 
246,000 - Maximum CTC EpCAM expression 
49,700 - Mean CTC EpCAM expression 
9,900 - Minimum CTC EpCAM expression 
 
The full expressions for variables in the Chang-Hammer model,147 which were simplified by substitution 
to produce the expressions presented in Chapter 2. 
Derived Variables  Expression Description 
Pe  V a / D Peclet number 
Nu  2 Pe / π Nusselt number 
δ  a2 kin / D Damköhler number 
τ  8 a / (3 π V) Average time of encounter duration 
Λ  τ D / a2 Dimensional duration time 
C∞  Nr / (4 π R
2) Antigen (EpCAM) surface density 
ko  π D Nu Encounter rate 
P  Λ δ / (1 + Λ  δ) Binding probability 
kf  ko P Effective forward rate constant 
kad  kf C∞ Overall rate of cell adhesion 
%bound  1 − 1/𝑒
𝑘𝑎𝑑𝐿




APPENDIX 3.1. UV-VISIBLE ABSORPTION SPECTRA OF THERMOPLASTIC SUBSTRATES 
Sheets (250 µm thick) of PMMA, COC, and PC were UV-activated for 15 min (254 nm, 22 mW/cm2). 
At several time increments, the UV-Vis spectra of these sheets were acquired to observe the polymers’ 
transmittance as a function of dose. Note that PC’s transmittance most likely decreased with increased 
UV irradiation time, but our instrument was incapable of measuring percent transmittances less than 
0.1%. 
 




PMMA COC PC 
0 1.2 53.8 0.1 
2 1.1 56.5 0.1 
5 0.8 53.0 0.1 
10 0.6 43.5 0.1 




APPENDIX 3.2. CALIBRATION CURVE FOR TBO ASSAY 
TBO electrostatically binds to aliphatic or aromatic carboxylic acids due to their anionic charge 
when deprotonated at relatively high pH values (pH = 10.5).304,305 Thus, surface carboxylic acid functional 
group densities can be calculated for the polymers investigated in this study using a TBO assay. After 
incubating the UV-activated polymers with TBO, the substrates were thoroughly rinsed in the same buffer 
used for the TBO solution. Following washing, surface bound TBO molecules were released from the 
surface using a 40% acetic acid solution. After release of the surface-bound TBO, an aliquot of this solution 
was analyzed via UV-Vis spectroscopy to determine the concentration of TBO bound to the surface via the 
calibration curve. Using the concentration, volume, and surface area, we calculated the surface-confined 
functional group densities, and this value was corrected using surface roughness factors generated from 
atomic force microscopy (AFM) images of the same substrate (Appendix 3.4). A small amount of non-
specific adsorption of TBO to the activated polymer surfaces was observed.306 
 
 
Calibration curve for TBO in 40% acetic acid measured at TBO’s absorption maximum, which is 630 nm. 
For this calibration curve, known amounts of TBO were directly added to the buffer solution. 
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APPENDIX 3.3. PMMA FRAGMENTATION DURING UV ACTIVATION 
If we incubated a UV-activated PMMA surface with IPA and let the solvent evaporate, we visually 
observed an opaque residue deposit that was not observed for pristine PMMA. This residue was likely 
crystallization of PMMA photo-fragments. Furthermore, this residue’s contact angle was 95.4 ± 15.8˚. This 
indicates that rearrangement of these fragments after solvent evaporation was similar to that generated 
during heating, where hydrophobic moieties are more prone to orient themselves towards the surface 
due to the interfacial air boundary, and perhaps shows that fragment rearrangement may also negatively 
impact functional group surface density. Note that the hydrophobicity indicated by this water contact 
angle is likely influenced by trapped air pockets393 within the high roughness of the opaque residue, which 
had an RMS roughness of 326.5 nm.  Neither pristine nor UV-activated COC or PC exhibited the presence 
of this opaque residue as seen for PMMA. In the case of PC, photo-fragmentation is a minor process 
associated with UV treatment, and it is likely that crystallized fragments would be in too low quantity to 
be visually observable. Most likely, this is also the case for UV-activated COC. The fact that TBO signals 
were significantly greater on UV-COC compared to UV-PMMA is likely a result of more efficient UV-
induced carboxyl group formation on COC and less photo-fragmentation compared to PMMA. 
 
 
Opaque residue formed on a PMMA surface that was irradiated at 254 nm for 15 min (Power = 22 
mW/cm2) after treatment with IPA and letting the solvent evaporate. AFM images were acquired on this 
residue and the clear surface. 
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APPENDIX 3.4. ABLATION OF THERMOPLASTIC SURFACES DURING UV ACTIVATION 
To qualitatively assess photolytic ablation of the polymer substrates during UV-activation, we 
irradiated substrates through a fine copper grid that masked regions of the surface so that relative 
changes in UV-induced ablation could be determined with respect to unexposed regions. After 
modification, we secured brightfield images of these surfaces to observe the contrast between the 
irradiated and masked regions. No contrast was observed for the UV-treated PC surface, indicating very 
little photo-induced ablation. However, a fluorescence image of this surface showed significant increases 
in its autofluorescence in regions exposed to UV radiation.295 
 
 
10X optical images of (A) PMMA, (B) COC, and (C) PC substrates there were irradiated at 254 nm for 15 
min (Power = 22 mW/cm2) through a Cu grid. Both (A) and (B) were taken in brightfield mode. Image (C) 
shows a fluorescence image taken with a FITC filter set of the PC substrate after UV-irradiation showing 
autofluorescence for those areas exposed to UV radiation, but no contrast was seen for PC when acquired 






APPENDIX 3.5. AFM IMAGING OF THERMOPLASTIC SUBSTRATES THROUGHOUT ACTIVATION 
AFM images were acquired to determine the surface morphology and RMS roughness for pristine, 
UV, and UV/thermal treatments of PMMA, COC, and PC substrates. RMS values and surface roughness 
correction factors were calculated, and these values were used to correct the functional group surface 
densities obtained from the TBO analyses. 
 
 
AFM images and their corresponding RMS values for pristine, UV, and UV/thermal treated PMMA, COC, 
and PC substrates. All y-axes were scaled from values of -325 nm to 325 nm and all images were scanned 
over a surface area of 10 µm by 10 µm. The RMS value for pristine PC was calculated after removing 20 
µm2 of the surface area, which included the large object near the back of the image that was likely due to 



















APPENDIX 3.6. WATER CONTACT ANGLES OF DIFFERENT PMMA GRADES THROUGH ACTIVATION 
PMMA sheets are produced by manufacturing processes with various blends of additives to 
enhance the structural properties and to prevent yellowing and/or degradation of the polymer by light 
exposure. For example, clinical-grade PMMA is produced with superior quality to ensure a higher and 
narrower molecular weight range. In addition, substrates acquired from the same manufacturer, but 
produced at different times, can compositionally differ as well.394 The concern is that optimization of UV-
activation procedures may have to be reassessed every time a new batch of PMMA is acquired. We briefly 
addressed this concern via water contact angle analysis as described in the main text. 
We performed sessile water contact angle analysis on several types of PMMA. These substrates 
were obtained from different suppliers, numbers listed following the polymer name correspond to the 
numbering in the figure below: Altuglas International (1); Lucite International (2); MacMaster (3); Perspex 
(4); and two batches from Plaskolite Optics (5,6). Also, we tested a clinical grade PMMA sample from 
Plaskolite Optics (7). The figure below compares the water contact angles over the course of UV-activation 
and thermal treatment, which was used to simulate thermal fusion bonding of a cover plate over the 
fluidic substrate 
For the pristine PMMA samples, water contact angles ranged from 71.7 ± 0.9˚ to 77.9 ± 2.1˚. This 
variability could simply be due to differences in the substrates’ thermal histories rather than due to 
differences in their chemical compositions. However, variations in the wettability of the substrates after 
UV modification were much larger, ranging from 29.8 ± 2.0˚ to 49.0 ± 1.2˚. As mentioned, this could be 
due to different UV/radical scavengers present in the polymers and/or molecular weight distributions 
between different batches. Of interest was the return of all contact angles to nearly the same wettability 




Water contact angles for seven PMMA samples from different suppliers, different batches and different 
grades. Refer to the text for numerical assignments of the samples and details of UV and UV/thermal 
treatments. 
 
Return to the pristine wettability of the UV-activated material following thermal processing may 
be independent of chemical composition, additives, and/or molecular weight range of the polymer, but 
additional analyses must be performed to verify this. The hypotheses posed in the main text regarding 
photo-fragment rearrangement could account for these observations. Thus, high doses of 254 nm 
radiation (22 mW/cm2, 15 min) may cause significant fragmentation of the PMMA polymer, and after 
heating, surface photo-fragments rearranged, generating nearly the same surface regardless of the initial 
material’s composition. 
 Finally, using the Plaskolite sample 6, we observed that return to the pristine water contact angle 
was dependent on both annealing temperature and time. Heating the sample to 87°C for 20 min gave a 
contact angle of 59.6 ± 0.8°; heating to 87°C for 30 min gave a water contact angle of 66.5 ± 0.8°; and 
thermal treatment at 102°C for 20 min gave a water contact angle of 63.9 ± 2.1°. Again, these results can 




APPENDIX 3.7. DECONVOLUTION OF X-RAY PHOTOELECTRON SPECTRA 
For all high resolution XPS spectra, a Shirley background was subtracted by averaging at least 10 
end points that were associated with the background. Pristine C 1s spectra for PMMA, COC, and PC were 
deconvoluted based on previously published functional group binding energies.287,290,311 After UV 
modification, peaks attributed to oxidized functionalities, namely alcohols/ethers, aldehydes/ketones, 
and carboxylic acids/esters, were added to the deconvolution method. As there were many sets of 
deconvoluted peaks, we logically deduced several realistic constraints to improve the accuracy of the  
resultant deconvoluted signals. As a matter of reference for the following description of the deconvolution 
methods, we present deconvoluted and labeled C 1s spectra for pristine and UV-activated substrates 
below, the accompanying deconvoluted C 1s atomic concentrations (as a percent of the total C 1s signal) 
and O 1s atomic concentrations (as a percent of total signal) are provided for all substrates and 
treatments.  
Pristine PMMA’s C 1s spectrum was deconvoluted into four Gaussian components: (1) 285.0 eV 
aliphatic C-C and C-H; (2) 285.6 eV quaternary C-C α to the pristine ester; (3) 286.8 eV methoxy C-O ester; 
and (4) 289.1 eV carbonyl C=O ester. This fitting was in good agreement with previous literature, albeit 
the theoretical peak area ratio of the C 1s components (1) to (4) of 2:1:1:1 was found to be 
2.00:1.00:1.29:1.24 in our data likely due to additives and plasticizers introduced by the manufacturer.310  
The C 1s spectra of UV-activated PMMA contained three additional peaks accompanying the four 
pristine signals: (5) 286.6 eV alcohol and non-pristine ester C-O; (6) 288.0 eV aldehyde and ketone C=O; 
and (7) 289.8 eV carboxylic acid C=O. During the fitting of these additional peaks, we emplaced two 





Deconvoluted C 1s spectra with inlaid O 1s spectra for pristine and UV-activated (A,B) PMMA, (C,D) COC, 
and (E,F) PC substrates, respectively. Pristine peaks are labeled and assigned to the polymer’s monomer. 
UV-activated spectra contained additional peaks for C-O (light grey), aldehyde/ketone (medium grey), and 
ester/COOH (dark grey) functionalities. 254 nm UV irradiation was performed for 15 min (Power = 22 
mW/cm2). 
 
applied to all deconvolution methods unless otherwise stated). Secondly, we recognized that if the 
pristine ester were photodegraded and generated additional functionalities, both the methoxy peak (3) 
and the carbonyl peak (4) would be equally affected. Therefore, the ratio of peak area between peaks (3) 
and (4) was maintained as close to 1.04 as possible, and the relative shift in binding energy was also 
constrained to the pristine value, 2.3 eV. Besides widths, no constraints were emplaced on peaks (1) and 
(2) due to potential chemical crosslinking and fragmentation of the polymer backbone.289 




Deconvoluted C 1s atomic concentrations (as percent of total C 1s signal), O 1s atomic concentration (as 
percent of total signal), and integrated FTIR absorbance peaks for the O-H and C=O absorption regions for 
all treatments of the PMMA, COC, and PC substrates. UV-activated substrates were irradiated at 254 nm 
for 15 min (Power = 22 mW/cm2). 
Substrate Treatment 
C 1s Atomic Concentration (%) O/C 
Ratio 
FTIR Peak Area (au·cm-1) 
(1) (2) (3) (4) (5) (6) (7) O-H C=O 
PMMA 
Pristine 36.2 18.1 23.3 22.4 - - - 0.32 3.1 21.4 
UV 36.2 17.3 15.2 14.6 5.9 8.9 2.0 0.38 13.9 25.2 
UV+102˚C 38.9 20.1 16.4 15.7 1.7 6.0 1.2 0.32 8.5 24.8 
COC 
Pristine 78.1 22.0 - - - - - 0.01 0.0 0.0 
UV 43.5 28.6 - - 11.4 7.6 8.9 0.27 13.4 11.2 
UV+130˚C 62.7 22.9 - - 6.4 4.7 3.4 0.10 7.8 10.5 
PC 
Pristine 56.9 19.3 3.6 6.8 13.5 - - 0.15 1.3 18.1 
UV 30.4 19.8 0.4 1.2 21.8 6.7 19.51 0.48 7.6 18.6 
UV+145˚C 37.7 19.8 0.8 1.2 19.0 6.6 14.91 0.40 5.7 19.3 
 
C-C and C-H, which should comprise the entirety of carbon signals within pure COC; (2) 285.6 eV unknown 
carbon signals, likely due to additives; and (5) a small 287.0 eV C-O peak, which we attributed to a small 
amount of oxidized material.290 After UV-activation, three peaks were added, C 1s components (5), (6), 
and (7), which have identical assignments as UV-activated PMMA. However, peak (7) is attributed entirely 
to carboxylic acids as esters are improbable photo-oxidation products for COC, which contains no alcohol 
or ether groups. Because the UV reaction pathway is unknown for COC, this is an assumption that could 
slightly skew the reported carboxyl group peak intensities. The widths of C 1s (1) and C 1s (2) peaks were 
not constrained after fitting the UV-activated material because the chemical environment of these atoms 
likely changed significantly after modification, but the widths of the UV/thermal peaks were constrained 
relative to the UV fitting data. 
Pristine PC’s C 1s spectrum was deconvoluted into the following peaks: (1) 284.5 eV aromatic C-C 
and C-H; (2) 285.0 eV aliphatic C-C and C-H; (3) 290.4 eV carbonate C=O; (4) 291.8 π-π* shake-up satellite; 
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and (5) 286.2 eV aromatic C-O. The ratio of peak areas of C 1s (1):(2):(3):(5) was 8.42:2.85:1.00:1.99, and 
matches reasonably well with the theoretical ratio of 10:3:1:2.  
Modified PC spectra were deconvoluted by calibrating the C 1s (2) peak to 285.0 eV, fixing the C 
1s (3) and C 1s (4) peaks at their pristine positions, adjusting the C 1s (1) peak within ± 0.2 eV of its pristine 
position, and adding C 1s (5), C 1s (6), and C 1s (7) peaks corresponding to phenols, alcohols, or ethers, 
aldehyde or ketone carbonyls, and ester or carboxylic acid carbonyls, respectively. 
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APPENDIX 3.8. RAMAN SPECTROSCOPY OF ACTIVATED COC SUBSTRATES 
We acquired background subtracted Raman spectra for pristine COC, UV-treated COC and 
UV/thermally treated COC. We did not observe any new peaks over the course of the UV-activation 
process. Thus, the 1637 cm-1 shoulder in UV-activated COC’s FTIR spectra (Figure 3.4B) is not due to alkene 
formation but rather likely low energy stretching of aldehydes, ketones, or H-bonded carboxyls. Not 
shown in the figure below are differences in the uncorrected spectra’s baselines. After UV treatment, a 
sloping baseline was observed that increased with the Raman shift. The intensity of this baseline increased 
further after thermal treatment. Due to the increase in signal at lower energies relative to the excitation 




Background-subtracted Raman spectra of pristine, UV, and UV/thermal treated COC samples. The samples 






APPENDIX 3.9. ANALYSIS OF UV-ACTIVATED AND THERMALLY TREATED PC SUBSTRATES 
Within the context of our results showing that functionalized photo-fragments bury into the bulk 
polymer upon thermal treatment and become inaccessible, PC serves as an excellent comparison to 
PMMA and COC as PC tends to resist ablation and scissioning due to the well-known photo-Fries 
rearrangement.395 For instance, no ablation of the PC surface was apparent after UV-activation via 
contrast in brightfield microscopy, only an increase in autofluorescence was apparent (Appendix 3.3).295 
Therefore, we expect that the thermal effects observed for PMMA and COC should be less pronounced 
for PC. 
 PC’s pristine water contact angle was 87.0 ± 2.0˚, which reduced to 17.3 ± 1.0° after UV exposure. 
Correspondingly, the pristine-subtracted TBO results produced a functional group density of 4.0 ± 0.6 
nmol/cm2. This value is again greater than physically possible for a monolayer and indicates some 
fragmentation on the UV-activated PC surface, albeit to a much less extent than that observed for PMMA 
and COC. For instance, there is clear degradation of the UV-PC surface in the AFM image shown in 
Appendix 3.4. However, the TBO analysis was fundamentally complicated by the photo-Fries 
rearrangement products, which included phenols that can be deprotonated at the carbonate buffer’s pH 
(10.5). Therefore, for TBO analysis of PC, we cannot discern the presence of carboxy products, which are 
generated via competitive side-chain oxidation287, from the phenol photo-Fries products. 
To identify the photo-products on the UV-PC surface, we employed both XPS and ATR-FTIR 
spectroscopies. After UV-activation, a 0.33-fold increase in the O/C ratio was observed due to the 





Structures and carbonyl stretching frequencies of PC’s photo-Fries rearrangement and photo-oxidation 
products; adapted from Rivaton, et al.287 
 
outlined above. Note that we could not logically deduce an accurate method to deconvolute ester signals, 
such as in the phenylsalicylate photo-Fries rearrangement product, from carboxyl signals. Together, these 
signals comprised 19.6% of the C 1s signal after UV-activation. 
ATR-FTIR peak areas indicated the presence of several new oxidized functionalities, such as an 
increase of 0.5 au·cm-1 and 6.3 au·cm-1 for the C=O (1650-1850 cm-1) and O-H (3200-3700) regions, 
respectively. More specifically, using the work of Rivaton, et al., we were able to identify several photo-
products from the pristine-subtracted carbonyl region of PC’s ATR-FTIR spectra.287 These products along 
with their corresponding carbonyl stretching energies, which are matched to the pristine-subtracted UV 
PC and UV/thermal PC spectra as shown in the above figures.
  Despite being convoluted, we were able to identify several peaks in addition to the pristine 
carbonate stretch (1767 cm-1) that were generated by UV-activation. The photo-Fries rearrangement 
products, 2,2’-dihydroxybenzophenone (1627 cm-1) and phenylsalicylate (1687 cm-1), were apparent along 
with their associated O-H ring substitutions (1617 and 1585 cm-1) and H-bonded carbonate groups (1748 
cm-1).287 The constant level of atomic oxygen and ozone in the modification chamber (see main text) may 





Carbonyl regions of the pristine background subtracted FTIR spectra for PC substrates that were UV-
activated (UV) and subsequently thermally treated (UV/thermal) at 145°C for 20 min. 
 
(1713 cm-1) and benzoic acids (1696 cm-1). There was also a very small peak at 1840 cm-1, which could 
have originated from ring scissions producing aliphatic carboxylic acids that can rearrange to form cyclic 
anhydrides at the elevated temperatures present in our system. Rivaton, et al. observed this 
rearrangement from 45°C to 75°C , and these conditions occurred within the modification chamber, which 
heated to 50°C after a 15 min UV exposure time.287 However, this peak is small enough that it could be an 
artifact of background subtraction.  
After thermally treating UV-PC, the surface retained enhanced wettability compared to the 
pristine material with a water contact angle of 50.9 ± 0.5°; degradation of the surface’s morphology was 
still evident in AFM images (Appendix 3.1); the TBO signal decreased by 30 ± 9%; the O/C ratio and 
COOH/ester C 1s signals decreased by 17% and 24.0%, respectively; the O-H ATR-FTIR peak area decreased 
by 30%, and the C=O ATR-FTIR peak area increased by 140% due to reemergence of the pristine signal and 
potentially reordering of the surface (Appendix 3.7). It is also interesting to note when analyzing the ATR-
FTIR C=O region (Figure S9), nearly all photo-products’ signals decreased except for the peaks attributed 
to the primary photo-Fries products, 2,2’-dihydroxybenzophenone and phenylsalicylate.  These trends 
qualitatively match that of PMMA and COC, most likely due to some photo-fragmentation, but in terms 
of magnitude, thermal effects were less significant because clear signs of oxidative species remained. 
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Fluorescence imaging of Cy3-labelled oligonucleotide reporters was complicated by PC’s 
considerable autofluorescence post-modification (Appendix 3.1).295 The background-subtracted 
fluorescence signal of Cy3-labelled oligonucleotides covalently coupled to carboxy groups on planar, UV 
and UV/thermal PC was 296 ± 169 cps and 282 ± 168 cps, respectively. The carboxy content on the UV-PC 
surface was relatively unaffected by thermal treatment, which supports the hypothesis that the resistance 
of a modified surface to thermal migration of hydrophilic functional groups away from the surface is 
intimately tied with its tendency to scission upon modification. 
PC microchannel modification showed little correlation with aspect ratio, retaining 82 ± 6% and 
72 ± 33% TBO signal (relative to a planar surface) at aspect ratios of 1.25 and 2.00, respectively. 
Considering the poor transmissivity of the polymer, this was unexpected and may be due to PC’s 
propensity for undergoing the photo-Fries rearrangement even at low fluxes of UV radiation.287 Because 
we are incapable of distinguishing phenols from carboxyls on modified PC surfaces using TBO analyses 
and were unable to acquire fluorescence data within microstructures, this interpretation is far from 
certain. Finally, the PC polymer was disqualified from CTC analysis because we would be unable to image 
and identify fluorescently-labeled cells due to its large autofluorescence background.295  
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APPENDIX 4.1. CELL RECOVERIES USING THE CLEAVABLE LINKER SYSTEM 
Recovery of SKBR3, Hs578T and KG-1 cell lines spiked in PBS using direct mAb attachment to the activated 
thermoplastic (COC) surface and mAb attachment using the ssDNA linker. The number given in 
parentheses represents the number of experimental trials performed. In these experiments, anti-EpCAM 
mAbs were used for the selection of the SKBR3 cells, anti-FAPα mAbs for selection of the Hs578T cells, 
and anti-CD34 mAbs were used for selection of KG-1 cells. Note that for all cell lines, no statistically 
significant difference (p > 0.05) was observed between the Ab attachment methods. 
Linker Name/Ab 
Absolute Cell Recovery (%) Mean ± SD 
Hs578T SKBR3 KG-1 
No linker/direct 
attachment 
76 8 (n=8) 81 10 (n=4) 69 ±  5 (n=7) 
No linker/IgG 0.9 ± 0.1 (n=3) 0.5 ± 0.2 (n=3) -- 
25dX 73.0 -- -- 
34dX 63 ± 6  (n=3) -- -- 
40dX 68 5% (n=5) 85 4 (n=3) 64 ± 4 (n=5) 
20dT -- -- 63 ± 6 (n=9) 
40dT -- -- 65 ± 4 (n=6) 
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APPENDIX 4.2. RELEASE EFFICIENCY BY USER™ ENZYME DIGESTION OF THE CLEAVABLE LINKERS 
Enzymatic release efficiency of viable and fixed KG-1, SKBR3 and Hs578T cells isolated as a function of cell 
incubation time with USER (n ≥ 3). nd = not determined. 
Cell Status Linker Type 
KG-1 Mean Release Efficiency SD (%)  
15 min  30 min  45 min  
Viable Cells 
20dT 58 ± 8† 83 ± 5 86 ± 3 
40dT 67 ± 3† 84 ± 4 88 ± 2 
40dX 69 ± 6† 87 ± 3 89 ± 3 
Fixed Cells 
20dT 62 ± 7† 79 ± 4 81 ± 2 
40dT 59 ± 6† 77 ± 5 83 ± 6 
Cell Status Linker Type 
SKBR3 Mean Release Efficiency SD (%) 
15 min 30 min 45 min 
Viable Cells 40dX 89 ± 3 93 ± 4 nd 
Fixed Cells 40dX 82 ± 3 84 ± 2 nd 
Cell Status Linker Type 
Hs578T Mean Release Efficiency SD (%) 
15 min 30 min 60 min 
Viable Cells 34dX 83 ± 6 nd nd 
Viable Cells 40dX 86 ± 4 nd nd 
Fixed Cells/CF* 34dX 49 ± 9†,‡ 75 ± 8 84 ± 5 
Fixed Cells 40dX 84 ± 3 89 ± 6 nd 
CF*- continuous flow experiment 
† The release efficiency after 15 min was statistically different (p < 0.05) from the efficiency observed after 30 min. 
‡ For this cell line, this release format was statistically different (p < 0.05) from all other release formats at this time point. 
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APPENDIX 4.3. CELL CULTURE AFTER USER™ RELEASE 
SKBR3 cells upon release were collected into a titer well (2 cm2) of a 24-well plate and culturing 
medium was introduced. Observations of cell culturing using a microscope were made in 24 h intervals. 
Appendix 4.1A-E shows micrographs collected during a 5 d period for 5 SKBR3 cells (out of 113 present 
in the well). After 16 h following release, a group of cells was identified (Appendix 4.1A1). After 30 min, 
we observed morphological changes occurring in the largest cell of the group (Appendix 4.1A2). After an 
additional 30 min, the same cell divided (Appendix 4.1A3). The area presented in Appendix 4.1A1-A3, 
was further observed during a 67 h time period and showed 2 cells migrating out of the field of view 
(see Appendix 4.1C). After 5 d, a new cell group of 8 cells was formed. In the 5th day, from the initial 113 
cells, 203 cells were counted in the culture dish. Clearly, cells divided and grew in culture. We suspect 
the low seeding density caused a slow growth rate of the SKBR3 cells. By looking at individual cells (or a 
small group of cells) in the culture dish, we concluded that cells were capable of dividing after selection 
and the subsequent release from the selection microfluidic chip. Another example of SKBR3 dividing is 
shown in Appendix 4.1F-J, where from an initial 7 cells there were 15 cells after 5 d of cultivation.  
 
 
Micrographs of two SKBR3 cell groups, (A-E) group #1 and (F-J) group #2, identified on a culture plate after 
cells were isolated using the cell selection device, released from the device with USER, collected into a 
well, and grown in McCoy medium supplemented with 10% FBS at 37oC, 5% CO2 for 5 d. 
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APPENDIX 4.4. FLOW CYTOMETRY RESULTS FOR THE RELEASED KG-1 CELL LINE 
KG-1 cells affinity selected using the cell selection device via anti-CD34 mAb isolation were stained 
with a cocktail of fluorescently conjugated antibodies, 20 µL each of 0.4 mg/mL CD34-FITC, 0.2 mg/mL 
CD33-PE and 0.1 mg/mL CD117-APC mAbs (BioLegend) and incubated in the dark at 4°C for 30 min. The 
cell selection device was then rinsed with 100 µL of PBS/0.5% BSA at 25 µL/min and stained with 10 ng/mL 
DAPI followed by post-rinsing with 100 µL of PBS/0.5% BSA at 25 µL/min. Cells were released via USERTM 
and collected into 250 µL of PBS.  
The following samples were prepared as controls: Unstained KG-1 cells serving as an 
autofluorescence control; isotype controls where cells were stained with a cocktail of isotype mAbs 
consisting of 5 μL of 0.2 mg/mL IgG1-PE, 2.5 µL of 0.2 mg/mL IgG1-APC and 4 µL of 0.5 mg/mL IgG2a-FITC 
mAbs in 200 µL PBS; positive controls with the cells stained using a cocktail of mAbs containing 5 μL each 
of 0.2 mg/mL CD33-PE, 0.1 mg/mL CD117-APC and 0.4 mg/mL CD34-FITC in 200 µL PBS; and cells stained 
on-chip following selection with the same concentration of mAbs used as the positive control cells. For 
the control cells, the samples were incubated in the dark at 4°C for 30 min following which the cells were 
washed three times with 1 mL of PBS/0.5% BSA and centrifuged. The supernatants were decanted and 
the cells were resuspended in 250 µL PBS/0.5% BSA. DAPI staining (1 ng/mL) was performed on the 
positive and negative controls just prior to the analysis for the determination of cell viability. Samples 
were analyzed on a MACSQuant Analyzer (Miltenyi Biotech, Inc.). Data acquisition and analysis was 







CD33, CD34, and CD117 expression of the KG-1 cell line as determined in a bench top experiment versus 
immunostaining when bound to the surface of a microfluidic device. 
Antigen (Ag) MFI vs. Isotype 
% Stained Cells*,** Change in Ag expression 
(positive control  
vs released cell)* Positive Control Released Cells 
CD33 10x 94% 83% 47% 
CD34 89x 96% 92% 54% 
CD117 2x 77% 46% 61% 
*- vs. unstained cells 
**- Overton Method was used to calculate % stained cells. 
 
 
Flow cytometry scatter plots for: (A) Unstained KG-1 cells serving as an autofluorescence control; (B) 
isotype controls; (C) positive controls with cells stained in suspension; and (D) cells stained on-chip then 
released by USER™ incubation. KG-1 cells were gated as DAPI-positive and forward scatter (FSC) positive 
before assessing antigen expression. 
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APPENDIX 4.5. CLINICAL CTC YIELDS FROM M-OVC PATIENTS USING CLEAVABLE LINKER 
Clinical yields from two M-OVC patients via anti-EpCAM Abs immobilized by direct attachment or by the 
cleavable linker system. 
Sample ID Affinity Bed 
mAb direct attachment 
CTC/mL 
mAb attachment via linker 
CTC/mL 
M-OVC1 anti-EpCAM 397 331 
M-OVC2 anti-EpCAM 680 717 
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APPENDIX 5.1 LONG TERM SHELF-LIFE OF C ELL ISOLATION DEVICES 
For the long term stability experiments, we prepared a large batch of anti-EpCAM modified 
isolation beds during a single work day. After antibody attachment, one group of beds was left filled with 
PBS buffer, and another group was filled with commercial protein stabilizing agent (Thermo Fisher) in PBS 
buffer (2X concentration). CTC isolation beds prepared daily served as the controls. Isolation units were 
refrigerated at 4°C until use. The isolation efficiency of SKBR3 cells spiked in PBS buffer was evaluated 
over the period of 35 days using self-referencing method described in details in previous reports.30,87 Here, 
two devices were connected in series, which we have shown to be accurate for recoveries >70%.30 Below 
a recovery of 70%, more devices are needed to accurately deplete the total cell count, and the measured 
recovery will approach a minimum of 50% for very low recoveries and two devices in series. The isolated 
cells were fixed, permeabilized, stained with DAPI, fluorescently imaged, and counted. The figure below 
presents the results of long-term stability studies. It is clear that after 6 days of refrigerated storage, the 
isolation beds without stabilizing agent showed diminished performance and approached the 50% 
recovery minimum. On the other hand, stabilized isolation beds showed cell recovery of 85-90% similar 
to freshly prepared isolation beds even after long term (measured up to 35 days) cold storage.   
 
 
Long-term antibody stabilization test. Error bars represent standard deviation (N = 2). 
 
Day
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APPENDIX 5.2 CLINICAL CHARACTERISTICS OF PTS #1-5 AT DIAGNOSIS AND TRANSPLANT. 
The clinical characteristics of Pts #1-5 prior to allogeneic SCT are available below. For Pt #4, CLCs 
had a cytogenetic abnormality (complex karyotype, deletion of the long arm of chromosome 5, adverse 
risk).396 Pts #1 and #5 had common NPM1 mutations (found in ~30% of all AMLs). NPM1 mutations are 
associated with a low risk of relapse (Pt #5) unless there is a concomitant FLT3-ITD mutation,397 which was 
observed in Pt #1, that stimulates proliferation and inhibits apoptosis.398 CEBPa mutations, present in Pt 
#3, disrupt differentiation and are associated with a favorable risk (Pt #2’s CEBPa mutation did not encode 
an amino acid change). DNMT3A mutations, detected in Pt #5, have been suggested to impart a high risk 
of relapse, but the ELN has not incorporated DNMT3A into their risk assessment.364,399,400 These gDNA 
mutations have been suggested as therapeutic targets.397,401-404 
While Pts #1-3 had intermediate or favorable risk of relapse, these patients presented with cases 
of relapsed AML prior to SCT, which is an absolute indication to proceed with SCT.405 Pts #4-5 had high risk 
for disease relapse and were referred for SCT. All patients had ideal (10/10) human leukocyte antigen 
(HLA) matches with their donors, decreasing the likelihood of graft-versus-host disease, and responded 
to chemotherapy and achieved CR. Pts #1, #4, and #5 were eligible for additional MRD tracking by FISH 
(5×10-2 sensitivity), PCR (10-4 sensitivity), or MFC (10-3 – 10-4 sensitivity). These results showed that all 
three of the patients were MRD(+) pre-SCT while technically in CR. Pts #1, #2, and #5 were treated with 
intense myeloablative conditioning, and Pts #3 and #4 received reduced intensity conditioning (RIC) due 
to their age. RIC therapy is less strenuous and retains higher disease burden at SCT, relying on the GvL 
effect to combat MRD but has a higher relapse risk.406  
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APPENDIX 5.3 LAP PROFILES FOR PTS #1-5 AS DETERMINED BY MFC ANALYSIS. 
Each patient’s AML was profiled by MFC to identify unique aberrant markers that could be used 
for post-SCT MRD tracking. “Immature cells” were first gated by low CD45 signal and low side scatter407 
and aberrant marker expression was assessed. A patient-specific aberrant marker was selected based on 
the following criteria: (i) The aberrant marker was expressed on as large a proportion of blasts as possible; 
and (ii) normal blood components did not co-express the aberrant marker and CD33, CD34, or CD117. For 
example, Pt #5 had 89% CD64(+) leukemic blasts, but normal monocytes that co-expressed CD33 and 
CD64. For typical MFC analyses, monocytes are gated out of the blast subpopulations, but in the 
microfluidic assay, monocytes are extracted in the anti-CD33 device along with CLCs and would present 
false-positives based on positive staining for CD45 and the CD64 aberrant marker. Instead, CD56 was 
chosen as the aberrant marker for this study, which was expressed on 52% of CLCs and would not generate 
false positives arising from monocytes. While the presented study is limited by applicable aberrant 
markers for these reasons, we are currently developing a microfluidic flow cytometry system to identify 
CLCs isolated in the microfluidic devices. By incorporating side scatter measurements into this system, 
normal blood cells that co-express the isolation and aberrant marker can be reliably discerned from CLCs 





The percentage of CLCs with markers relevant to this study (CD7, CD56, and the isolation antigens) are 
shown along with full leukemic associated phenotype panels. Refer to legend to interpret the heat map. 
Role in LAP Antigen 
Proportion of leukemic blasts 
Pt #1 Pt #2 Pt #3* Pt #4 Pt #5 




CD33 91% 34% (+) 70% 99% 
CD34 4% 69% (-) 57% 1% 
CD117 72% 71% (+) 28% 6% 
Lineage infidelity CD7 51% 50% (+) 6% 3% 
Asynchronous CD56 5% 1% (-) 34% 52% 
Lineage infidelity 
CD2 1% 5% (-) 9% 0% 
CD3 1% 2%  1% 0% 
CD5 1% 2% (-) 3% 0% 
CD10 2% 3% (-) 0% 2% 
CD19 8% 1% (-) 1% 3% 
CD20 1% 2%  0% 0% 
Asynchronous 
CD11b 21% 19% (-) 19% 90% 
CD14 10% 6% (-) 1% 6% 
CD15 55% 15%  27%  
CD64 22% 26% (-) 24% 89% 
Leukemic blasts in sample 3% 1% 26% 2% 66% 
     
 
 
    
213 
APPENDIX 5.4 MFC OF AML CELL LINES 
Three AML cell lines were analyzed by MFC to determine co-expression of the CD33, CD34 and 
CD117 isolation antigens. The U937 cell line358 was a gift from Dr. Gregory Lizee at MD Anderson and the 
Kasumi-1 cell line359 was a gift from Dr. Douglas Graham at the University of Colorado, Denver. The HL60360 
and KG-1361 cell lines were purchased from the American Type Culture Collection (ATCC) through the 
Tissue Culture Facility at UNC. The cell lines were immunostained with anti-CD33-APC, anti-CD34-PE-Cy7, 
anti-CD117-PE antibodies (BD Biosciences) and analyzed by MFC using a MACSQuant Analyzer (Miltenyi 
Biotec GmbH). Data was analyzed using FlowJo (FlowJo, LLC) and is shown below. Both the U937 and HL60 
cell lines highly expressed the CD33 antigen, while the KG1 cell line showed expression of CD33, CD34, 
and to a lesser extent CD117. The Kasumi-1 cell line was also tested (data not shown) and expressed both 
CD33 and CD117 (mean fluorescence intensity of 29× the isotype control and 230× the isotype control, 
respectively). Given the diversity of antigen expression and co-expression in the cell lines, we decided to 





CD33, CD34, and CD117 expression in U937, HL60, and KG-1 AML cell lines. Iso = isotype control. 
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APPENDIX 5.5 HEALTHY DONOR CELL COUNTS 
Aberrant(+) and non-aberrant(-) cell counts for healthy donors. For healthy donors #1 and #2, 0.5 mL of 
PB was processed with counts normalized to 1 mL. For healthy donor #3, 1 mL of PB was processed. The 
threshold for identifying MRD positive was based on aberrant(+) cell counts (3-times the standard 
deviation; 99% confidence interval) was calculated prior to rounding the cell counts. 
Healthy 
donor 
Aberrant(+) cells / mL blood Aberrant(-) cells / mL blood 
Total CD33 CD34 CD117 Total CD33 CD34 CD117 
#1 6 4 0 2 428 176 34 218 
#2 0 0 0 0 158 52 14 92 
#3 6 3 1 2 247 224 9 14 
Mean 4 2 0 1 278 151 19 108 
SD 3 2 1 1 138 89 13 103 
Threshold - 8 3 5 - - - - 
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APPENDIX 6.1 OPTICAL SCHEMATIC OF THE GRC MICROFLUIDIC MFC SYSTEM 
The GRC MFC system contains 2 excitation lasers (532 nm and 637 nm) that are shaped to produce 
a top-hat excitation profile, which provides more uniform illumination when incident on a microfluidic 
channel. Emission is collected by epifluorescence and passed to 4 detectors: backscatter is detected by a 
silicon detector, and fluorescence is split via dichroic filters and passed to three PMTs (575 nm, 665 nm, 
and 715 nm emission channels).  
 
 
(A) Schematic of the 3-color MFC system developed by GRC. The system uses epi-illumination and contains 
a backscatter channel. (B) Laser intensity of a Gaussian profile is made more uniform by a Flat-Top beam 
spatial filter. (C) Excitation beam profiles for the 532 nm and 637 nm lasers measured after incorporation 
of the top hat lens to the system. For (A): M = mirrors; L = lens; DC = dichroic filters; PBS = partial beam 
splitter; BP = band pass filter; PMT = photo-multiplier tubes. 
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APPENDIX 6.2 FLOW CELL FOR TDI IMAGING 
In TDI mode (depicted in the cartoon below), the translational velocity of the imaged object is 
limited by the rate of ADC conversion by the CCD. That is, the cell’s image cannot move into a new row on 
the CCD until that row has been read by the serial register. Without binning, the fastest readout we have 
observed with our camera is 1.5 ms, so with a total of 100 rows, the minimum total exposure time is 150 
ms. We have approximated the CCD’s field of view as 600 µm (20X objective magnification / 6X beam 
reduction = 3.3X effective magnification; 2 mm CCD size / 3.3X = 600 µm field of view). Thus, the cell’s 
maximum linear velocity is ~4 mm/s. Note that we would likely operate at a lower linear velocity to 
increase total exposure time and overall signal, especially for low signal membrane protein markers. 
To elute cells from a cell isolation device at ~1 mm/s is not trivial. If we imaged the cells in a 100 
µm × 50 µm (W × H) microchannel, the elution flow rate would be 0.3 µL/min, two orders of magnitude 
lower than the empirically validated release process, and the analysis time would require >1 h. 
Furthermore, the microscope objective used in the TDI-Spectral MFC system (20X, 0.75 NA) has an 
approximate depth of focus of only a few micrometers, and the fluorescence collected from cells 
distributed evenly through a 50 µm deep microchannel will generate highly variable signals (high 
coefficient of variations, CVs) that will deteriorate system performance. Thus, mating the cell isolation 
device and the TDI-Spectral MFC system requires high volumetric flow rates but low slow linear velocities 
and also a tight control over cell position. These criteria require carefully engineered microfluidic 
architectures. 
We have designed a custom microfluidic flow cell (shown below) for the TDI-Spectral MFC system. 





Cartoon illustrating TDI operation. A cell (red dot) moves in time (black arrows) as it travels through the 
CCD’s field of view. The cell’s fluorescence emission spectrum, which is sorted by the holographic grating, 
is shuttled through the rows of the CCD at the same rate as the cell’s forward motion. The fluorescence 
emission spectrum builds in the CCD’s pixels, increasing signal-to-noise, and is read in one analog-to-
digital (ADC) conversion. Because the cell’s signal is contained in a discrete region of the CCD, multiple 
cells can be tracked simultaneously without their images overlapping. 
 
and compresses the sample stream into a much smaller cross section than the channel dimensions. Fluid 
dynamics simulation were used to optimize channel dimensions and produce a symmetrical compression 
of the sample stream (data not shown). Of note, the sheathing fluid compresses the sample stream into 
the center of the focusing channel where velocity is approximately uniform. This required sheathing 
microstructures to be both deeper and taller than the sample stream. Rather than using multi-level 
lithographic fabrication, we hot-embossed two symmetrical halves of the device into a 500 µm and 2.5 
mm PMMA coverslip and substrate, which were combined and solvent-bonded to form the functional 
device. Alignment of the two substrates was critical, and we achieved highly precise alignment (5-10 µm 
misalignment; smallest microstructure was 100 µm wide) using passive alignment pin-groove 
microstructures409 that “click” the two substrates in place and constrain motions that would cause 
misalignment. Thus, we fabricated a complex system of multi-level microstructures in thermoplastic 




(A) 3D renderings of (top right) the entire flow cell and (center) a zoomed cross section of the 2 stages of 
focusing and the expansion region, where the cross section has been cut in half in both the lateral and 
depth dimensions. (B) Alignment of a patterned coverslip and substrate to generate multi-level fluidic 
channels in one-step by using sets of passive alignment microstructures. (C) Fluorescence images of FITC 
dye at stage 1 and stage 2 of the focusing architecture under two different sheathing flow rates. (D) Width 
of the focused sample stream under various sheathing and sample flow rates. Minimum widths based on 
lateral diffusion of the FITC dye are also plotted. Diffusion limits are plotted as two standard deviations 
(𝝈, 95% of diffused dye), where 𝝈 = √𝟐𝑫𝒍/𝒗 and 𝑫 is 640 µm2/s, 𝒍 is 1 mm, and 𝒗 is the linear velocity is 
based on total flow rate and the focusing channel’s cross section of 100 µm × 100 µm (W × D). (E) 
Performance of the flow cell using the GRC MFC system, which shows the most uniform signal from 
calibration beads at a total flow rate of 170 µL/min with a sample stream flow rate of 2.5 µL/min, which 
corresponds to a Sheath:Sample flow rate ratio of 33.5. 
 
Using these assembled and fully functional devices, we empirically tested the width of the focused 
sample stream by imaging a fluorescein tracking dye. Dye visualization was chosen in place of particle 
imaging velocimetry because the velocity of calibration beads in the focusing channels was too fast 
(approximately 100-400 mm/s) to be imaged using a standard microscope. Optimal focusing (smallest 
cross section of the focused sample stream) was achieved when the volumetric flow rate of each 
sheathing channel network was approximately 25 times larger than the sample stream; larger flow rates 
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in the sheathing networks were possible but at certain limits created large back pressures that stopped 
sample flow entirely.  
These preliminary results indicating a well-focused dye stream were confirmed by mating the 
customized flow cell with the GRC MFC system (Appendix 6.1), which detected calibration beads just after 
the second focusing stage. The GRC MFC optical system used a data processing algorithm to identify and 
record peaks, which were later smoothed by Gaussian fitting to extract peak values. The performance of 
this approach was best when at least 3-4 data points were recorded per pulse. The necessary 3-4 data 
points per pulse occurred when the total flow rate was around 170 L/min or less in the flow cell. At 
higher flow rates, fluorescence CVs were observed to increase due to poorer data quality (fit inaccuracy). 
For a given sample flow rate, the confinement of the sample flow was reduced at lower total flow rates 
(thus lower sheath rates), thereby increasing the observed CVs. A sample flow rate of 2.5 L/min gave the 
lowest CVs while allowing for maintained flow. At 2.5 L/min sample flow and 80 L/min sheath flow, the 
fluorescence CVs were 14% (665 nm channel) and 11% (715 nm channel). On a standard benchtop MFC 
system, the same beads were measured with CVs of 10% (675 nm channel) and 14% (755 nm channel). 
While the channels cannot be directly compared due to the different filters (different band pass widths in 
particular) that alter signal-to-noise ratios per event, the results show that the system (the fluidic focusing 
and the excitation uniformity) performed comparably to a benchtop cytometer in terms of signal spread. 
Due to the high cell velocity after the second focusing stage (on the order of 100 mm/s), tightly 
focused cells must be slowed by two orders of magnitude for TDI-Spectral MFC imaging, but the focused 
spatial distribution of the cells, particularly with respect to their position along the microchannel’s depth, 
must be retained. We first tested a method outlined by a previous report,410 which indicated that if cells 
are focused into a single streamline (cross section of the compressed sample stream is less than the cell’s 
cross section), cells will continue to follow this streamline and remain focused even if the channel abruptly 
widens. Thus, cells can be slowed due to the increasing channel dimensions, but they will retain a uniform 
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trajectory that enables consistent imaging. Our initial attempts with a single expansion chamber did not 
produce these results, and the spatial distribution of focused cells in the expansion chamber was 
extremely variable (data not shown). We suspect based on fluid dynamics simulation that the extremely 
large dimensions of the expansion chamber (8 mm × 700 µm) that were necessary to drop the cell’s linear 
velocity by two to three orders of magnitude created slow but time-dependent recirculation profiles in 
the expansion chamber, which would “randomly” distribute cells during expansion by variable axial forces.  
We are now designing a second generation device that “skims” sheathing fluid from the outer 25 
µm sections of the 100 µm wide focusing channel. This skimmed fluid can then deposit into two channels 
that feed to atmospheric pressure as waste. The three channels (imaging channel plus two skimming 
channels) then behave as a set of parallel fluidic resistors. For example, it can be shown that the flow rate 







where 𝑈𝑓𝑜𝑐𝑢𝑠  is the total flow rate in the second stage of focusing, 𝑅𝑖𝑚𝑎𝑔𝑒  is the hydraulic resistance of 
the imaging channel, and 𝑅𝑠𝑘𝑖𝑚  is the hydraulic resistance of a single skimming channel. This equation 
shows that 𝑈𝑓𝑜𝑐𝑢𝑠  can be decreased by enlarging the skimming channels, which will slow the linear 
velocity in the imaging region without changing the imaging channel dimensions at all. It may also be 
possible to incorporate a smaller expansion chamber as well. Most critical to success of this skimming 
design, no fluid recirculation can occur in either the skimming channels or the imaging channel. Time-
dependent fluid recirculation in any channel would create variable resistances in the parallel channel 
network that would constantly vary 𝑈𝑖𝑚𝑎𝑔𝑒 in Eq. A7.2.1, and this would compromise high fidelity TDI 
imaging because the variable cell velocities could not be tracked with a fixed CCD clock rate. 
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